Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

Abstract

The disclosure is directed to compounds of Formula I R1 AN R2 NN HO R5 R411119 X HO Y Ar I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described. 20 24 20 42 64 21 J un 2 02 4 2 0 2 4 2 0 4 2 6 4 2 1 J u n 2 0 2 4 A B S T R A C T A N R ² N N H O I I I I N H O Y A r

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a divisional application of Australian Patent Application No. 2019235912, filed 14 March 2019, and is related to International Patent Application No. PCT / US2019 / 022288, filed 14 March 2019, and claims the benefit of priority to U.S. Provisional Patent Application No. 62 / 742,048, filed 5 October 2018; U.S. Provisional Patent Application No. 62 / 666,726 filed 4 May 2018; and U.S. Provisional Patent Application No 62 / 642,727, filed 14 March 2018. Each of these applications is incorporated by reference herein in its entirety. TECHNICAL FIELD

[0001] The disclosure is directed to PRMT5 inhibitors and methods of their use. BACKGROUND

[0002] Protein arginine methylation is a common post-translational modification that regulates numerous cellular processes, including gene transcription, mRNA splicing, DNA repair, protein cellular localization, cell fate determination, and signaling. Three types of methyl-arginine species exist: w NG monomethylarginine (MMA), w NG, NG asymmetric dimethylarginine (ADMA) and w NG, N’G symmetric dimethylarginine (SDMA). The formation of methylated arginines is catalyzed by the protein arginine methyl transferases (PRMTs) family of methyltransferases. Currently, there are nine PRMTs annotated in the human genome. The majority of these enzymes are Type I enzymes (PRMT1, -2, -3, -4, -6, -8) that are capable of mono- and asymmetric dimethylation of arginine, with S-adenosylmethionine (SAM) as the methyl donor. PRMT-5, -7 and -9 are considered to be Type II enzymes that catalyze symmetric dimethylation of arginines. Each PRMT species harbors the characteristic motifs of seven beta strand methyltransferases (Katz et al., 2003), as well as additional ‘‘double E’’ and ‘‘THW’’ sequence motifs particular to the PRMT subfamily.

[0003] PRMT5 is as a general transcriptional repressor that functions with numerous transcription factors and repressor complexes, including BRG1 and hBRM, Blimp1, and Snail. This enzyme, once recruited to a promoter, symmetrically dimethylates H3R8 and H4R3. Importantly, 2024204264   21 Jun 2024 the H4R3 site is a major target for PRMT1 methylation (ADMA) and is generally regarded as a transcriptional activating mark. Thus, both H4R3me2s (repressive; me2s indicates SDMA [TEXT CONTINUES ON PAGE 2] 2024204264   21 Jun 2024 modification) and H4R3me2a (active; me2a indicates ADMA modification) marks are produced in vivo. The specificity of PRMT5 for H3R8 and H4R3 can be altered by its interaction with COPR5 and this could perhaps play an important role in determining PRMT5 corepressor status. Role of PRMTs in Cancer

[0004] Aberrant expression of PRMTs has been identified in human cancers, and PRMTs are considered to be therapeutic targets. Global analysis of histone modifications in prostate cancer has shown that the dimethylation of histone H4R3 is positively correlated with increasing grade, and these changes are predictive of clinical outcome.

[0005] PRMT5 levels have been shown to be elevated in a panel of lymphoid cancer cell lines as well as mantle cell lymphoma clinical samples. PRMT5 interacts with a number of substrates that are involved in a variety of cellular processes, including RNA processing, signal transduction, and transcriptional regulation. PRMT5 can directly modify histone H3 and H4, resulting in the repression of gene expression. PRMT5 overexpression can stimulate cell growth and induce transformation by directly repressing tumor suppressor genes. Pal et al., Mol. Cell. Biol. 2003, 7475; Pal et al. Mol. Cell. Biol. 2004, 9630; Wang et al. Mol. Cell. Biol. 2008, 6262; Chung et al. J Biol Chern 2013, 5534. In addition to its well-documented oncogenic functions in transcription and translation, the transcription factor MYC also safeguards proper pre-messenger-RNA splicing as an essential step in lymphomagenesis. Koh et al. Nature 2015, 523 7558; Hsu et al. Nature 2015 525, 384.

[0006] The discovery of cancer dependencies has the potential to inform therapeutic strategies and to identify putative drug targets. Integrating data from comprehensive genomic profiling of cancer cell lines and from functional characterization of cancer cell dependencies, it has been recently discovered that loss of the enzyme methylthioadenosine phosphorylase (MTAP) confers a selective dependence on protein arginine methyltransferase 5 (PRMT5) and its binding partner WDR77. MTAP is frequently lost due to its proximity to the commonly deleted tumor suppressor gene, CDKN2A. Cells harboring MTAP deletions possess increased intracellular concentrations of methylthioadenosine (MTA, the metabolite cleaved by MTAP). Furthermore, MTA specifically inhibits PRMT5 enzymatic activity. Administration of either MTA or a smallmolecule PRMT5 inhibitor shows a preferential impairment of cell viability for MTAP-null cancer cell lines compared to isogenic MTAP-expressing counterparts. Together, these findings reveal 2024204264   05 Aug 2026 PRMT5 as a potential vulnerability across multiple cancer lineages augmented by a common “passenger” genomic alteration. Role of PRMT5 in Hemoglobinopathies

[0007] The developmental switch in human globin gene subtype from fetal to adult that begins at birth heralds the onset of the hemoglobinopathies, b-thalassemia and sickle cell disease (SCD). The observation that increased adult globin gene expression (in the setting of hereditary persistence of fetal hemoglobin [HPFH] mutations) significantly ameliorates the clinical severity of thalassemia and SCD has prompted the search for therapeutic strategies to reverse gamma-globin gene silencing. Central to silencing of the gamma-genes is DNA methylation, which marks critical CpG dinucleotides flanking the gene transcriptional start site in adult bone marrow erythroid cells. It has been shown that these marks are established as a consequence of recruitment of the DNA methyltransferase, DNMT3A to the gammapromoter by the protein arginine methyltransferase PRMT5. Zhao et al. Nat Struct Mol Biol. 2009 16, 304. PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing.

[0008] PRMT5 induces the repressive histone mark, H4R3me2s, which serves as a template for direct binding of DNMT3A, and subsequent DNA methylation. Loss of PRMT5 binding or its enzymatic activity leads to demethylation of the CpG dinucleotides and gene activation. In addition to the H4R3me2s mark and DNA methylation, PRMT5 binding to the gamma-promoter, and its enzymatic activity are essential for assembly of a multiprotein complex on the gamma-promoter, which induces a range of coordinated repressive epigenetic marks. Disruption of this complex leads to reactivation of gamma gene expression. These studies provide the basis for developing PRMT5 inhibitors as targeted therapies for thalassemia and SCD. [0008a] Any discussion of the prior art throughout the specification should not be considered as an express or implied admission that such prior art is widely known or forms part of the common general knowledge in the field. [0008b] It is an object of the present invention to overcome or ameliorate one or more of the disadvantages of the prior art, or at least to provide a useful alternative. 2024204264   05 Aug 2026 SUMMARY [0008c] According to a first aspect, the present disclosure provides a compound, or pharmaceutically acceptable salt or solvate thereof, wherein the compound is: (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1,3- dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; (1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1,3- dihydroisobenzofuran-1-yl)cyclopentane-1,2-diol; (S)-3-((1S,2R,3S,4R)-4-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3- dihydroxycyclopentyl)-6-chloroisobenzofuran-1(3H)-one; (R)-3-((1S,2R,3S,4R)-4-(4-amino-6H-7l4-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3- dihydroxycyclopentyl)-6-chloroisobenzofuran-1(3H)-one; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-5-chloro-1,3- dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; (1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-5-chloro-1,3- dihydroisobenzofuran-1-yl)cyclopentane-1,2-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H- pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-butyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1-yl)-5-(4-(ethoxymethyl)- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-4-chloro-1,3- dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloro-1,3- dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; 2024204264   05 Aug 2026 (2S,3S,4R,5R)-2-((R)-5-chloro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-4-chloro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-7-chloro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-6-chloro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-((R)-5-chloro-1,3-dihydroisobenzofuran-1-yl)-3-methyltetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-2-((R)-5-chloro-1,3-dihydroisobenzofuran-1-yl)-3-methyl-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1-methyl-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-5-chloro-1-methyl-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-5-chloro-3,3-difluoro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-5-chloro-3,3-dimethyl-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-5-chloro-1,3-dihydrobenzo[c]thiophen-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (R)-5-chloro-1-((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-1,3-dihydrobenzo[c]thiophene 2,2-dioxide; (2R,3R,4S,5S)-2-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5- (trifluoromethoxy)-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol; 2024204264   05 Aug 2026 (2S,3S,4R,5R)-2-((R)-6-fluoro-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-6-fluoro-5-(trifluoromethoxy)-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-2-((R)-5-chloro-2-methylisoindolin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (R)-6-chloro-3-((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-2-methylisoindolin-1-one (2S,3S,4R,5R)-2-((R)-1,3-dihydrofuro[3,4-c]pyridin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-6-chloro-1,3-dihydrofuro[3,4-c]pyridin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-4,6-dihydrofuro[3,4-d]thiazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-2-chloro-4,6-dihydrofuro[3,4-d]thiazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-4,6-dihydrothieno[2,3-c]furan-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-2-chloro-4,6-dihydrothieno[2,3-c]furan-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-4,6-dihydro-1H-furo[3,4-c]pyrazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-2-methyl-2,6-dihydro-4H-furo[3,4-c]pyrazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-2-((R)-5-chloroisoindolin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (R)-6-chloro-3-((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)isoindolin-1-one; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((1R)-6-chloro-3-methoxyisochroman-1-yl)tetrahydrofuran-3,4-diol; 2024204264   05 Aug 2026 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((1R)-6-chloro-3-hydroxyisochroman-1-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((1R)-6-chloro-3-methoxyisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-6-chloro-1H-isochromen-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (R)-6-chloro-1-((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)isochroman-3-one; (2S,3S,4R,5R)-2-((R)-6-chloro-4,4-dimethylisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((S)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-1H-pyrano[3,4-c]pyridin-1-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((1R)-6-chloro-3-hydroxyisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-3,4-dihydro-1H-pyrano[3,4-c]pyridin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-6-chloro-4,4-difluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-7-chloro-4H-benzo[d][1,3]dioxin-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-7-chloro-2,2-difluoro-4H-benzo[d][1,3]dioxin-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-7-chloro-1,5-dihydrobenzo[e][1,3]dioxepin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-7-chloro-3,3-difluoro-1,5-dihydrobenzo[e][1,3]dioxepin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (R)-7-chloro-1-((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-1,5-dihydrobenzo[e][1,3]dioxepin-3-one; 2024204264   05 Aug 2026 (2S,3S,4R,5R)-2-((R)-8-chloro-5,6-dihydro-1H-benzo[e][1,3]dioxocin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-8-chloro-3,3-difluoro-5,6-dihydro-1H-benzo[e][1,3]dioxocin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (R)-8-chloro-1-((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-5,6-dihydro-1H-benzo[e][1,3]dioxocin-3-one; (2R,3S,4R,5R)-2-((R)-6-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((1R)-6-chloro-4-(trifluoromethyl)isochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((1R)-6-chloro-4-fluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((1R)-6-chloro-4-hydroxyisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((1R)-6-chloro-4-methylisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((1R)-6-chloro-3-methylisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-6-chloroisochroman-1-yl-4,4-d2)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-6-chloroisochroman-1-yl)-5-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-7-chloroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloroisochroman-1-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloroisochroman-1-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6,7-difluoroisochroman-1-yl)tetrahydrofuran-3,4-diol; 2024204264   05 Aug 2026 (2S,3S,4R,5R)-2-((R)-6,7-difluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-5-chloroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-4,4-difluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5,6-difluoroisochroman-1-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-4,4-difluoroisochroman-1-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-5,6-difluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((S)-6-chloroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloro-1,5-dihydrobenzo[e][1,3]dioxepin-1-yl)tetrahydrofuran-3,4-diol; (R)-1-((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-6-chloroisochroman-3-one; (2S,3S,4R,5R)-2-((R)-6-chloro-5-fluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6-chloro-5-fluoroisochroman-1-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-6-chloroisochroman-1-yl)-5-(5-fluoro-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6-chloroisochroman-1-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-6,7-dichloroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6,7-dichloroisochroman-1-yl)tetrahydrofuran-3,4-diol; 2024204264   05 Aug 2026 (2S,3S,4R,5R)-2-((S)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((1R,4S)-6-chloro-4-fluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(1R,4S)-6-chloro-4-fluoro-isochroman-1-yl]tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(1R,4R)-6-chloro-4-fluoro-isochroman-1-yl]tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((1R,4R)-6-chloro-4-fluoroisochroman-1-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-7,8-difluoro-4H-benzo[d][1,3]dioxin-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3S,4R,5R)-2-[(1R)-6-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-6-chloro-7-methylisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6-chloro-7-methylisochroman-1-yl)tetrahydrofuran-3,4-diol; (2S,3S,4R,5R)-2-((R)-7-chloro-1,3,4,5-tetrahydrobenzo[c]oxepin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol; (2R,3R,4S,5S)-2-(4-amino-6H-7l4-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloro-1,3,4,5-tetrahydrobenzo[c]oxepin-1-yl)tetrahydrofuran-3,4-diol; or (2S,3S,4R,5R)-2-((R)-6,7-difluoroisochroman-1-yl)-5-(4-(methyl-d3)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol. 2024204264   05 Aug 2026 [0008d] According to a second aspect, the present disclosure provides a pharmaceutical composition comprising a compound of the first aspect, or a pharmaceutically acceptable salt or solvate thereof. [0008e] According to a third aspect, the present disclosure provides a method of inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme, comprising: contacting the PRMT5 enzyme with an effective amount of a compound of the first aspect, or a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition of the second aspect. [0008f] According to a fourth aspect, the present disclosure provides a method of treating a disease or disorder associated with aberrant PRMT5 activity in a subject comprising administering to the subject, a compound of the first aspect, or a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition of the second aspect. [0008g] Use of a compound of the first aspect or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating a disease or disorder associated with aberrant PRMT5 activity.

[0009] The disclosure is directed to compounds of Formula I: 2024204264   21 Jun 2024 or a pharmaceutically acceptable salt or solvate thereof; wherein A is N or C-R3; R1 is H, halo, -Ci-Cealkyl, -Ci-Cealkoxy, -Ci-C4haloalkyl, -Cs-Cecycloalkyl, -C3-Cehalocycloalkyl, -Ci-C6alk-O-Ci-C6alkyl, -Ci-C6alk-S(O)-Ci-C6alkyl, -Ci-C6alk-S(O)2-Ci-C6alkyl, -CR6R6 CN, -NR6R6’, -NHCR6R6CN, -NHCONR6R6’, - NHC(O)OR7, NHC(O)-Ci-C6alkyl, NHC(O)-Ci-C6haloalkyl, -NH-Ci-C6alk-C(O)-Ci-Cealkyl, -NHC(S)NR6R6’, -NH-O-R6, or -NH-NR6R6’; R2 is H, halo, -Ci-Cealkyl, or NH2; R3 is H, halo, -Ci-Cealkyl, -Ci-Cealkoxy, -C2-Cealkenyl, or-C2-Cealkynyl; R4 is H, -Ci-Cealkyl, -Ci-Cehaloalkyl, -C2-Cealkenyl, or -C2-Cealkynyl; R5 is H or -Ci-Cealkyl; R6 and R6 are each independently H, Ci-Cealkyl, or -Ci-Cealk-OCi-Cealkyl; or R6 and R6, together with the atom to which they are attached, form a C2-Ceheterocycloalkyl ring or a Cs-Cecycloalkyl ring; R7 is -Ci-Cealkyl or -Co-Cealk-Cs-Cecycloalkyl; X is O, S, NH, or N(Ci-C6alkyl), and Y is -(CR9R9’)n-, -CR9=CR9’-, C(=O), -C(=O)-(CR9R9’)n-, -C(=O)-O-(CR9R9 )n-, -CR9R9’-O-, -(CR9R9’)n-O-(CR9R9’)m-, -(CR9R9’)n-NR10, C(=O)NR10, or CH-Ci-C4alk-NH2; or 2024204264   21 Jun 2024 X is -SO2- and Y is -(CR9R9’)n-, -CR9=CR9’-, -CR9R9’-O-, -(CR9R9’)n-O-(CR9R9’)m-, -(CR9R9’)n-NR10, or CH-Ci-C4alk-NH2; wherein n = 1, 2, or 3; m = 1 or 2; each instance of R9 or R9 is independently H, D, Ci-Cealkyl, Ci-Cehaloalkyl, halo, -Ci-Cealkoxy, or hydroxy; R10 is H or Ci-Cealkyl; Z is O, CEE, or CF2; and Ar is an optionally substituted 6-membered aryl ring, an optionally substituted 6-membered heteroaryl ring, or an optionally substituted 5-membered heteroaryl ring.

[0010] Stereoisomers of the compounds of Formula I, and the pharmaceutical salts and solvates thereof, are also contemplated, described, and encompassed herein. Methods of using compounds of Formula I are described, as well as pharmaceutical compositions including the compounds of Formula I. DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

[0011] The disclosure may be more fully appreciated by reference to the following description, including the following definitions and examples. Certain features of the disclosed compositions and methods which are described herein in the context of separate aspects, may also be provided in combination in a single aspect. Alternatively, various features of the disclosed compositions and methods that are, for brevity, described in the context of a single aspect, may also be provided separately or in any subcombination.

[0012] The term “alkyl,” when used alone or as part of a substituent group, refers to a straight- or branched-chain hydrocarbon group having from 1 to 12 carbon atoms (“Ci-Ci2”), preferably 1 to 6 carbons atoms (“Ci-Ce”), in the group. Examples of alkyl groups include methyl (Me, Cialkyl), ethyl (Et, C2alkyl), n-propyl (Csalkyl), isopropyl (Csalkyl), butyl (C4alkyl), isobutyl (C4alkyl), sec-butyl (C4alkyl), tert-butyl (C4alkyl), pentyl (Csalkyl), isopentyl (Csalkyl), tert-pentyl (Csalkyl), hexyl (Cealkyl), isohexyl (Cealkyl), and the like.

[0013] The term “alkoxy,” when used alone or as part of a substituent group, refers to an oxygen radical to which is attached an alkyl group (i.e., -O-alkyl) Examples of alkoxy groups 2024204264   21 Jun 2024 include methoxy (-OMe, Cialkoxy), ethoxy (-OEt, C2alkoxy), n-propoxy (Csalkoxy), isopropoxy (Csalkoxy), and the like.

[0014] The term “halo” when used alone or as part of a substituent group refers to chloro, fluoro, bromo, or iodo.

[0015] The term “haloalkyl” when used alone or as part of a substituent group refers to refers to an alkyl group wherein one or more of the hydrogen atoms has been replaced with one or more halogen atoms. Halogen atoms include chlorine, fluorine, bromine, and iodine. Examples of haloalkyl groups of the disclosure include, for example, trifluoromethyl (-CF3), chloromethyl (-CH2CI), and the like.

[0016] The term “haloalkoxy,” when used alone or as part of a substituent group, refers to an oxygen radical to which is attached a haloalkyl group (i.e., -O-haloalkyl). Examples of haloalkoxy groups include trifluoromethoxy (-OCF3, Cihaloalkoxy), difluoromethoxy (-OCHF2, Cihaloalkoxy), fluoromethoxy (-OCH2F, Cihaloalkoxy), trifluoroethoxy (-OCH2CF3, C2 haloalkoxy), and the like.

[0017] The term “cycloalkyl” when used alone or as part of a substituent group refers to cyclic-containing, non-aromatic hydrocarbon groups having from 3 to 10 carbon atoms (“C3-C10”), preferably from 3 to 6 carbon atoms (“C3-C6”). Examples of cycloalkyl groups include, for example, cyclopropyl (C3), cyclobutyl (C4), cyclopropylmethyl (C4), cyclopentyl (C5), cyclohexyl (Ce), 1-methylcyclopropyl (C4), 2-methylcyclopentyl (C4), adamantanyl (C10), and the like.

[0018] The term “halocycloalkyl” when used alone or as part of a substituent group refers to cyclic-containing, non-aromatic hydrocarbon groups having from 3 to 10 carbon atoms (“C3-C10”), preferably from 3 to 6 carbon atoms (“C3-C6”), wherein one or more of the hydrogen atoms has been replaced with one or more halogen atoms. Halogen atoms include chlorine, fluorine, bromine, and iodine. Examples of halocycloalkyl groups include, for example, halocyclopropyl (C3), halocyclobutyl (C4), halocyclopropylmethyl (C4), halocyclopentyl (C5), halocyclohexyl (Ce), and the like.

[0019] The term “heterocycloalkyl” when used alone or as part of a substituent group refers to any three to ten membered monocyclic or bicyclic, saturated ring structure containing at least one heteroatom selected from the group consisting of O, N and S. The heterocycloalkyl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure. Examples of suitable heterocycloalkyl groups include, but are not limited to, azepanyl, 2024204264   21 Jun 2024 aziridinyl, azetidinyl, pyrrolidinyl, dioxolanyl, imidazolidinyl, pyrazolidinyl, piperazinyl, piperidinyl, dioxanyl, morpholinyl, dithianyl, thiomorpholinyl, oxazepanyl, oxiranyl, oxetanyl, quinuclidinyl, tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, and the like.

[0020] The term “alkenyl” when used alone or as part of a substituent group refers to a straight- or branched-chain group having from 2 to 12 carbon atoms (“C2-C12”), preferably 2 to 4 carbons atoms (“C2-C4”), in the group, wherein the group includes at least one carbon-carbon double bond. Examples of alkenyl groups include vinyl (-CH=CH2; C2alkenyl) allyl (-CH2- CH=CH2; Csalkenyl), propenyl (-CH=CHCH3; Csalkenyl); isopropenyl (-C(CH3)=CH2; Csalkenyl), butenyl (-CH=CHCH2CH3; C4alkenyl), sec-butenyl (-C(CH3)=CHCH3; C4alkenyl), iso-butenyl (-CH=C(CH3)2; C4alkenyl), 2-butenyl (-CH2CH=CHCH3; C4alkyl), pentenyl (CH=CHCH2CH2CH3; Csalkenyl), and the like.

[0021] The term “alkynyl” when used alone or as part of a substituent group refers to a straight- or branched-chain group having from 1 to 12 carbon atoms (“C1-C12”), preferably 1 to 4 carbons atoms (“C2-C4”), in the group, and wherein the group includes at least one carbon-carbon triple bond. Examples of alkynyl groups include ethynyl (-C=CH; C2alkynyl); propargyl (-CH2-C=CH; Csalkynyl), propynyl (-C=CCH3; Csalkynyl); butynyl (-C=CCH2CH3; C4alkynyl), pentynyl (OCCH2CH2CH3; Csalkynyl), and the like.

[0022] The term “aryl” when used alone or as part of a substituent group refers to a mono-or bicyclic- aromatic hydrocarbon ring structure having 6 or 10 carbon atoms in the ring, wherein one or more of the carbon atoms in the ring is optionally substituted. Exemplary substituents include halogen atoms, -C1-C3 alkyl groups, and Ci-Cshaloalkyl groups. Halogen atoms include chlorine, fluorine, bromine, and iodine. Ci-Cshaloalkyl groups include, for example, -CF3, -CH2CF3, and the like.

[0023] The term “heteroaryl” when used alone or as part of a substituent group refers to a mono- or bicyclic- aromatic ring structure including carbon atoms as well as up to four heteroatoms selected from nitrogen, oxygen, and sulfur. Heteroaryl rings can include a total of 5, 6, 9, or 10 ring atoms. The heteroaryl moiety can be optionally substituted. Exemplary substituents include halogen atoms; -C1-C3 alkyl groups, and Ci-Cshaloalkyl groups. Halogen atoms include chlorine, fluorine, bromine, and iodine. 2024204264   21 Jun 2024

[0024] When a range of carbon atoms is used herein, for example, Ci-Ce, all ranges, as well as individual numbers of carbon atoms are encompassed. For example, “C1-C3” includes C1-C3, C1-C2, C2-C3, Ci, C2, and C3.

[0025] The term “Ci-Cealk” when used alone or as part of a substituent group refers to an aliphatic linker having 1, 2, 3, 4, 5, or 6 carbon atoms and includes, for example, -CH2-, -CH(CH3)-, -CH(CH3)-CH2-, and -C(CH3)2-. The term “-Coalk-” refers to a bond. In some aspects, the Ci-Cealk can be substituted with one or more -OH, -NH2, or halo (e.g., -F, -Cl, -Br, with -F being preferred) substituents.

[0026] “Pharmaceutically acceptable” means approved or approvable by a regulatory agency of the Federal or a state government or the corresponding agency in countries other than the United States, or that is listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, e.g., in humans.

[0027] “Pharmaceutically acceptable salt” refers to a salt of a compound of the disclosure that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. In particular, such salts are non-toxic may be inorganic or organic acid addition salts and base addition salts. Specifically, such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-l-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, N-methylglucamine and the like. Salts further include, by way of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the compound contains a basic functionality, salts of 2024204264   21 Jun 2024 non-toxic organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

[0028] A “pharmaceutically acceptable excipient” refers to a substance that is non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

[0029] A “solvate” refers to a physical association of a compound of Formula I with one or more solvent molecules.

[0030] “Subject” includes humans. The terms “human,” “patient,” and “subject” are used interchangeably herein.

[0031] “Treating” or “treatment” of any disease or disorder refers, in one embodiment, to ameliorating the disease or disorder (i.e., arresting or reducing the development of the disease or at least one of the clinical symptoms thereof). In another embodiment “treating” or “treatment” refers to ameliorating at least one physical parameter, which may not be discernible by the subject. In yet another embodiment, “treating” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both. In yet another embodiment, “treating” or “treatment” refers to delaying the onset of the disease or disorder. In some embodiments, “treating” or “treatment” refers to prophylactic treatment, i.e., preventing the onset of the disease or disorder.

[0032] “Compounds of the present disclosure,” and equivalent expressions, are meant to embrace compounds of Formula I as described herein, as well as their subgenera, which expression includes the stereoisomers (e.g., entaniomers, diastereomers) and constitutional isomers (e.g., tautomers) of compounds of Formula I as well as the pharmaceutically acceptable salts, where the context so permits.

[0033] As used herein, the term “isotopic variant” refers to a compound that contains proportions of isotopes at one or more of the atoms that constitute such compound that is greater than natural abundance. For example, an “isotopic variant” of a compound can be radiolabeled, that is, contain one or more radioactive isotopes, or can be labeled with non-radioactive isotopes such as for example, deuterium (2H or D), carbon-13 (13C), nitrogen-15 (15N), or the like. It will be -9- 2024204264   21 Jun 2024 understood that, in a compound where such isotopic substitution is made, the following atoms, where present, may vary, so that for example, any hydrogen may be 2H / D, any carbon may be 13C, or any nitrogen may be 15N, and that the presence and placement of such atoms may be determined within the skill of the art.

[0034] It is also to be understood that compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers.” Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers,” for example, diastereomers, enantiomers, and atropisomers. The compounds of this disclosure may possess one or more asymmetric centers; such compounds can therefore be produced as individual (7?)-or (5)-stereoisomers at each asymmetric center, or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include all stereoisomers and mixtures, racemic or otherwise, thereof. Where one chiral center exists in a structure, but no specific stereochemistry is shown for that center, both enantiomers, individually or as a mixture of enantiomers, are encompassed by that structure. Where more than one chiral center exists in a structure, but no specific stereochemistry is shown for the centers, all enantiomers and diastereomers, individually or as a mixture, are encompassed by that structure. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.

[0035] In some aspects, the disclosure is directed to compounds of Formula I: 2024204264   21 Jun 2024

[0036] According to the disclosure, R1 in Formula I is H, halo, -Ci-Cealkyl, -Ci-Cealkoxy, -Ci-C4haloalkyl, -C3-C6cycloalkyl, -C3-C6halocycloalkyl, -Ci-C6alk-O-Ci-C6alkyl, -Ci-C6alk-S(O)-Ci-C6alkyl, -Ci-C6alk-S(O)2-Ci-C6alkyl, -CR6R6 CN, -NR6R6’, -NHCR6R6CN, -NHCONR6R6’, -NHC(O)OR7, NHC(O)-Ci-C6alkyl, NHC(O)-Ci-C6haloalkyl, -NH-Ci-C6alk-C(O)-Ci-C6alkyl, -NHC(S)NR6R6’, -NH-O-R6, or -NH-NR6R6’

[0037] In some embodiments, R1 in Formula I is H.

[0038] In some embodiments, R1 is halo (e.g., -F, -Cl, -Br, or -I), preferably -F.

[0039] In other embodiments, R1 is -Ci-Cealkyl, for example, -Cialkyl, -C2alkyl, -Csalkyl, -C4alkyl, -Csalkyl, -Cealkyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like. In some embodiments, R1 is methyl.

[0040] In some embodiments, when R1 is -Cialkyl, R1 is -CD3.

[0041] In yet other embodiments R1 is -Ci-Cealkoxy, for example, -Cialkoxy, -C2alkoxy, -Csalkoxy, -C4alkoxy, -Csalkoxy, -Cealkoxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, s-butoxy, t-butox, pentoxy, and the like.

[0042] In other embodiments, R1 is -Ci-C4haloalkyl, for example, -CF3 or -CHF2, -CH2CH2CI, -CH2CH2F, or -CH2CHF2. In some embodiments, R1 is -CH2CH2CI. In other embodiments, R1 is -CH2CH2F. In yet other embodiments, R1 is -CH2CHF2.

[0043] In other embodiments, R1 is -Cs-Cecycloalkyl, for example, for example, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, R1 is cyclopropyl.

[0044] In other embodiments, R1 is -Cs-Cehalocycloalkyl, for example chlorocyclopropyl, fluorocyclobutyl, bromocyclopentyl, iodocyclohexyl, and the like.

[0045] In other embodiments, R1 is -Ci-Cealk-O-Ci-Cealkyl, for example, -Cialk-O-Cialkyl, -C2alk-O-Cialkyl, -C3alk-O-Cialkyl, -C4alk-O-Cialkyl, -Csalk-O-Cialkyl, -C6alk-O-Cialkyl, -Cialk-O-C2alkyl, -C2alk-O-C2alkyl, -C3alk-O-C2alkyl, -C4alk-O-C2alkyl, -C5alk-O-C2alkylj -Cealk-O-C2alkyl, -Cialk-O-C3alkyl, -C2alk-O-C3alkyl, -C3alk-O-C3alkyl, -C4alk-O-C3alkyl, -C5alk-O-C3alkylj -C6alk-O-C3alkyl, -Cialk-O-C4alkyl, -C2alk-O-C4alkyl, -C3alk-O-C4alkyl, -C4alk-O-C4alkyl, -C5alk-O-C4alkylj -C6alk-O-C4alkyl, -Cialk-O-Csalkyl, -C2alk-O-C5alkyl, -C3alk-O-C5alkyl, -C4alk-O-C5alkyl, -Csalk-O-Csalkyl, -C6alk-O-C5alkyl, -Cialk-O-C6alkyl, -C2alk-O-C6alkyl, -C3alk-O-Cealkyl, -C4alk-O-Cealkyl, -Csalk-O-Cealkyl, -Cealk-O-Cealkyl, -CH2CH2OMe, -CH2OMe, -CH2CH2OCH2CH3, -CH2OCH2CH3, -CH2CH2CH2OCH3, and the like. 2024204264   21 Jun 2024

[0046] In other embodiments, R1 is -Ci-C6alk-S(O)-Ci-C6alkyl, for example, -Cialk-S(O)-Cialkyl, -C2alk-S(O)-Cialkyl, -C3alk-S(O)-Cialkyl, -C4alk-S(O)-Cialkyl, -Csalk-S^-Cialkyl, -C6alk-S(O)-Cialkyl, -Cialk-S(O)-C2alkyl, -C2alk-S(O)-C2alkyl, -C3alk-S(O)-C2alkyl, -C4alk-S(O)-C2alkyl, -C5alk-S(O)-C2alkylj -C6alk-S(O)-C2alkyl, -Cialk-S(O)-C3alkyl, -C2alk-S(O)-C3alkyl, -C3alk-S(O)-C3alkyl, -C4alk-S(O)-C3alkyl, -C5alk-S(O)-C3alkylj -C6alk-S(O)-C3alkyl, -Cialk-S(O)-C4alkyl, -C2alk-S(O)-C4alkyl, -C3alk-S(O)-C4alkyl, -C4alk-S(O)-C4alkyl, -C5alk-S(O)-C4alkylj -C6alk-S(O)-C4alkyl, -Cialk-S(O)-C5alkyl, -C2alk-S(O)-C5alkyl, -C3alk-S(O)-C5alkyl, -C4alk-S(O)-Csalkyl, -C5alk-S(O)-C5alkylj -C6alk-S(O)-C5alkyl, -Cialk-S(O)-C6alkyl, -C2alk-S(O)-C6alkyl, -C3alk-S(O)-C6alkyl, -C4alk-S(O)-C6alkyl, -C5alk-S(O)-C6alkylj -C6alk-S(O)-C6alkyl, -CH2CH2S(O)Me, and the like.

[0047] In other embodiments, R1 is -Ci-C6alk-S(O)2-Ci-C6alkyl, for example, -Cialk-S(O)2-Cialkyl, -C2alk-S(O)2-Cialkyl, -C3alk-S(O)2-Cialkyl, -C4alk-S(O)2-Cialkyl, -C5alk-S(O)2-Cialkylj -C6alk-S(O)2-Cialkyl, -Cialk-S(O)2-C2alkyl, -C2alk-S(O)2-C2alkyl, -C3alk-S(O)2-C2alkyl, -C4alk-S(O)2-C2alkyl, -C5alk-S(O)2-C2alkylj -C6alk-S(O)2-C2alkyl, -Cialk-S(O)2-C3alkyl, -C2alk-S(O)2-C3alkyl, -C3alk-S(O)2-C3alkyl, -C4alk-S(O)2-C3alkyl, -C5alk-S(O)2-C3alkylj -C6alk-S(O)2-C3alkyl, -Cialk-S(O)2-C4alkyl, -C2alk-S(O)2-C4alkyl, -C3alk-S(O)2-C4alkyl, -C4alk-S(O)2-C4alkyl, -Csalk-S(O)2-C4alkylj -C6alk-S(O)2-C4alkyl, -Cialk-S(O)2-C5alkyl, -C2alk-S(O)2-C5alkyl, -C3alk-S(O)2-Csalkyl, -C4alk-S(O)2-C5alkyl, -C5alk-S(O)2-C5alkylj -C6alk-S(O)2-C5alkyl, -Cialk-S(O)2-C6alkyl, -C2alk-S(O)2-C6alkyl, -C3alk-S(O)2-C6alkyl, -C4alk-S(O)2-C6alkyl, -C5alk-S(O)2-C6alkylj -Cealk-S(O)2-Cealkyl, -CH2CH2SO2Me, and the like.

[0048] In some embodiments, R1 is -CR6R6 CN. Thus, in some embodiments wherein R6 andR6 are both H, R1 is cyanomethyl (i.e., -CH2CN).

[0049] In some embodiments, R1 is -NR6R6 . Thus, in some embodiments wherein R6 and R6 are both H, R1 is -NH2. In some embodiments wherein R6 andR6 are both methyl, R1 is -N(CH3)2. In embodiments wherein R6 is H and R6 is methyl, R1 is -NH(CH3).

[0050] In some embodiments, R1 is -NHCR6R6 CN. Thus, in some embodiments wherein R6 andR6’ are both H, R1 is -NHCH2CN.

[0051] In some embodiments, R1 is -NHCONR6R6 . Thus, in some embodiments wherein R6 andR6 are both H, R1 is -NHCONH2. In embodiments wherein R6 andR6 are both methyl, R1 is -NHCON(CH3)2. In embodiments wherein R6is H andR6 is methyl, R1 is -NHCONHCH3. 2024204264   21 Jun 2024

[0052] In some embodiments, R1 is or -NHC(O)OR7. Thus, in some embodiments wherein R7is methyl, R1 is or -NHC(O)OCH3.

[0053] In some aspects, R1 is -NHC(O)-Ci-C6alkyl, for example, -NHC(O)-Cialkyl, NHC(O)-C2alkyl, NHC(O)-C3alkyl, NHC(O)-C4alkyl, NHC(O)-C5alkyl, NHC(O)-C6alkyl, NHC(O)-methyl, NHC(O)-ethyl, and the like.

[0054] In other aspects, R1 is NHC(O)-Ci-C6haloalkyl, for example, -NHC(O)-Cihaloalkyl, NHC(O)-C2haloalkyl, NHC(O)-C3haloalkyl, NHC(O)-C4haloalkyl, NHC(O)-C5haloalkyl, -NHC(O)-Cehaloalkyl, -NHC(O)-chloromethyl, -NHC(O)-chloroethyl, -NHC(O)-fluoromethyl, -NHC(O)-fluoroethyl and the like.

[0055] In other aspects, R1 is -NH-Ci-C6alk-C(O)-Ci-C6alkyl, for example, -NH-Cialk-C(O)-Ci-C6alkyl, -NH-C2alk-C(O)-Ci-C6alkyl, -NH-C3alk-C(O)-Ci-C6alkyl, -NH-C4alk-C(O)-Ci-Cealkyl, -NH-C5alk-C(O)-Ci-C6alkyl, -NH-C6alk-C(O)-Ci-C6alkyl, -NH-Ci-C6alk-C(O)-Cialkyl, -NH-Ci-C6alk-C(O)-C2alkyl, -NH-Ci-C6alk-C(O)-C3alkyl, -NH-Ci-C6alk-C(O)-C4alkyl, -NH-Ci-C6alk-C(O)-Csalkyl, -NH-Ci-C6alk-C(O)-C6alkyl and the like. In some aspects, R1 is -NH-CH2-C(O)-CH3.

[0056] In some aspects, R1 is NHC(S)NR6R6 . Thus, in some embodiments wherein R6 and R6 are both H, R1 is —NHC(S)NH2. In embodiments wherein R6 andR6 are both methyl, R1 is — NHC(S)N(CH3)2. In embodiments wherein R6is H andR6 is methyl, R1 is -NHC(S)NHCH3.

[0057] In some aspects, R1 is -NH-O-R6. In some embodiments wherein R6 is Ci-Cealkyl, for example, methyl, R1 is -NH-OCH3. In some embodiments wherein R6 is H, R1 is -NH-OH.

[0058] In some aspects, R1 is -NH-NR6R6 . In some embodiments wherein R6 andR6 are both H, R1 is -NH-NH2. In embodiments wherein R6 andR6 are both Ci-Cealkyl, for example, methyl, R1 is -NH-N(CH3)2. In embodiments wherein R6 is H and R6 is Ci-Cealkyl, for example, methyl, R1 is -NH-NHCH3.

[0059] It will be apparent that when R1 is -NH-O-R6 or -NH-NR6R6 , the compounds of Formula I may exist as tautomers having (E)- or (Z)- geometry at the exocyclic carbon-nitrogen double bond. The compounds of Formula I described and claimed herein are meant to encompass all such tautomers and geometric isomers. The depiction of a particular tautomer or geometric isomer is not intended to be limiting.

[0060] In embodiments of the disclosure, R6 and R6 in Formula I are each independently H, Ci-Cealkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the 2024204264   21 Jun 2024 like), or-Co-Cealk-OCi-Cealkyl (e.g., -Coalk-OCi-C6alkyl, -Ci-Cealk-OCi-Cealkyl, -Ci-Csalk-OCi-Cealkyl, -Ci-C4alk-OCi-C6alkyl, -Ci-C3alk-OCi-C6alkyl, -Ci-C2alk-OCi-C6alkyl, -Cialk-OCi-Cealkyl, -Co-C6alk-OCi-Csalkyl, -Co-C6alk-OCi-C4alkyl, -Co-Cealk-OCi-Csalkyl, -Co-C6alk-OCi-C2alkyl, or -Co-C6alk-OCialkyl).

[0061] In some embodiments, R6 is H or Ci-Cealkyl. In some embodiments, R6 is H or Ci-Cealkyl.

[0062] In some embodiments, R6 and R6 are each H.

[0063] In other embodiments, R6 and R6 are each independently Ci-Cealkyl. Thus, in some embodiments R6 is methyl and R6 is methyl.

[0064] In some aspects, R6 is Ci-Cealkyl and R6 is H. Thus, in some embodiments, R6 is methyl and R6 is H.

[0065] In other aspects, R6 and R6 are each independently -Co-Cealk-OCi-Cealkyl.

[0066] In other aspects, R6 is -Co-Cealk-OCi-Cealkyl and R6 is H.

[0067] In embodiments of the disclosure, R6 and R6 , together with the atom to which they are attached, may form a C3-Cecycloalkyl ring, for example, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In other embodiments of the disclosure, R6 and R6 , together with the atom to which they are attached, form a C2-C6heterocycloalkyl, for example, azepanyl, aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperazinyl, piperidinyl, morpholinyl, thiomorpholinyl, oxazepanyl, piperazinyl, and the like.

[0068] In embodiments of the disclosure, R7 is -Ci-Cealkyl, or -Co-C6alk-C3-C6cycloalkyl. In some embodiments, R7 is Ci-Cealkyl, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like. Thus, in some embodiments, R7 is methyl.

[0069] In other aspects, R7 is -Co-C6alk-C3-C6cycloalkyl, for example, -Coalk-C3cycloalkyl, -Cialk-C3cycloalkyl, -C2alk-C3cycloalkyl, -Csalk-Cscycloalkyl, -C4alk-C3cycloalkyl, -Csalk-C3cycloalkyl, -C6alk-C3cycloalkyl, -Coalk-C4cycloalkyl, -Cialk-C4cycloalkyl, -C2alk-C4cycloalkyl, -C3alk-C4cycloalkyl, -C4alk-C4cycloalkyl, -Csalk-Qcycloalkyl, -C6alk-C4cycloalkyl, -Coalk-Cscycloalkyl, -Cialk-Cscycloalkyl, -C2alk-C5cycloalkyl, -Csalk-Cscycloalkyl, -C4alk-C5cycloalkyl, -Csalk-Cscycloalkyl, -Cealk-Cscycloalkyl, -Coalk-Cecycloalkyl, -Cialk-Cecycloalkyl, -C2alk-Cecycloalkyl, -C3alk-C6cycloalkyl, -C4alk-C6cycloalkyl, -Csalk-Cecycloalkyl, -Cealk-Cecycloalkyl.

[0070] According to the disclosure, R2 in Formula I is H, halo, -Ci-Cealkyl, or NH2. Thus in some embodiments, R2 is H. In other embodiments, R2 is halo, for example F, Cl, Br, or I. In 2024204264   21 Jun 2024 other embodiments, R2 is -Ci-Cealkyl, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like. Thus, in some embodiments, R2 is methyl (Me). In yet other embodiments, R2 is NH2. In the most preferred embodiments, R2 is H.

[0071] According to the disclosure, R4 in Formula I is H,-Ci-Cealkyl, -Ci-Cehaloalkyl, -C2-Cealkenyl, or -C2-Cealkynyl. Thus in some embodiments, R4 is H.

[0072] In other embodiments, R4 is -Ci-Cealkyl, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like. Thus, in some embodiments, R4 is methyl (Me).

[0073] In other aspects, R4 is -Ci-Cehaloalkyl, for example, -CF3 or -CHF2. In some embodiments, R4 is -CF3.

[0074] In some aspects, R4 is -C2-Cealkenyl, preferably -C2-C4alkenyl, for example, vinyl, allyl, and the like.

[0075] In other aspects, R4 is -C2-Cealkynyl, preferably -C2-C4alkynyl, for example, ethynyl, propargyl, and the like.

[0076] According to the disclosure, R5 in Formula I is H or -Ci-Cealkyl. Thus in some embodiments, R5 is H. In other embodiments, R5 is -Ci-Cealkyl, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like. Thus, in some embodiments, R5 is methyl (Me).

[0077] In some aspects of the disclosure, X in Formula I is O, S, NH, or N(Ci-Cealkyl); and Y in Formula I is -(CR9R9’)n-, -CR9=CR9’-, C(=O), -C(=O)-(CR9R9’)n-, -C(=O)-O-(CR9R9’)n-, -CR9R9’-O-, -(CR9R9’)n-O-(CR9R9’)m-, -(CR9R9’)n-NR10, C(=O)NR10, or CH-Ci-C4alk-NH2, wherein n = 1 or 2, m = 1 or 2, and wherein each instance of R9 or R9 is independently H, D (i.e., deuterium), Ci-Cealkyl, Ci-Cehaloalkyl, halo, -Ci-Cealkoxy, or hydroxy, and wherein R10 is H or Ci-Cealkyl.

[0078] In other aspects of the disclosure, X in Formula I is -SO2- and Y in Formula I is -(CR9R9’)n-, -CR9=CR9’-, -CR9R9’-O-, -(CR9R9’)n-O-(CR9R9’)m-, -(CR9R9’)n-NR10, or CH-Ci-C4alk-NH2, wherein n = 1 or 2, m = 1 or 2, and wherein each instance of R9 or R9 is independently H, D (i.e., deuterium), Ci-Cealkyl, Ci-Cehaloalkyl, halo, -Ci-Cealkoxy, or hydroxy, and wherein R10 is H or Ci-Cealkyl.

[0079] In some embodiments, X is O. In other embodiments, X is S. In other embodiments, X is SO2. In yet other embodiments, X is NH. In some embodiments, X is N(Ci- 2024204264   21 Jun 2024 Cealkyl), for example, N(Cialkyl), N(C2alkyl), N(C3alkyl), N(C4alkyl), NfCsalkylh N(Cealkyl), N(CH3), N(CH2CH3), and the like.

[0080] In some aspects, Y is -(CR9R9 )n-. In some embodiments n= 1, and Y is -CR9R9 -. In some embodiments n= 1, R9 and R9 are each H, and Y is -CH2-.

[0081] In other embodiments wherein Y is -(CR9R9 )n- , n= 1, R9 and R9 are each F, and Y is -CF2-.

[0082] In some embodiments wherein Y is -(CR9R9 )n-, n= 1, R9 and R9 are each Ci-Cealkyl, and Y is -C(Ci-Cealkyl)2-. In some embodiments, Ci-Cealkyl is -CH3, and Y is -C(CH3)2-.

[0083] In some embodiments wherein Y is -(CR9R9 )n-, n= 2, and Y is -CR9R9 - CR9R9 -. In some embodiments wherein Y is -(CR9R9 )n- and n= 2, each R9 and each R9 is H, and Y is -CH2CH2-.

[0084] In some embodiments wherein Y is -(CR9R9 )n- and n= 2, one R9 is -Ci-Cealkoxy , the other R9 is H, and each R9 is H, and Y is -CH2CH(Ci-C6alkoxy)-. In some embodiments, Ci-Cealkoxy is -OCH3, and Y is -CH2CH(OCH3)-.

[0085] In some embodiments wherein Y is -(CR9R9 )n- and n= 2, one R9 is -hydroxy , the other R9 is H, and each R9 is H, and Y is -CH2CH(OH)-.

[0086] In some embodiments wherein Y is -(CR9R9 )n- and n= 2, one R9 is -Ci-Cealkyl, the other R9 is H, and each R9 is H, and Y is -CH2CH(Ci-C6alkyl). In some embodiments, Ci-Cealkyl is -CH3, and Y is -CH2CH(CH3)-.

[0087] In some embodiments wherein Y is -(CR9R9 )n- and n= 2, one R9 is -Ci-Cealkyl, one R9 is H, one R9 is -Ci-Cealkyl, one R9 is H, and Y is -CH2C(Ci-C6alkyl)2-. In some embodiments, Ci-Cealkyl is -CH3, and Y is -CH2C(CH3)2-.

[0088] In some embodiments wherein Y is -(CR9R9 )n- and n= 2, one R9 is -Ci-Cehaloalkyl, the other R9 is H, and each R9 is H, and Y is -CH2CH(Ci-C6haloalkyl)-. In some embodiments, Ci-Cehaloalkyl is -CF3, and Y is -CH2CH(CF3)-.

[0089] In some embodiments wherein Y is -(CR9R9 )n- and n= 2, one R9 is -F , the other R9 is H, and each R9 is H, and Y is -CH2CHF-.

[0090] In some embodiments wherein Y is -(CR9R9 )n- and n= 2, one R9 is F , the other R9 is H, one R9 is F, and the other R9 is H, and Y is -CH2CF2-.

[0091] In some embodiments wherein Y is -(CR9R9 )n- and n= 2, one R9 is D , the other R9 is H, one R9 is D, and the other R9 is H, and Y is -CH2CD2-. 2024204264   21 Jun 2024

[0092] In some embodiments wherein Y is -(CR9R9 )n- and n= 1, R9 and R9 are each Ci-Cealkyl, and Y is -C(Ci-Cealkyl)2-. In some embodiments, Ci-Cealkyl is -CH3, and Y is -C(CH3)2-.

[0093] In some embodiments, Y is -(CR9R9 )n- and n = 3. In some embodiments n= 3, R9 and R9 are each H, and Y is -CH2CH2CH2-.

[0094] In some aspects, Y is -CR9=CR9 -. In some embodiments wherein Y is -CR9=CR9 -, R9 and R9 are each H, and Y is -CH=CH-.

[0095] In other aspects, Y is C(=O).

[0096] In some aspects, Y is -C(=O)-(CR9R9 )n-. In some embodiments, n = 1, R9 and R9 are both H, and Y is -C(=O)-CH2-.

[0097] In some aspects, Y is -C(=O)-O-(CR9R9 )n-. In some embodiments, n=l, R9 and R9 are both H, and Y is -C(=O)-O-CH2-. In other embodiments, n=2, R9 and R9 are both H, and Y is -C(=O)-O-CH2CH2-.

[0098] In some aspects, Y is -CR9R9 -O-. In some embodiments, R9 and R9 are both H, and Y is -CH2-O-. In other embodiments, R9 and R9 are both F, and Y is -CF2-O-.

[0099] In some aspects, Y is -(CR9R9 )n-O-(CR9R9 )m-. In some embodiments, n = m = 1, and each R9 and each R9 is H, and Y is -CH2-O-CH2-. In other embodiments, n = m = 1, and one R9 is H and one R9 is F, and one R9 is H and one R9 is F, and Y is -CF2-O-CH2-. In other embodiments, n = 1, m = 2, each R9 and each R9 is H, and Y is -CH2-O-CH2CH2-. In other embodiments, n=l, m=2, one R9 is F and the other R9 are H, and one R9 is F and the other R9 are H, and Y is -CF2-O-CH2CH2-.

[00100] In some aspects, Y is -(CR9R9 )n-NR10-. In some embodiments, n = 1, R9, R9, and R10 is H, and Y is -CH2-NH-. In other embodiments, n = 1, R9 are R9 are both H, R10 is Ci-Cealkyl, and Y is -CH2-N(Ci-C6alkyl)-.

[00101] In some aspects, Y is -C(=O)NR10. In some embodiments, R10 is H, and Y is -C(=O)NH-. In other embodiments, R10 is Ci-Cealkyl, and Y is -C(=O)N(Ci-C6alkyl)-.

[00102] It will be apparent to those skilled in the art that some embodiments of the element Y attach to the element X of Formula I through one atom, and to the Ar group of Formula I through a different atom (i.e., when Y is -(CR9R9’)n- with n=2, -CR9=CR9’-, -C(=O)-(CR9R9’)n-, -C(=O)-O-(CR9R9’)n-, -CR9R9’-O-, -(CR9R9’)n-O-(CR9R9’)m-, -(CR9R9’)n-NR10, and -C(=O)NR10). When such embodiments of Y attach to X and Ar through only non-carbonyl carbon atoms (i.e., when Y is -(CR9R9 )n- with n= 2, -CR9=CR9 -, or -(CR9R9 )n-O-(CR9R9 )m-, then Y may attach to X or to Ar 2024204264   21 Jun 2024 through either carbon atom. For example, when Y is -CR9=CR9 -, Y may attach as either Ar-CR9=CR9 -X or as X-CR9=CR9 -Ar. Similarly, when Y is -(CR9R9 )n-O-(CR9R9 )m-, Y may attach as either Ar-(CR9R9’)n-O-(CR9R9’)m-X or as X-(CR9R9’)n-O-(CR9R9’)m-Ar.

[00103] When such embodiments of Y attach through a non-carbonyl carbon atom and a carbonyl carbon atom (i.e., when Y is -C(=O)-(CR9R9 )n- or -C(=O)-O-(CR9R9 )n-), then the carbonyl carbon atom of Y attaches to X, and the non-carbonyl carbon atom of Y attaches to Ar. The following examples illustrate this point. When Y is -C(=O)-(CR9R9 )n-, then Y attaches as:

[00104] Similarly, when Y is -C(=O)-O-(CR9R9 )n-, then Y attaches as:

[00105] When embodiments of Y attach to X and Ar through a carbon atom of Y and an oxygen or nitrogen atom of Y (i.e., when Y is -CR9R9 -O-, -(CR9R9 )n-NR10-, or -C(=O)NR10-), then Y attaches to Ar through only the oxygen or nitrogen atom, and Y attaches to X through only the carbon atom. That is, Y attaches as X-CR9R9 -O-Ar, X-(CR9R9 )n-NR10-Ar, or X-C(=O)NR10-Ar. The following examples illustrate this point. When Y is -CR9R9 -O-, or -(CR9R9 )n-NR10-, then Y attaches as: 2024204264   21 Jun 2024

[00106] When Y is -C(=O)NR10-, then Y attaches as:

[00107] In other embodiments, Y is CH-Ci-C4alk-NH2, for example, CH-Cialk-NH2, CH-C2alk-NH2, CH-C3alk-NH2, CH-C4alk-NH2, CH-CH2-NH2, CH-CH2CH2-NH2, and the like.

[00108] According to the disclosure, Ar in Formula I is an optionally substituted 6membered aryl ring, an optionally substituted 6-membered heteroaryl ring, or an optionally substituted 5-membered heteroaryl ring. In some embodiments, Ar is an optionally substituted 6membered aryl ring. In some embodiments, the 6-membered aryl ring is unsubstituted. In other embodiments, the 6-membered aryl ring is substituted with one or more substituents, independently selected from halo, Ci-Cealkyl, Ci-Cehaloalkyl, Ci-Cealkoxy, and Ci-Cehaloalkoxy. In some preferred embodiments, the 6-membered aryl ring is substituted with one or more -F, -Cl, -CH3, -CF3, or -OCF3 substituents.

[00109] In some embodiments, Ar is an optionally substituted 6-membered heteroaryl ring. In some embodiments, the 6-membered heteroaryl ring is unsubstituted. In other embodiments, the 6-membered heteroaryl ring is substituted with one or more substituents, independently selected from halo, Ci-Cealkyl, Ci-Cehaloalkyl, Ci-Cealkoxy, and Ci-Cehaloalkoxy. In some preferred 2024204264   21 Jun 2024 embodiments, the 6-membered heteroaryl ring is substituted with one or more -F, -Cl, -CH3, -CF3, or -OCF 3substituents.

[00110] In some embodiments, Ar is an optionally substituted 5-membered heteroaryl ring. In some embodiments, the 5-membered heteroaryl ring is unsubstituted. In other embodiments, the 5-membered heteroaryl ring is substituted with one or more substituents, independently selected from halo, Ci-Cealkyl, Ci-Cehaloalkyl, Ci-Cealkoxy, and Ci-Cehaloalkoxy. In some preferred embodiments, the 5-membered heteroaryl ring is substituted with one or more -F, -Cl, -CH3, -CF3, or -OCF 3substituents.

[00111] According to the disclosure, A in Formula I is N or C-R3. In some embodiments, A is N and the compounds of Formula I are of the Formula I-B:

[00112] In other embodiments, A is C-R3 and the compounds of Formula I are of the Formula I-C: 2024204264   21 Jun 2024

[00113] In embodiments of the disclosure that are compounds of Formula I-C, R3 is H, halo, -Ci-Cealkyl, -Ci-Cealkoxy, -C2-Cealkenyl, or -C2-Cealkynyl.

[00114] In some embodiments of the compound of Formula I-C, R3 is H. In other embodiments of the compound of Formula I-C, R3 is halo (i.e., -F, -Cl, -Br, or -I), preferably F. In other embodiments of the compounds of Formula I-C, R3 is -Ci-Cealkyl, for example, -Cialkyl, -C2alkyl, -Csalkyl, -C4alkyl, -Csalkyl, -Cealkyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like. In yet other embodiments of the compounds of Formula I-C, R3 is -Ci-Cealkoxy, for example, -Cialkoxy, -C2alkoxy, -Csalkoxy, -C4alkoxy, -Csalkoxy, -Cealkoxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, s-butoxy, t-butox, pentoxy, and the like. In some other embodiments, R3 is -C2-Cealkenyl, preferably -C2-C4alkenyl, for example, vinyl, allyl, and the like. In yet other embodiments, R3 is -C2-Cealkynyl, preferably -C2-C4alkynyl, for example, ethynyl, propargyl, and the like.

[00115] According to the disclosure, Z in Formula I is O, CH2, or CF2. , In some embodiments, Z is O, and the compounds of Formula I are of the Formula I-D: 2024204264   21 Jun 2024 R1

[00116] Formula I-E: In other embodiments, Z is CH2, and the compounds of Formula I are of the R1

[00117] Formula I-F: In yet other embodiments, Z is CF2, and the compounds of Formula I are of the 2024204264   21 Jun 2024 R1

[00118] In some embodiments, Ar in the compounds of Formula I is an optionally substituted 6-membered aryl ring, or an optionally substituted 6-membered heteroaryl ring, and the compounds of Formula I are of the Formula I-G: wherein Q1, Q2, Q3, and Q4 are each independently selected from CH, C-R8, or N; and R8 is halo, Ci-Cealkyl, Ci-Cehaloalkyl, Ci-Cealkoxy, or Ci-Cehaloalkoxy. 2024204264   21 Jun 2024

[00119] Thus, in some embodiments of compounds of Formula I-G, R8is halo (e.g., -F, -Cl, -Br, -I), preferably -F or -Cl. In other embodiments of compounds of Formula I-G, R8 is Ci-Cealkyl, for example, -Cialkyl, -C2alkyl, -Csalkyl, -C4alkyl, -Csalkyl, -Cealkyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like.

[00120] In other embodiments of compounds of Formula I-G, R8is Ci-Cehaloalkyl, for example, -Cihaloalkyl, -C2haloalkyl, -Cshaloalkyl, -Cdialoalkyl, -Cshaloalkyl, -Cehaloalkyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl, fluoropentyl, chloromethyl, chloroethyl, chloropropyl, chlorobutyl, chloropentyl, bromomethyl, bromoethyl, bromopropyl, bromobutyl, bromopentyl, iodomethyl, iodoethyl, iodopropyl, iodobutyl, iodopentyl, and the like.

[00121] In other embodiments of compounds of Formula I-G, R8is is -Ci-Cealkoxy, for example, -Cialkoxy, -C2alkoxy, -Csalkoxy, -C4alkoxy, -Csalkoxy, -Cealkoxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, s-butoxy, t-butox, pentoxy, and the like.

[00122] In other embodiments of compounds of Formula I-G, R8is is -Ci-Cehaloalkoxy, for example, -Cihaloalkoxy, -C2haloalkoxy, -Cshaloalkoxy, -C4haloalkoxy, -Cshaloalkoxy, -Cehaloalkoxy, halomethoxy, haloethoxy, halopropoxy, haloisopropoxy, halobutoxy, haloisobutoxy, halo-s-butoxy, halo-t-butoxy, halopentoxy, and the like.

[00123] In other embodiments, Ar is a 5-membered heteroaryl group, and the compounds of Formula I are of the Formula I-H: 2024204264   21 Jun 2024 wherein Q5 and Q6 are CH, C-R8, or N, and Q7 is NH, N(Ci-Cealkyl), S, O, or, when at least one of Q5 and Q6 is N, Q7 may be CH2 or CH-R8; and wherein and R8 is halo, Ci-Cealkyl, Ci-Cehaloalkyl, Ci-Cealkoxy, or Ci-Cehaloalkoxy.

[00124] It will be apparent that when Q7 is NH, CH2, or CH-R8, then the 5-membered heteroaryl group in compounds of Formula I-H may exist in tautomeric forms. All such tautomeric forms are encompassed by the present disclosure.

[00125] Thus, in some embodiments of compounds of Formula I-H, R8is halo (e.g., -F, -Cl, -Br, -I), preferably -F or -Cl. In other embodiments of compounds of Formula I-H, R8 is Ci-Cealkyl, for example, -Cialkyl, -C2alkyl, -Csalkyl, -C4alkyl, -Csalkyl, -Cealkyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like.

[00126] In other embodiments of compounds of Formula I-H, R8is Ci-Cehaloalkyl, for example, -Cihaloalkyl, -C2haloalkyl, -Cshaloalkyl, -Cdialoalkyl, -Cshaloalkyl, -Cehaloalkyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl, fluoropentyl, chloromethyl, chloroethyl, chloropropyl, chlorobutyl, chloropentyl, bromomethyl, bromoethyl, bromopropyl, bromobutyl, bromopentyl, iodomethyl, iodoethyl, iodopropyl, iodobutyl, iodopentyl, and the like.

[00127] In other embodiments of compounds of Formula I-H, R8is is -Ci-Cealkoxy, for example, -Cialkoxy, -C2alkoxy, -Csalkoxy, -C4alkoxy, -Csalkoxy, -Cealkoxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, s-butoxy, t-butox, pentoxy, and the like.

[00128] In other embodiments of compounds of Formula I-H, R8is is -Ci-Cehaloalkoxy, for example, -Cihaloalkoxy, -C2haloalkoxy, -Cshaloalkoxy, -C4haloalkoxy, -Cshaloalkoxy, -Cehaloalkoxy, halomethoxy, haloethoxy, halopropoxy, haloisopropoxy, halobutoxy, haloisobutoxy, halo-s-butoxy, halo-t-butoxy, halopentoxy, and the like.

[00129] In other embodiments, Ar is a 5-membered heteroaryl group, and the compounds of Formula I are of the Formula I-I: 2024204264   21 Jun 2024 wherein Q8 and Q10 are CH, C-R8, or N, and Q9 is NH, N(Ci-Cealkyl), S, O, or, when at least one of Q8 and Q10 is N, Q9 may be CH2 or CH-R8; and wherein R8 is halo, Ci-Cealkyl, Ci-Cehaloalkyl, Ci-Cealkoxy, or Ci-Cehaloalkoxy.

[00130] It will be apparent that when Q9 is NH, CH2, or CH-R8, then the 5-membered heteroaryl group in compounds of Formula I-I may exist in tautomeric forms. All such tautomeric forms are encompassed by the present disclosure.

[00131] Thus, in some embodiments of compounds of Formula I-I, R8is halo (e.g., -F, -Cl, -Br, -I), preferably -F or -Cl. In other embodiments of compounds of Formula I-I, R8is Ci-Cealkyl, for example, -Cialkyl, -C2alkyl, -Csalkyl, -C4alkyl, -Csalkyl, -Cealkyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like.

[00132] In other embodiments of compounds of Formula I-I, R8is Ci-Cehaloalkyl, for example, -Cihaloalkyl, -C2haloalkyl, -Cshaloalkyl, -Cdialoalkyl, -Cshaloalkyl, -Cehaloalkyl, fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl, fluoropentyl, chloromethyl, chloroethyl, chloropropyl, chlorobutyl, chloropentyl, bromomethyl, bromoethyl, bromopropyl, bromobutyl, bromopentyl, iodomethyl, iodoethyl, iodopropyl, iodobutyl, iodopentyl, and the like.

[00133] In other embodiments of compounds of Formula I-I, R8is is -Ci-Cealkoxy, for example, -Cialkoxy, -C2alkoxy, -Csalkoxy, -C4alkoxy, -Csalkoxy, -Cealkoxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, s-butoxy, t-butox, pentoxy, and the like. 2024204264   21 Jun 2024

[00134] In other embodiments of compounds of Formula I-I, R8is is -Ci-Cehaloalkoxy, for example, -Cihaloalkoxy, -C2haloalkoxy, -Cshaloalkoxy, -C4haloalkoxy, -Cshaloalkoxy, -Cehaloalkoxy, halomethoxy, haloethoxy, halopropoxy, haloisopropoxy, halobutoxy, haloisobutoxy, halo-s-butoxy, halo-t-butoxy, halopentoxy, and the like.

[00135] In yet other embodiments, Ar is a 5-membered heteroaryl group, and the compounds of Formula I are of the Formula I-J: wherein Q12 and Q13 are CH, C-R8, or N, and Q11 is NH, N(Ci-Cealkyl), S, O, or, when at least one of Q12 and Q13 is N, Q11 may be CH2 or CH-R8; and wherein R8 is halo, Ci-Cealkyl, Ci-Cehaloalkyl, Ci-Cealkoxy, or Ci-Cehaloalkoxy.

[00136] It will be apparent that when Q11 is NH, CH2, or CH-R8, then the 5-membered heteroaryl group in compounds of Formula I-J may exist in tautomeric forms. All such tautomeric forms are encompassed by the present disclosure.

[00137] Thus, in some embodiments of compounds of Formula I-J, R8is halo (e.g., -F, -Cl, -Br, -I), preferably -F or -Cl. In other embodiments of compounds of Formula I-J, R8 is Ci-Cealkyl, for example, -Cialkyl, -C2alkyl, -Csalkyl, -C4alkyl, -Csalkyl, -Cealkyl, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, s-butyl, t-butyl, pentyl, and the like.

[00138] In other embodiments of compounds of Formula I-J, R8is Ci-Cehaloalkyl, for example, -Cihaloalkyl, -C2haloalkyl, -Cshaloalkyl, -C4haloalkylj -Cshaloalkyl, -Cehaloalkyl, 2024204264   21 Jun 2024 fluoromethyl, fluoroethyl, fluoropropyl, fluorobutyl, fluoropentyl, chloromethyl, chloroethyl, chloropropyl, chlorobutyl, chloropentyl, bromomethyl, bromoethyl, bromopropyl, bromobutyl, bromopentyl, iodomethyl, iodoethyl, iodopropyl, iodobutyl, iodopentyl, and the like.

[00139] In other embodiments of compounds of Formula I-J, R8is is -Ci-Cealkoxy, for example, -Cialkoxy, -C2alkoxy, -C3alkoxy, -C4alkoxy, -Csalkoxy, -Cealkoxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, s-butoxy, t-butox, pentoxy, and the like.

[00140] In other embodiments of compounds of Formula I-J, R8is is -Ci-Cehaloalkoxy, for example, -Cihaloalkoxy, -C2haloalkoxy, -C3haloalkoxy, -C4haloalkoxy, -Cshaloalkoxy, -Cehaloalkoxy, halomethoxy, haloethoxy, halopropoxy, haloisopropoxy, halobutoxy, haloisobutoxy, halo-s-butoxy, halo-t-butoxy, halopentoxy, and the like.

[00141] In some embodiments, compounds of formula I-J are those wherein A is C-H; R2 is H, R3 is -NH2 or -CH3; R4 = R5 = H; X = Z = O; Y = -CH2CH2-; Q11 is S, Q13 is CH, and Q12 is C-R8, wherein R8 is halogen.

[00142] Some preferred embodiments of the compounds of Formula I are compounds of Formula I-A: or a pharmaceutically acceptable salt, or solvate thereof; wherein A is N or C-R3; R1 is halo, NH2, -Ci-Cealkyl, -Ci-Cealkoxy, or -Ci-Cealk-O-Ci-Cealkyl; 2024204264   21 Jun 2024 R2 is H, halo, -Ci-Cealkyl, or NH2; R3 is H, halo, -Ci-Cealkyl, or -Ci-Cealkoxy; R4 is H or -Ci-Cealkyl; R5 is H or -Ci-Cealkyl; X is O, S, NH, or N(Ci-Cealkyl); and Y is CH2, -CH2CH2-, C(CH3)2, CF2, C(=O), or CH-Ci- C4alk-NH2; or X is SO2; and Y is CH2, -CH2CH2-, C(CH3)2, CF2, or CH-Ci-C4alk-NH2; Z is O, CH2, or CF2; and Ar is an optionally substituted 6-membered aryl ring, an optionally substituted 6-membered heteroaryl ring, or an optionally substituted 5-membered heteroaryl ring.

[00143] Other preferred embodiments of the compounds of Formula I are compounds of Formula I-A, or a pharmaceutically acceptable salt, or solvate thereof; wherein A is N or C-R3; R1 is halo, NH2, -Ci-Cealkyl, -Ci-Cealkoxy, or -Ci-Cealk-O-Ci-Cealkyl; R2 is H, halo, -Ci-Cealkyl, or NH2; R3 is H, halo, -Ci-Cealkyl, or -Ci-Cealkoxy; R4 is H or -Ci-Cealkyl; R5 is H or -Ci-Cealkyl; X is O, S, NH, or N(Ci-Cealkyl); Y is -C(=O)-(CR9R9 )n-, wherein n = 1 or 2, each R9 and R9 is H; Z is O, CH2, or CF2; and Ar is an optionally substituted 6-membered aryl ring, an optionally substituted 6-membered heteroaryl ring, or an optionally substituted 5-membered heteroaryl ring.

[00144] Other preferred embodiments of the compounds of Formula I are compounds of Formula I-A, or a pharmaceutically acceptable salt, or solvate thereof; wherein A is N or C-R3; R1 is halo, NH2, -Ci-Cealkyl, -Ci-Cealkoxy, or -Ci-Cealk-O-Ci-Cealkyl; R2 is H, halo, -Ci-Cealkyl, or NH2; R3 is H, halo, -Ci-Cealkyl, or -Ci-Cealkoxy; 2024204264   21 Jun 2024 R4 is H or -Ci-Cealkyl; R5 is H or -Ci-Cealkyl; X is O, S, SO2, NH, or N(Ci-C6alkyl); Y is -CR9=CR9’-, each R9 and R9 is H; Z is O, CH2, or CF2; and Ar is an optionally substituted 6-membered aryl ring, an optionally substituted 6-membered heteroaryl ring, or an optionally substituted 5-membered heteroaryl ring.

[00145] Other preferred embodiments of the compounds of Formula I are compounds of Formula I-A, or a pharmaceutically acceptable salt, or solvate thereof; wherein A is N or C-R3; R1 is halo, NH2, -Ci-Cealkyl, -Ci-Cealkoxy, or -Ci-Cealk-O-Ci-Cealkyl; R2 is H, halo, -Ci-Cealkyl, or NH2; R3 is H, halo, -Ci-Cealkyl, or -Ci-Cealkoxy; R4 is H or -Ci-Cealkyl; R5 is H or -Ci-Cealkyl; X is O, S, NH, or N(Ci-Cealkyl); Y is -C(=O)-O-(CR9R9 )n- wherein n = 1 or 2 and each R9 and R9 is H; Z is O, CH2, or CF2; and Ar is an optionally substituted 6-membered aryl ring, an optionally substituted 6-membered heteroaryl ring, or an optionally substituted 5-membered heteroaryl ring.

[00146] Other preferred embodiments of the compounds of Formula I are compounds of Formula I-A-l: 2024204264   21 Jun 2024 or a pharmaceutically acceptable salt, or solvate thereof; wherein A is N or C-R3; R1 is halo, NH2, -Ci-Cealkyl, -Ci-Cealkoxy, or -Ci-Cealk-O-Ci-Cealkyl; R2 is H, halo, -Ci-Cealkyl, or NH2; R3 is H, halo, -Ci-Cealkyl, or -Ci-Cealkoxy; R4 is H or -Ci-Cealkyl; R5 is H or -Ci-Cealkyl; X is O, S, SO2, NH, or N(Ci-C6alkyl); each R9 is independently selected from H, D, F, OH, OCH3, CH3, or CF3; each R9 is independently selected from H, D, F, OH, OCH3, CH3, or CF3; Z is O, CH2, or CF2; and Ar is an optionally substituted 6-membered aryl ring, an optionally substituted 6-membered heteroaryl ring, or an optionally substituted 5-membered heteroaryl ring.

[00147] Other preferred embodiments of the compounds of Formula I are compounds of Formula I-A-2: 2024204264   21 Jun 2024 or a pharmaceutically acceptable salt, or solvate thereof; wherein A is N or C-R3; R1 is halo, NH2, -Ci-Cealkyl, -Ci-Cealkoxy, or -Ci-Cealk-O-Ci-Cealkyl; R2 is H, halo, -Ci-Cealkyl, or NH2; R3 is H, halo, -Ci-Cealkyl, or -Ci-Cealkoxy; R4 is H or -Ci-Cealkyl; R5 is H or -Ci-Cealkyl; X is O, S, SO2, NH, or N(Ci-C6alkyl); each R9 is independently selected from H, D, or F; each R9 is independently selected from H, D, or F; Z is O, CH2, or CF2; and Ar is an optionally substituted 6-membered aryl ring, an optionally substituted 6-membered heteroaryl ring, or an optionally substituted 5-membered heteroaryl ring.

[00148] In some preferred embodiments, the compounds of Formula I-A-2 are those wherein A is C-R3; R1 is -NH2 or -CH3; R2 = R3 = R4 = R5 = R9 = R9 = H; Z is O; X is O; and Ar is a phenyl ring substituted with 1-2 halogen atoms.

[00149] Other preferred embodiments of the compounds of Formula I are compounds of Formula I-A-3: 2024204264   21 Jun 2024 or a pharmaceutically acceptable salt, or solvate thereof; wherein A is N or C-R3; R1 is halo, NH2, -Ci-Cealkyl, -Ci-Cealkoxy, or -Ci-Cealk-O-Ci-Cealkyl; R2 is H, halo, -Ci-Cealkyl, or NH2; R3 is H, halo, -Ci-Cealkyl, or -Ci-Cealkoxy; R4 is H or -Ci-Cealkyl; R5 is H or -Ci-Cealkyl; X is O, S, SO2, NH, or N(Ci-C6alkyl); R9 is selected from H, D, or F; R9 is selected from H, D, or F; Z is O, CH2, or CF2; and Ar is an optionally substituted 6-membered aryl ring, an optionally substituted 6-membered heteroaryl ring, or an optionally substituted 5-membered heteroaryl ring.

[00150] In some preferred embodiments, the compounds of Formula I-A-3 are those wherein A is C-R3; R1 is -NH2 or -CH3; R2 = R3 = R4 = R5 = R9 = R9 = H; Z is O; X is O; and Ar is a phenyl ring substituted with 1-2 halogen atoms.

[00151] Other preferred embodiments of the compounds of Formula I are compounds of Formula I-A-4: 2024204264   21 Jun 2024 or a pharmaceutically acceptable salt, or solvate thereof; wherein A is N or C-R3; R1 is halo, NH2, -Ci-Cealkyl, -Ci-Cealkoxy, or -Ci-Cealk-O-Ci-Cealkyl; R2 is H, halo, -Ci-Cealkyl, or NH2; R3 is H, halo, -Ci-Cealkyl, or -Ci-Cealkoxy; R4 is H or -Ci-Cealkyl; R5 is H or -Ci-Cealkyl; X is O, S, SO2, NH, or N(Ci-C6alkyl); R9 is selected from H, D, or F; R9 is selected from H, D, or F; Z is O, CH2, or CF2; and Ar is an optionally substituted 6-membered aryl ring, an optionally substituted 6-membered heteroaryl ring, or an optionally substituted 5-membered heteroaryl ring.

[00152] In other preferred embodiments, the compounds of the disclosure are compounds of Formula I-G-l 2024204264   21 Jun 2024 wherein R1 is NH2, -Ci-Cealkyl, or -Ci-Cealk-O-Ci-Cealkyl; R3 is H or halo; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is halo, -Cihaloalkyl, or Cihaloalkoxy.

[00153] In some preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is NH2 -CH3, or -CH2-O-CH2CH3; R3 is H or F; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00154] In other preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. In some preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein at least one of Q1, Q2, Q3, and Q4 is C-R8, and wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00155] In other preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. In some preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein at least one of Q1, Q2, Q3, and Q4 is C-R8, and wherein R8 is -F, -Cl, -CF3, or -OCF3. 2024204264   21 Jun 2024

[00156] In other preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. In other preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00157] In other preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl. In some preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein at least one of Q1, Q2, Q3, and Q4 is C-R8, and wherein R8 is -F or -Cl.

[00158] In other preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl. In some preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein at least one of Q1, Q2, Q3, and Q4 is C-R8, and wherein R8 is -F or -Cl.

[00159] In other preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-l are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl.

[00160] In other preferred embodiments, the compounds of the disclosure are compounds of Formula I-G-2: 2024204264   21 Jun 2024 wherein R1 is NH2 or -Ci-Cealkyl; R3 is H or halo; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is halo, -Cihaloalkyl, or Cihaloalkoxy.

[00161] In some preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is NH2 or -CH3; R3 is H or F; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00162] In other preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. In some preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein at least one of Q1, Q2, Q3, and Q4 is C-R8, and wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00163] In other preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. In some preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein at least one of Q1, Q2, Q3, and Q4 is C-R8, and wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00164] In other preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C- 2024204264   21 Jun 2024 R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl.

[00165] In other preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl. In some preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein at least one of Q1, Q2, Q3, and Q4 is C-R8, and wherein R8 is -F or -Cl.

[00166] In other preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl. In some preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein at least one of Q1, Q2, Q3, and Q4 is C-R8, and wherein R8 is -F or -Cl.

[00167] In other preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is NH2; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl.

[00168] In other preferred embodiments, the compounds of formula I-G-2 are those wherein wherein R1 is NH2, -Ci-Cealkyl, or -Ci-Cealk-O-Ci-Cealkyl; R3 is H or halo; Y is -(CR9R9 )n-, -CR9=CR9’-, C(=O), -C(=O)-(CR9R9 )n-, -C(=O)-O-(CR9R9 )n-, -CR9R9’-O, -(CR9R9’)n-O-(CR9R9’)m-, -(CR9R9 )n-NR10-, -C(=O)NR10-; n = 1 or 2; m = 1 or 2; R9 and R9 are each independently H, D, CH3, CF3, OH, OCH3, or F; R10 is H or Ci-Cealkyl; each and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is halo, -Cihaloalkyl, or Cihaloalkoxy.

[00169] In some preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is NH2 or -CH3; R3 is H or F; Y is -CH2CH2-, -CH2CH(Ci-C6alkoxy)-, -CH2CH(OCH3)-, -CH(OH)CH2-, -CH(Ci-C6alkyl)CH2-, -CH(CH3)CH2-, -CH2C(Ci-C6alkyl)2-, -CH2C(CH3)2-, -CH(Ci-C6haloalkyl)CH2-, -CH2 CH(CF3)-, -CH2CHF-, -CH2CF2-, -CH2CD2, -CH=CH-, -C(=O)-CH2-, -C(=O)-O-CH2-, -C(=O)-O-CH2CH2-, -CH2-0-, -CF2-0-, -CH2-0-CH2-, -CF2-0-CH2-, -CH2-O-CH2CH2-, -CF2-O-CH2CH2-; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. 2024204264   21 Jun 2024

[00170] In other preferred embodiments, the compounds of Formula I-G-2 are those wherein R1 is NH2 or -CH3; R3 is H; Y is -CH2CH2-, -CH(OCH3)CH2 -, -CH(OH)CH2 -, -CH2CH(CH3)-, -CH2C(Ci-C6alkyl)2-, -CH2C(CH3)2 -, -CH2CH(CF3)-, -CH2CHF-, -CH2CF2-, -CH2CD2-, -CH=CH-, -C(=O)CH2-, -C(=O)-O-CH2-, -C(=O)-O-CH2CH2-, -CH2-O-, -CF2-O-, -CH2-O-CH2-, -CF2-O-CH2-, -CH2-O-CH2CH2-, -CF2-O-CH2CH2-; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl.

[00171] In some preferred embodiments, the compounds of the disclosure are compounds of Formula I-G-3 wherein R1 is NH2, -Ci-Cealkyl, or -Ci-Cealk-O-Ci-Cealkyl; R3 is H or halo; Y is -CH2CH2-, C(CH3)2, CF2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is halo, -Cihaloalkyl, or Cihaloalkoxy.

[00172] In some preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2 -CH3, or -CH2-O-CH2CH3; R3 is H or F; Y is -CH2CH2-, C(CH3)2, CF2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00173] In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2; R3 is H; Y is -CH2CH2-, C(CH3)2, CF2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is -CH3; R3 is H; Y is 2024204264   21 Jun 2024 -CH2CH2-, C(CH3)2, CF2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00174] In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2; R3 is H; Y is -CH2CH2-, C(CH3)2, CF2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is -CH3; R3 is H; Y is -CH2CH2-, C(CH3)2, CF2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00175] In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2; R3 is H; Y is -CH2CH2-, C(CH3)2, CF2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is -CH3; R3 is H; Y is -CH2CH2-, C(CH3)2, CF2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl.

[00176] In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2; R3 is H; Y is -CH2CH2-, C(CH3)2, CF2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is -CH3; R3 is H; Y is -CH2CH2-, C(CH3)2, CF2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl.

[00177] In other preferred embodiments, the compounds of formula I-G-3 are those wherein wherein R1 is NH2, -Ci-Cealkyl, or -Ci-Cealk-O-Ci-Cealkyl; R3 is H or halo; Y is -(CR9R9 )n-, -CR9=CR9’-, -C(=O)-(CR9R9 )n-, -C(=O)-O-(CR9R9 )n-, -CR9R9’-O, -(CR9R9’)n-O-(CR9R9’)m-, n = 1 or 2, R9 and R9 are each independently H, D, CH3, CF3, OH, OCH3, of F; each and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is halo, -Cihaloalkyl, or Cihaloalkoxy.

[00178] In some preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2 or -CH3; R3 is H or F; Y is -CH2CH2-, -CH2CH(Ci-C6alkoxy)-, -CH2CH(OCH3)-, -CH(OH)CH2-, -CH(Ci-C6alkyl)CH2-, -CH(CH3)CH2-, -CH2C(Ci-C6alkyl)2-, -CH2C(CH3)2-, -CH(Ci-C6haloalkyl)CH2-, -CH2 CH(CF3)-, -CH2CHF-, -CH2CF2-, -CH2CD2, -CH=CH-, -C(=O)-CH2-, -C(=O)-O-CH2-, -C(=O)-O-CH2CH2-, -CH2-0-, -CF2-0-, -CH2-0-CH2-, -CF2-0-CH2-, -CH2- 2024204264   21 Jun 2024 O-CH2CH2-, -CF2-O-CH2CH2-, and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00179] In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2 or -CH3; R3 is H; Y is -CH2CH2-, -CH(OCH3)CH2 -, -CH(OH)CH2 -, -CH2CH(CH3)-, -CH2C(Ci-C6alkyl)2-, -CH2C(CH3)2-, -CH2CH(CF3)-, -CH2CHF-, -CH2CF2-, -CH2CD2-, -CH=CH-, -C(=O)CH2-, -C(=O)-O-CH2-, -C(=O)-O-CH2CH2-, -CH2-O-, -CF2-O-, -CH2-O-CH2-, -CF2-O-CH2-, -CH2-O-CH2CH2-, -CF2-O-CH2CH2-; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl.

[00180] In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2, -CH3, or -CD3; R3 is H or F; Y is -CH2CH2-, -CH2CH2CH2-, -C(=O)CH2-, or -CH2CHF-; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, or -CH3.

[00181] In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2, -CH3, or -CD3; R3 is H or F; Y is -CH2CH2-, -CH2CH2CH2-, -C(=O)CH2-, or -CH2CHF-; and Q1, Q2, and Q4 are each independently selected from CH or C-R8, wherein R8 is -F, -Cl, or -CH3; and Q3 is C-R8, wherein R8 is -Cl.

[00182] In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2, or -CH3; R3 is H; Y is -CH2CH2-, -CH2CH2CH2-, -C(=O)CH2-, or -CH2CHF-; and Q1, Q2, and Q4 are each independently selected from CH or C-R8, wherein R8 is -F, -Cl, or -CH3; and Q3 is C-R8, wherein R8 is -Cl.

[00183] In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2, -CH3, or -CD3; R3 is H or F; Y is -CH2CH2-, -CH2CH2CH2-, -C(=O)CH2-, or -CH2CHF-; and Q1 is CH; Q2 and Q4 are each independently selected from CH or C-R8, wherein R8 is -F, -Cl, or -CH3; and Q3 is C-R8, wherein R8 is -Cl.

[00184] In other preferred embodiments, the compounds of Formula I-G-3 are those wherein R1 is NH2, or -CH3; R3 is H; Y is -CH2CH2-, -CH2CH2CH2-, -C(=O)CH2-, or -CH2CHF-; and Q1 is CH; Q2, and Q4 are each independently selected from CH or C-R8, wherein R8 is -F, -Cl, or -CH3; and Q3 is C-R8, wherein R8 is -Cl.

[00185] In some preferred embodiments, the compounds of the disclosure are compounds of Formula I-G-4 2024204264   21 Jun 2024 wherein R1 is NH2, -Ci-Cealkyl, or -Ci-Cealk-O-Ci-Cealkyl; R3 is H or halo; X is S, NH, or N(Ci-Cealkyl); Y is CH2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is halo, -Cihaloalkyl, or Cihaloalkoxy.

[00186] In some preferred embodiments, the compounds of Formula I-G-4 are those wherein R1 is NH2 -CH3, or -CH2-O-CH2CH3; R3 is H or F; X is S, NH, or N(Ci-Cealkyl); Y is CH2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is-F, -Cl, -CF3, or -OCF3.

[00187] In other preferred embodiments, the compounds of Formula I-G-4 are those wherein R1 is NH2; R3 is H; X is S, SO2, NH, or N(Ci-Cealkyl); Y is CH2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. In other preferred embodiments, the compounds of Formula I-G-4 are those wherein R1 is -CH3; R3 is H; X is S, NH, or N(Ci-Cealkyl); Y is CH2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00188] In other preferred embodiments, the compounds of Formula I-G-4 are those wherein R1 is NH2; R3 is H; X is S, NH, or N(Ci-Cealkyl); Y is CH2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. In other preferred embodiments, the compounds of Formula I-G-4 are those wherein R1 is -CH3; R3 is H; X is S, NH, or N(Ci-Cealkyl); Y is CH2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. 2024204264   21 Jun 2024

[00189] In other preferred embodiments, the compounds of Formula I-G-4 are those wherein R1 is NH2; R3 is H; X is S, NH, or N(Ci-Cealkyl); Y is CH2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-4 are those wherein R1 is -CH3; R3 is H; X is S, NH, or N(Ci-Cealkyl); Y is CH2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl.

[00190] In other preferred embodiments, the compounds of Formula I-G-4 are those wherein R1 is NH2; R3 is H; X is S, NH, or N(Ci-Cealkyl); Y is CH2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-4 are those wherein R1 is -CH3; R3 is H; X is S, NH, or N(Ci-Cealkyl); Y is CH2, or C(=O); and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl.

[00191] In some preferred embodiments, the compounds of Formula I-G-4 are those wherein R1 is NH2 or CH3; R3 is H; X is NH; Y is -CH2CH2-; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl.

[00192] In some preferred embodiments, the compounds of the disclosure are compounds of Formula I-G-5 wherein R1 is NH2, or -Ci-Cealkyl, Y is -CH2- or C(=O); and Q1, Q2, Q3, and Q4 are each independently N, CH, or C-R8, wherein R8 is halo. 2024204264   21 Jun 2024

[00193] In some preferred embodiments, the compounds of Formula I-G-5 are those wherein R1 is NH2, Y is -CH2-; and Q1, Q2, Q3, and Q4 are each independently CH, or C-R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-5 are those wherein R1 is -CH3, Y is -CH2-; and Q1, Q2, Q3, and Q4 are each independently CH, or C-R8, wherein R8 is -F or-Cl.

[00194] In some preferred embodiments, the compounds of Formula I-G-5 are those wherein R1 is NH2, Y is C(=O); and Q1, Q2, Q3, and Q4 are each independently CH, or C-R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-5 are those wherein R1 is -CH3, Y is C(=O); and Q1, Q2, Q3, and Q4 are each independently CH, or C-R8, wherein R8 is -F or-Cl.

[00195] In some preferred embodiments, the compounds of the disclosure are compounds of Formula I-G-6 wherein R1 is NH2, or -Ci-Cealkyl; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is halo, -Cihaloalkyl, or Cihaloalkoxy.

[00196] In some preferred embodiments, the compounds of Formula I-G-6 are those wherein R1 is NH2, or-CH3, and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00197] In other preferred embodiments, the compounds of Formula I-G-6 are those wherein R1 is NH2; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, 2024204264   21 Jun 2024 wherein R8 is -F, -Cl, -CF3, or -OCF3. In other preferred embodiments, the compounds of Formula I-G-6 are those wherein R1 is -CH3; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00198] In other preferred embodiments, the compounds of Formula I-G-6 are those wherein R1 is NH2; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3. In other preferred embodiments, the compounds of Formula I-G-6 are those wherein R1 is -CH3; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F, -Cl, -CF3, or -OCF3.

[00199] In other preferred embodiments, the compounds of Formula I-G-6 are those wherein R1 is NH2; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-6 are those wherein R1 is -CH3; and Q1, Q2, Q3, and Q4 are each independently selected from N, CH, or C-R8, wherein R8 is -F or -Cl.

[00200] In other preferred embodiments, the compounds of Formula I-G-6 are those wherein R1 is NH2; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl. In other preferred embodiments, the compounds of Formula I-G-6 are those wherein R1 is -CH3; R3 is H; and Q1, Q2, Q3, and Q4 are each independently selected from CH, or C-R8, wherein R8 is -F or -Cl.

[00201] In other aspects, the disclosure is directed to compounds of Formula I-H-l: 2024204264   21 Jun 2024 wherein R1 is NH2 or Ci-Cealkyl; Q5 and Q6 are independently CH, C-R8, or N, and Q7 is NH, or S, and R8 is halo, Ci-Cealkyl, Ci-Cehaloalkyl, Ci-Cealkoxy, or Ci-Cehaloalkoxy. In preferred embodiments, compounds of Formula I-H-l are those wherein R1 is NH2; Q5 and Q6 are independently CH, C-R8, or N, Q7 is NH, or S; and R8 is -F or -Cl. In other preferred embodiments, compounds of Formula I-H-l are those wherein R1 is -CH3; Q5 and Q6 are independently CH, C-R8, or N, Q7 is NH, or S; and R8 is -F or -Cl.

[00202] In other aspects, the disclosure is directed to compounds Formula I-I-1: 2024204264   21 Jun 2024 wherein R1 is NH2 or Ci-Cealkyl; Q8 and Q10 are independently CH, C-R8, or N, and Q9 is N(Ci-Cealkyl), and R8 is halo, Ci-Cealkyl, Ci-Cehaloalkyl, Ci-Cealkoxy, or Ci-Cehaloalkoxy. In preferred embodiments, compounds of Formula I-I-1 are those wherein R1 is NH2; Q8 and Q10 are independently CH, C-R8, or N, and Q9 is N(CH3), and R8 is -F, or -Cl. In other preferred embodiments, compounds of Formula I-I-1 are those wherein R1 is -CH3; Q8 and Q10 are independently CH, C-R8, orN; Q9isN(CH3), and R8 is -F, or-Cl.

[00203] References to compounds of Formula I herein also refer to all subgenera described herein, including, for example, compounds of Formula I-A, LA-1, I-A-2,1-A-3,1-A-4,1-B, I-C, I-D, I-E, I-F, LG, LG-1,LG-2, LG-3, LG-4, LG-5, LG-6, LH, LH-1, LI, LL1, and LJ.

[00204] It will be apparent that the compounds of Formula I, including all subgenera described herein, have multiple stereogenic centers. As a result, there exist multiple stereoisomers (enantiomers and diastereomers) of the compounds of Formula I (subgenera described herein). The present disclosure contemplates and encompasses each stereoisomer of any compound of Formula I (and subgenera described herein), as well as mixtures of said stereoisomers.

[00205] Pharmaceutically acceptable salts and solvates of the compounds of Formula I (including all subgenera described herein) are also within the scope of the disclosure.

[00206] Isotopic variants of the compounds of Formula I (including all subgenera described herein) are also contemplated by the present disclosure. 2024204264   21 Jun 2024 Pharmaceutical compositions and methods of administration

[00207] The subject pharmaceutical compositions are typically formulated to provide a therapeutically effective amount of a compound of the present disclosure as the active ingredient, or a pharmaceutically acceptable salt, ester, prodrug, solvate, hydrate or derivative thereof. Where desired, the pharmaceutical compositions contain pharmaceutically acceptable salt and / or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.

[00208] The subject pharmaceutical compositions can be administered alone or in combination with one or more other agents, which are also typically administered in the form of pharmaceutical compositions. Where desired, the one or more compounds of the invention and other agent(s) may be mixed into a preparation or both components may be formulated into separate preparations to use them in combination separately or at the same time.

[00209] In some embodiments, the concentration of one or more compounds provided in the pharmaceutical compositions of the present invention is less than 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w / w, w / v or v / v.

[00210] In some embodiments, the concentration of one or more compounds of the invention is greater than 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25% 14%, 13.75%, 13.50%, 13.25%, 13%, 12.75%, 12.50%, 12.25%, 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25%, 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25%, 7%, 6.75%, 6.50%, 6.25%, 6%, 5.75%, 5.50%, 5.25%, 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 1.25% , 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 2024204264   21 Jun 2024 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% (or a number in the range defined by and including any two numbers above) w / w, w / v, or v / v.

[00211] In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40%, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, approximately 0.08% to approximately 23%, approximately 0.09% to approximately 22%, approximately 0.1% to approximately 21%, approximately 0.2% to approximately 20%, approximately 0.3% to approximately 19%, approximately 0.4% to approximately 18%, approximately 0.5% to approximately 17%, approximately 0.6% to approximately 16%, approximately 0.7% to approximately 15%, approximately 0.8% to approximately 14%, approximately 0.9% to approximately 12%, approximately 1% to approximately 10% w / w, w / v or v / v.

[00212] In some embodiments, the concentration of one or more compounds of the invention is in the range from approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, approximately 0.1% to approximately 0.9% w / w, w / v or v / v.

[00213] In some embodiments, the amount of one or more compounds of the invention is equal to or less than 10 g, 9.5 g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g, 4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g, 0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35 g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g, 0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006 g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g, 0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 g (or a number in the range defined by and including any two numbers above).

[00214] In some embodiments, the amount of one or more compounds of the invention is more than 0.0001 g, 0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g, 0.0009 g, 2024204264   21 Jun 2024 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004 g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g, 0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g, 0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07 g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g,, 0.15 g, 0.2 g,, 0.25 g, 0.3 g,, 0.35 g, 0.4 g,, 0.45 g, 0.5 g, 0.55 g, 0.6 g,, 0.65 g, 0.7 g, 0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4 g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5g, 7 g, 7.5g, 8 g, 8.5 g, 9 g, 9.5 g, or 10 g (or a number in the range defined by and including any two numbers above).

[00215] In some embodiments, the amount of one or more compounds of the invention is in the range of 0.0001-10 g, 0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g, or 1-3 g.

[00216] The compounds according to the invention are effective over a wide dosage range. For example, in the treatment of adult humans, dosages from 0.01 to 1000 mg, from 0.5 to 100 mg, from 1 to 50 mg per day, and from 5 to 40 mg per day are examples of dosages that may be used. An exemplary dosage is 10 to 30 mg per day. The exact dosage will depend upon the route of administration, the form in which the compound is administered, the subject to be treated, the body weight of the subject to be treated, and the preference and experience of the attending physician.

[00217] A pharmaceutical composition of the invention typically contains an active ingredient (i.e., a compound of the disclosure) of the present invention or a pharmaceutically acceptable salt and / or coordination complex thereof, and one or more pharmaceutically acceptable excipients, carriers, including but not limited to inert solid diluents and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.

[00218] Described below are non- limiting exemplary pharmaceutical compositions and methods for preparing the same. Pharmaceutical compositions for oral administration.

[00219] In some embodiments, the invention provides a pharmaceutical composition for oral administration containing a compound of the invention, and a pharmaceutical excipient suitable for oral administration.

[00220] In some embodiments, the invention provides a solid pharmaceutical composition for oral administration containing: (i) an effective amount of a compound of the invention; optionally (ii) an effective amount of a second agent; and (iii) a pharmaceutical excipient suitable 2024204264   21 Jun 2024 for oral administration. In some embodiments, the composition further contains: (iv) an effective amount of a third agent.

[00221] In some embodiments, the pharmaceutical composition may be a liquid pharmaceutical composition suitable for oral consumption. Pharmaceutical compositions of the invention suitable for oral administration can be presented as discrete dosage forms, such as capsules, cachets, or tablets, or liquids or aerosol sprays each containing a predetermined amount of an active ingredient as a powder or in granules, a solution, or a suspension in an aqueous or nonaqueous liquid, an oil-in- water emulsion, or a water-in-oil liquid emulsion. Such dosage forms can be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier, which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet can be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free- flowing form such as powder or granules, optionally mixed with an excipient such as, but not limited to, a binder, a lubricant, an inert diluent, and / or a surface active or dispersing agent. Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.

[00222] This invention further encompasses anhydrous pharmaceutical compositions and dosage forms comprising an active ingredient, since water can facilitate the degradation of some compounds. For example, water may be added (e.g., 5%) in the pharmaceutical arts as a means of simulating long-term storage in order to determine characteristics such as shelf- life or the stability of formulations over time. Anhydrous pharmaceutical compositions and dosage forms of the invention can be prepared using anhydrous or low moisture containing ingredients and low moisture or low humidity conditions. Pharmaceutical compositions and dosage forms of the invention which contain lactose can be made anhydrous if substantial contact with moisture and / or humidity during manufacturing, packaging, and / or storage is expected. An anhydrous pharmaceutical composition may be prepared and stored such that its anhydrous nature is maintained. Accordingly, anhydrous compositions may be packaged using materials known to prevent exposure to water such that they can be included in suitable formulary kits. Examples of suitable packaging include, but are not 2024204264   21 Jun 2024 limited to, hermetically sealed foils, plastic or the like, unit dose containers, blister packs, and strip packs.

[00223] An active ingredient can be combined in an intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending on the form of preparation desired for administration. In preparing the compositions for an oral dosage form, any of the usual pharmaceutical media can be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions, and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, and disintegrating agents can be used in the case of oral solid preparations, in some embodiments without employing the use of lactose. For example, suitable carriers include powders, capsules, and tablets, with the solid oral preparations. If desired, tablets can be coated by standard aqueous or nonaqueous techniques.

[00224] Binders suitable for use in pharmaceutical compositions and dosage forms include, but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and synthetic gums such as acacia, sodium alginate, alginic acid, other alginates, powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose, cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose), polyvinyl pyrrolidone, methyl cellulose, pregelatinized starch, hydroxypropyl methyl cellulose, microcrystalline cellulose, and mixtures thereof.

[00225] Examples of suitable fillers for use in the pharmaceutical compositions and dosage forms disclosed herein include, but are not limited to, talc, calcium carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose, dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and mixtures thereof.

[00226] Disintegrants may be used in the compositions of the invention to provide tablets that disintegrate when exposed to an aqueous environment. Too much of a disintegrant may produce tablets which may disintegrate in the bottle. Too little may be insufficient for disintegration to occur and may thus alter the rate and extent of release of the active ingredient(s) from the dosage form. Thus, a sufficient amount of disintegrant that is neither too little nor too much to detrimentally alter the release of the active ingredient(s) may be used to form the dosage forms of the compounds disclosed herein. The amount of disintegrant used may vary based upon the type of formulation and 2024204264   21 Jun 2024 mode of administration, and may be readily discernible to those of ordinary skill in the art. About 0.5 to about 15 weight percent of disintegrant, or about 1 to about 5 weight percent of disintegrant, may be used in the pharmaceutical composition. Disintegrants that can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, agaragar, alginic acid, calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone, polacrilin potassium, sodium starch glycolate, potato or tapioca starch, other starches, pre-gelatinized starch, other starches, clays, other algins, other celluloses, gums or mixtures thereof.

[00227] Lubricants which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar, or mixtures thereof. Additional lubricants include, for example, a syloid silica gel, a coagulated aerosol of synthetic silica, or mixtures thereof. A lubricant can optionally be added, in an amount of less than about 1 weight percent of the pharmaceutical composition.

[00228] When aqueous suspensions and / or elixirs are desired for oral administration, the active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and / or suspending agents, together with such diluents as water, ethanol, propylene glycol, glycerin and various combinations thereof.

[00229] The tablets can be uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate can be employed. Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.

[00230] Surfactant which can be used to form pharmaceutical compositions and dosage forms of the invention include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants may be employed, a mixture of lipophilic surfactants may be employed, or a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant may be employed. - 53 - 2024204264   21 Jun 2024

[00231] A suitable hydrophilic surfactant may generally have an HLB value of at least 10, while suitable lipophilic surfactants may generally have an HLB value of or less than about 10. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of non-ionic amphiphilic compounds is the hydrophilic-lipophilic balance (" HLB" value). Surfactants with lower HLB values are more lipophilic or hydrophobic, and have greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, and have greater solubility in aqueous solutions.

[00232] Hydrophilic surfactants are generally considered to be those compounds having an HLB value greater than about 10, as well as anionic, cationic, or zwitterionic compounds for which the HLB scale is not generally applicable. Similarly, lipophilic (i.e., hydrophobic) surfactants are compounds having an HLB value equal to or less than about 10. However, HLB value of a surfactant is merely a rough guide generally used to enable formulation of industrial, pharmaceutical and cosmetic emulsions.

[00233] Hydrophilic surfactants may be either ionic or non-ionic. Suitable ionic surfactants include, but are not limited to, alkylammonium salts; fusidic acid salts; fatty acid derivatives of amino acids, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; lecithins and hydrogenated lecithins; lysolecithins and hydrogenated lysolecithins; phospholipids and derivatives thereof; lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkylsulfates; fatty acid salts; sodium docusate; acyl lactylates; mono- and diacetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

[00234] Within the aforementioned group, ionic surfactants include, by way of example: lecithins, lysolecithin, phospholipids, lysophospholipids and derivatives thereof; carnitine fatty acid ester salts; salts of alkyl sulfates; fatty acid salts; sodium docusate; acylactylates; mono- and diacetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-glycerides; and mixtures thereof.

[00235] Ionic surfactants may be the ionized forms of lecithin, lysolecithin, phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphatidylserine, lysophosphatidylcholine, lysophosphatidylethanolamine, lysophosphatidylglycerol, lysophosphatidic acid, lysophosphatidylserine, PEG-phosphatidylethanolamine, PVP -phosphatidylethanolamine, lactylic esters of fatty acids, stearoyl-2-lactylate, stearoyl lactylate, succinylated monoglycerides, mono / diacetylated tartaric acid esters of 2024204264   21 Jun 2024 mono / diglycerides, citric acid esters of mono / diglycerides, cholyl sarcosine, caproate, caprylate, caprate, laurate, myristate, palmitate, oleate, ricinoleate, linoleate, linolenate, stearate, lauryl sulfate, teracecyl sulfate, docusate, lauroyl carnitines, palmitoyl carnitines, myristoyl carnitines, and salts and mixtures thereof.

[00236] Hydrophilic non-ionic surfactants may include, but are not limited to, alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyalkylene alkyl ethers such as polyethylene glycol alkyl ethers; polyoxyalkylene alkylphenols such as polyethylene glycol alkyl phenols; polyoxyalkylene alkyl phenol fatty acid esters such as polyethylene glycol fatty acids monoesters and polyethylene glycol fatty acids diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkylene sorbitan fatty acid esters such as polyethylene glycol sorbitan fatty acid esters; hydrophilic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids, and sterols; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylated vitamins and derivatives thereof; polyoxyethylenepolyoxypropylene block copolymers; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydrophilic transesterification products of a polyol with at least one member of the group consisting of triglycerides, vegetable oils, and hydrogenated vegetable oils. The polyol may be glycerol, ethylene glycol, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, or a saccharide.

[00237] Other hydrophilic-non-ionic surfactants include, without limitation, PEG- 10 laurate, PEG- 12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG- 12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 di oleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG- 100 stearate, PEG-20 dilaurate, PEG-25 glyceryl trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 caprate / caprylate glycerides, PEG-8 caprate / caprylate glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phyto sterol, PEG-30 soya sterol, PEG-20 trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan laurate, polysorbate 20, polysorbate 80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, 2024204264   21 Jun 2024 tocopheryl PEG- 100 succinate, PEG-24 cholesterol, polyglyceryl-lOoleate, Tween 40, Tween 60, sucrose monostearate, sucrose mono laurate, sucrose monopalmitate, PEG 10-100 nonyl phenol series, PEG 15-100 octyl phenol series, and poloxamers.

[00238] Suitable lipophilic surfactants include, by way of example only: fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acids esters; propylene glycol fatty acid esters; sorbitan fatty acid esters; polyethylene glycol sorbitan fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; lactic acid derivatives of mono- and di-glycerides; hydrophobic transesterification products of a polyol with at least one member of the group consisting of glycerides, vegetable oils, hydrogenated vegetable oils, fatty acids and sterols; oilsoluble vitamins / vitamin derivatives; and mixtures thereof. Within this group, preferred lipophilic surfactants include glycerol fatty acid esters, propylene glycol fatty acid esters, and mixtures thereof, or are hydrophobic transesterification products of a polyol with at least one member of the group consisting of vegetable oils, hydrogenated vegetable oils, and triglycerides.

[00239] In one embodiment, the composition may include a solubilizer to ensure good solubilization and / or dissolution of the compound of the present invention and to minimize precipitation of the compound of the present invention. This can be especially important for compositions for non-oral use, e.g., compositions for injection. A solubilizer may also be added to increase the solubility of the hydrophilic drug and / or other components, such as surfactants, or to maintain the composition as a stable or homogeneous solution or dispersion.

[00240] Examples of suitable solubilizers include, but are not limited to, the following: alcohols and polyols, such as ethanol, isopropanol, butanol, benzyl alcohol, ethylene glycol, propylene glycol, butanediols and isomers thereof, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives; ethers of polyethylene glycols having an average molecular weight of about 200 to about 6000, such as tetrahydrofurfuryl alcohol PEG ether (glycofurol) or methoxy PEG ; amides and other nitrogen-containing compounds such as 2-pyrrolidone, 2-piperidone, s-caprolactam, N-alkylpyrrolidone, N-hydroxyalkylpyrrolidone, N-alkylpiperidone, N-alkylcaprolactam, dimethylacetamide and polyvinylpyrrolidone; esters such as ethyl propionate, tributylcitrate, acetyl triethylcitrate, acetyl tributyl citrate, tri ethyl citrate, ethyl oleate, ethyl caprylate, ethyl butyrate, 2024204264   21 Jun 2024 triacetin, propylene glycol monoacetate, propylene glycol diacetate, s-caprolactone and isomers thereof, 6-valerolactone and isomers thereof, P-butyrolactone and isomers thereof; and other solubilizers known in the art, such as dimethyl acetamide, dimethyl isosorbide, N-methyl pyrrolidones, monooctanoin, diethylene glycol monoethyl ether, and water.

[00241] Mixtures of solubilizers may also be used. Examples include, but not limited to, triacetin, tri ethyl citrate, ethyl oleate, ethyl caprylate, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrins, ethanol, polyethylene glycol 200-100, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide. Particularly preferred solubilizers include sorbitol, glycerol, triacetin, ethyl alcohol, PEG-400, glycofurol and propylene glycol.

[00242] The amount of solubilizer that can be included is not particularly limited. The amount of a given solubilizer may be limited to a bioacceptable amount, which may be readily determined by one of skill in the art. In some circumstances, it may be advantageous to include amounts of solubilizers far in excess of bioacceptable amounts, for example to maximize the concentration of the drug, with excess solubilizer removed prior to providing the composition to a subject using conventional techniques, such as distillation or evaporation. Thus, if present, the solubilizer can be in a weight ratio of 10%, 25%o, 50%), 100%o, or up to about 200%> by weight, based on the combined weight of the drug, and other excipients. If desired, very small amounts of solubilizer may also be used, such as 5%>, 2%>, 1%) or even less. Typically, the solubilizer may be present in an amount of about 1%> to about 100%, more typically about 5%> to about 25%> by weight.

[00243] The composition can further include one or more pharmaceutically acceptable additives and excipients. Such additives and excipients include, without limitation, detackifiers, antifoaming agents, buffering agents, polymers, antioxidants, preservatives, chelating agents, viscomodulators, tonicifiers, flavorants, colorants, odorants, opacifiers, suspending agents, binders, fillers, plasticizers, lubricants, and mixtures thereof.

[00244] In addition, an acid or a base may be incorporated into the composition to facilitate processing, to enhance stability, or for other reasons. Examples of pharmaceutically acceptable bases include amino acids, amino acid esters, ammonium hydroxide, potassium hydroxide, sodium hydroxide, sodium hydrogen carbonate, aluminum hydroxide, calcium carbonate, magnesium hydroxide, magnesium aluminum silicate, synthetic aluminum silicate, synthetic - 57 - 2024204264   21 Jun 2024 hydrocalcite, magnesium aluminum hydroxide, diisopropylethylamine, ethanolamine, ethylenediamine, triethanolamine, triethylamine, triisopropanol amine, trimethylamine, tris(hydroxymethyl)aminomethane (TRIS) and the like. Also suitable are bases that are salts of a pharmaceutically acceptable acid, such as acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acid, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, oxalic acid, para-bromophenylsulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid, and the like. Salts of polyprotic acids, such as sodium phosphate, disodium hydrogen phosphate, and sodium dihydrogen phosphate can also be used. When the base is a salt, the cation can be any convenient and pharmaceutically acceptable cation, such as ammonium, alkali metals, alkaline earth metals, and the like. Example may include, but not limited to, sodium, potassium, lithium, magnesium, calcium and ammonium.

[00245] Suitable acids are pharmaceutically acceptable organic or inorganic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, hydriodic acid, sulfuric acid, nitric acid, boric acid, phosphoric acid, and the like. Examples of suitable organic acids include acetic acid, acrylic acid, adipic acid, alginic acid, alkanesulfonic acids, amino acids, ascorbic acid, benzoic acid, boric acid, butyric acid, carbonic acid, citric acid, fatty acids, formic acid, fumaric acid, gluconic acid, hydroquinosulfonic acid, isoascorbic acid, lactic acid, maleic acid, methanesulfonic acid, oxalic acid, para-bromophenyl sulfonic acid, propionic acid, p-toluenesulfonic acid, salicylic acid, stearic acid, succinic acid, tannic acid, tartaric acid, thioglycolic acid, toluenesulfonic acid, uric acid and the like. Pharmaceutical compositions for injection.

[00246] In some embodiments, the invention provides a pharmaceutical composition for injection containing a compound of the present invention and a pharmaceutical excipient suitable for injection. Components and amounts of agents in the compositions are as described herein.

[00247] The forms in which the novel compositions of the present invention may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, com oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles. 2024204264   21 Jun 2024

[00248] Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, for the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

[00249] Sterile injectable solutions are prepared by incorporating the compound of the present invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, certain desirable methods of preparation are vacuum-drying and freeze- drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Pharmaceutical compositions for topical (e.g. transdermal) delivery.

[00250] In some embodiments, the invention provides a pharmaceutical composition for transdermal delivery containing a compound of the present invention and a pharmaceutical excipient suitable for transdermal delivery.

[00251] Compositions of the present invention can be formulated into preparations in solid, semisolid, or liquid forms suitable for local or topical administration, such as gels, water soluble jellies, creams, lotions, suspensions, foams, powders, slurries, ointments, solutions, oils, pastes, suppositories, sprays, emulsions, saline solutions, dimethylsulfoxide (DMSO)-based solutions. In general, carriers with higher densities are capable of providing an area with a prolonged exposure to the active ingredients. In contrast, a solution formulation may provide more immediate exposure of the active ingredient to the chosen area.

[00252] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients, which are compounds that allow increased penetration of, or assist in the delivery of, therapeutic molecules across the stratum corneum permeability barrier of the skin. There 2024204264   21 Jun 2024 are many of these penetration- enhancing molecules known to those trained in the art of topical formulation.

[00253] Examples of such carriers and excipients include, but are not limited to, humectants (e.g., urea), glycols (e.g., propylene glycol), alcohols (e.g., ethanol), fatty acids (e.g., oleic acid), surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), pyrrolidones, glycerol monolaurate, sulfoxides, terpenes (e.g., menthol), amines, amides, alkanes, alkanols, water, calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[00254] Another exemplary formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of a compound of the present invention in controlled amounts, either with or without another agent.

[00255] The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents. Pharmaceutical compositions for inhalation.

[00256] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner. Other pharmaceutical compositions.

[00257] Pharmaceutical compositions may also be prepared from compositions described herein and one or more pharmaceutically acceptable excipients suitable for sublingual, buccal, 2024204264   21 Jun 2024 rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical compositions are well-known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 20037ybg; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001 ; Remingtons Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999); all of which are incorporated by reference herein in their entirety.

[00258] Administration of the compounds or pharmaceutical composition of the present invention can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intraarterial, subcutaneous, intramuscular, intravascular, intraperitoneal or infusion), topical (e.g. transdermal application), rectal administration, via local delivery by catheter or stent or through inhalation. Compounds can also be administered intraadiposally or intrathecally.

[00259] The amount of the compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg / kg / day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to 7 g / day, preferably about 0.05 to about 2.5 g / day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, e.g. by dividing such larger doses into several small doses for administration throughout the day.

[00260] In some embodiments, a compound of the invention is administered in a single dose.

[00261] Typically, such administration will be by injection, e.g., intravenous injection, in order to introduce the agent quickly. However, other routes may be used as appropriate. A single dose of a compound of the invention may also be used for treatment of an acute condition. 2024204264   21 Jun 2024

[00262] In some embodiments, a compound of the invention is administered in multiple doses. Dosing may be about once, twice, three times, four times, five times, six times, or more than six times per day. Dosing may be about once a month, once every two weeks, once a week, or once every other day. In another embodiment a compound of the invention and another agent are administered together about once per day to about 6 times per day. In another embodiment the administration of a compound of the invention and an agent continues for less than about 7 days. In yet another embodiment the administration continues for more than about 6, 10, 14, 28 days, two months, six months, or one year. In some cases, continuous dosing is achieved and maintained as long as necessary.

[00263] Administration of the compounds of the invention may continue as long as necessary. In some embodiments, a compound of the invention is administered for more than 1, 2, 3, 4, 5, 6, 7, 14, or 28 days. In some embodiments, a compound of the invention is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, a compound of the invention is administered chronically on an ongoing basis, e.g., for the treatment of chronic effects.

[00264] An effective amount of a compound of the invention may be administered in either single or multiple doses by any of the accepted modes of administration of agents having similar utilities, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.

[00265] The compositions of the invention may also be delivered via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer. Such a method of administration may, for example, aid in the prevention or amelioration of restenosis following procedures such as balloon angioplasty. Without being bound by theory, compounds of the invention may slow or inhibit the migration and proliferation of smooth muscle cells in the arterial wall which contribute to restenosis. A compound of the invention may be administered, for example, by local delivery from the struts of a stent, from a stent graft, from grafts, or from the cover or sheath of a stent. In some embodiments, a compound of the invention is admixed with a matrix. Such a matrix may be a polymeric matrix, and may serve to bond the compound to the stent. Polymeric matrices suitable for such use, include, for example, lactone-based polyesters or copolyesters such as polylactide, polycaprolactonglycolide, polyorthoesters, polyanhydrides, polyaminoacids, polysaccharides, polyphosphazenes, poly (ether-ester) copolymers (e.g. PEO- 2024204264   21 Jun 2024 PLLA); polydimethylsiloxane, poly(ethylene-vinylacetate), acrylate-based polymers or copolymers (e.g. polyhydroxyethyl methylmethacrylate, polyvinyl pyrrolidinone), fluorinated polymers such as polytetrafluoroethylene and cellulose esters. Suitable matrices may be nondegrading or may degrade with time, releasing the compound or compounds. Compounds of the invention may be applied to the surface of the stent by various methods such as dip / spin coating, spray coating, dip-coating, and / or brush-coating. The compounds may be applied in a solvent and the solvent may be allowed to evaporate, thus forming a layer of compound onto the stent. Alternatively, the compound may be located in the body of the stent or graft, for example in microchannels or micropores. When implanted, the compound diffuses out of the body of the stent to contact the arterial wall. Such stents may be prepared by dipping a stent manufactured to contain such micropores or microchannels into a solution of the compound of the invention in a suitable solvent, followed by evaporation of the solvent. Excess drug on the surface of the stent may be removed via an additional brief solvent wash. In yet other embodiments, compounds of the invention may be covalently linked to a stent or graft. A covalent linker may be used which degrades in vivo, leading to the release of the compound of the invention. Any bio-labile linkage may be used for such a purpose, such as ester, amide or anhydride linkages. Compounds of the invention may additionally be administered intravascularly from a balloon used during angioplasty. Extravascular administration of the compounds via the pericard or via advential application of formulations of the invention may also be performed to decrease restenosis.

[00266] A variety of stent devices which may be used as described are disclosed, for example, in the following references, all of which are hereby incorporated by reference: U.S. Pat. No. 5451233; U.S. Pat. No. 5040548; U.S. Pat. No. 5061273; U.S. Pat. No. 5496346; U.S. Pat. No. 5292331; U.S. Pat. No. 5674278; U.S. Pat. No. 3657744; U.S. Pat. No. 4739762; U.S. Pat. No. 5195984; U.S. Pat. No. 5292331 ; U.S. Pat. No. 5674278; U.S. Pat. No. 5879382; U.S. Pat. No. 6344053.

[00267] The compounds of the invention may be administered in dosages. It is known in the art that due to intersubject variability in compound pharmacokinetics, individualization of dosing regimen is necessary for optimal therapy. Dosing for a compound of the invention may be found by routine experimentation in light of the instant disclosure.

[00268] When a compound of the invention is administered in a composition that comprises one or more agents, and the agent has a shorter half- life than the compound of the -63 - 2024204264   21 Jun 2024 invention unit dose forms of the agent and the compound of the invention may be adjusted accordingly.

[00269] The subject pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

[00270] Exemplary parenteral administration forms include solutions or suspensions of active compound in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired. Methods of Use

[00271] The method typically comprises administering to a subject a therapeutically effective amount of a compound of the invention. The therapeutically effective amount of the subject combination of compounds may vary depending upon the intended application (in vitro or in vivo), or the subject and disease condition being treated, e.g., the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art. The term also applies to a dose that will induce a particular response in target cells, e.g., reduction of proliferation or downregulation of activity of a target protein. The specific dose will vary depending on the particular compounds chosen, the dosing regimen to be followed, whether it is administered in combination with other compounds, timing of administration, the tissue to which it is administered, and the physical delivery system in which it is carried.

[00272] As used herein, the term "IC50" refers to the half maximal inhibitory concentration of an inhibitor in inhibiting biological or biochemical function. This quantitative measure indicates how much of a particular inhibitor is needed to inhibit a given biological process (or component of a process, i.e. an enzyme, cell, cell receptor or microorganism) by half. In other words, it is the half 2024204264   21 Jun 2024 maximal (50%) inhibitory concentration (IC) of a substance (50% IC, or IC50). EC50 refers to the plasma concentration required for obtaining 50%> of a maximum effect in vivo.

[00273] In some embodiments, the subject methods utilize a PRMT5 inhibitor with an IC50 value of about or less than a predetermined value, as ascertained in an in vitro assay. In some embodiments, the PRMT5 inhibitor inhibits PRMT5 a with an IC50 value of about 1 nM or less, 2 nM or less, 5 nM or less, 7 nM or less, 10 nM or less, 20 nM or less, 30 nM or less, 40 nM or less, 50 nM or less, 60 nM or less, 70 nM or less, 80 nM or less, 90 nM or less, 100 nM or less, 120 nM or less, 140 nM or less, 150 nM or less, 160 nM or less, 170 nM or less, 180 nM or less, 190 nM or less, 200 nM or less, 225 nM or less, 250 nM or less, 275 nM or less, 300 nM or less, 325 nM or less, 350 nM or less, 375 nM or less, 400 nM or less, 425 nM or less, 450 nM or less, 475 nM or less, 500 nM or less, 550 nM or less, 600 nM or less, 650 nM or less, 700 nM or less, 750 nM or less, 800 nM or less, 850 nM or less, 900 nM or less, 950 nM or less, 1 pM or less, 1.1 pM or less, 1.2 pM or less, 1.3 pM or less, 1.4 pM or less, 1.5 pM or less, 1.6 pM or less, 1.7 pM or less, 1.8 pM or less, 1.9 pM or less, 2 pM or less, 5 pM or less, 10 pM or less, 15 pM or less, 20 pM or less, 25 pM or less, 30 pM or less, 40 pM or less, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 100 pM, 200 pM, 300 pM, 400 pM, or 500 pM, or less, (or a number in the range defined by and including any two numbers above).

[00274] In some embodiments, the PRMT5 inhibitor selectively inhibits PRMT5 a with an IC50 value that is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or 1000 times less (or a number in the range defined by and including any two numbers above)than its IC50 value against one, two, or three other PRMTs.

[00275] In some embodiments, the PRMT5 inhibitor selectively inhibits PRMT5 a with an IC50 value that is less than about 1 nM, 2 nM, 5 nM, 7 nM, 10 nM, 20 nM, 30 nM, 40 nM, 50 nM, 60 nM, 70 nM, 80 nM, 90 nM, 100 nM, 120 nM, 140 nM, 150 nM, 160 nM, 170 nM, 180 nM, 190 nM, 200 nM, 225 nM, 250 nM, 275 nM, 300 nM, 325 nM, 350 nM, 375 nM, 400 nM, 425 nM, 450 nM, 475 nM, 500 nM, 550 nM, 600 nM, 650 nM, 700 nM, 750 nM, 800 nM, 850 nM, 900 nM, 950 nM, 1 pM, 1.1 pM, 1.2 pM, 1.3 pM, 1.4 pM, 1.5 pM, 1.6 pM, 1.7 pM, 1.8 pM, 1.9 pM, 2 pM, 5 pM, 10 pM, 15 pM, 20 pM, 25 pM, 30 pM, 40 pM, 50 pM, 60 pM, 70 pM, 80 pM, 90 pM, 100 pM, 200 pM, 300 pM, 400 pM, or 500 pM (or in the range defined by and including any two numbers above), and said IC50 value is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, or 2024204264   21 Jun 2024 1000 times less (or a number in the range defined by and including any two numbers above) than its IC50 value against one, two or three other PRMTs.

[00276] The subject methods are useful for treating a disease condition associated with PRMT5. Any disease condition that results directly or indirectly from an abnormal activity or expression level of PRMT5 can be an intended disease condition.

[00277] Different disease conditions associated with PRMT5 have been reported. PRMT5 has been implicated, for example, in a variety of human cancers as well as a number of hemoglobinopathies.

[00278] Non- limiting examples of such conditions include but are not limited to Acanthoma, Acinic cell carcinoma, Acoustic neuroma, Acral lentiginous melanoma, Acrospiroma, Acute eosinophilic leukemia, Acute lymphoblastic leukemia, Acute lymphocytic leukemia, Acute megakaryoblastic leukemia, Acute monocytic leukemia, Acute myeloblasts leukemia with maturation, Acute myeloid dendritic cell leukemia, Acute myeloid leukemia, Acute myelogenous leukemia, Acute promyelocytic leukemia, Adamantinoma, Adenocarcinoma, Adenoid cystic carcinoma, Adenoma, Adenomatoid odontogenic tumor, Adrenocortical carcinoma, Adult T-cell leukemia, Aggressive NK-cell leukemia, AIDS-Related Cancers, AIDS-related lymphoma, Alveolar soft part sarcoma, Ameloblastic fibroma, Anal cancer, Anaplastic large cell lymphoma, Anaplastic thyroid cancer, Angioimmunoblastic T-cell lymphoma, Angiomyolipoma, Angiosarcoma, Appendix cancer, Astrocytoma, Atypical teratoid rhabdoid tumor, Basal cell carcinoma, Basal-like carcinoma, B-cell leukemia, B-cell lymphoma, Bellini duct carcinoma, Biliary tract cancer, Bladder cancer, Blastoma, Bone Cancer, Bone tumor, Brain Stem Glioma, Brain Tumor, Breast Cancer, Brenner tumor, Bronchial Tumor, Bronchioloalveolar carcinoma, Brown tumor, Burkitt's lymphoma, Cancer of Unknown Primary Site, Carcinoid Tumor, Carcinoma, Carcinoma in situ, Carcinoma of the penis, Carcinoma of Unknown Primary Site, Carcinosarcoma, Castleman's Disease, Central Nervous System Embryonal Tumor, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Cholangiocarcinoma, Chondroma, Chondrosarcoma, Chordoma, Choriocarcinoma, Choroid plexus papilloma, Chronic Lymphocytic Leukemia, Chronic monocytic leukemia, Chronic myelogenous leukemia, Chronic Myeloproliferative Disorder, Chronic neutrophilic leukemia, Clear-cell tumor, Colon Cancer, Colorectal cancer, Craniopharyngioma, Cutaneous T-cell lymphoma, Degos disease, Dermatofibrosarcoma protuberans, Dermoid cyst, Desmoplastic small round cell tumor, Diffuse large B cell lymphoma, Dysembryoplastic neuroepithelial tumor, Embryonal carcinoma, 2024204264   21 Jun 2024 Endodermal sinus tumor, Endometrial cancer, Endometrial Uterine Cancer, Endometrioid tumor, Enteropathy-associated T-cell lymphoma, Ependymoblastoma, Ependymoma, Epidermoid cancer, Epithelioid sarcoma, Erythroleukemia, Esophageal cancer, Esthesioneuroblastoma, Ewing Family of Tumor, Ewing Family Sarcoma, Ewing's sarcoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Extramammary Paget's disease, Fallopian tube cancer, Fetus in fetu, Fibroma, Fibrosarcoma, Follicular lymphoma, Follicular thyroid cancer, Gallbladder Cancer, Gallbladder cancer, Ganglioglioma, Ganglioneuroma, Gastric Cancer, Gastric lymphoma, Gastrointestinal cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Gastrointestinal stromal tumor, Germ cell tumor, Germinoma, Gestational choriocarcinoma, Gestational Trophoblastic Tumor, Giant cell tumor of bone, Glioblastoma multiforme, Glioma, Gliomatosis cerebri, Glomus tumor, Glucagonoma, Gonadoblastoma, Granulosa cell tumor, Hairy Cell Leukemia, Head and Neck Cancer, Head and neck cancer, Heart cancer, Hemoglobinopathies such as b-thalassemia and sickle cell disease (SCD), Hemangioblastoma, Hemangiopericytoma, Hemangiosarcoma, Hematological malignancy, Hepatocellular carcinoma, Hepatosplenic T-cell lymphoma, Hereditary breast-ovarian cancer syndrome, Hodgkin Lymphoma, Hodgkin's lymphoma, Hypopharyngeal Cancer, Hypothalamic Glioma, Inflammatory breast cancer, Intraocular Melanoma, Islet cell carcinoma, Islet Cell Tumor, Juvenile myelomonocytic leukemia, Kaposi Sarcoma, Kaposi's sarcoma, Kidney Cancer, Klatskin tumor, Krukenberg tumor, Laryngeal Cancer, Laryngeal cancer, Lentigo maligna melanoma, Leukemia, Lip and Oral Cavity Cancer, Liposarcoma, Lung cancer, Luteoma, Lymphangioma, Lymphangiosarcoma, Lymphoepithelioma, Lymphoid leukemia, Lymphoma, Macroglobulinemia, Malignant Fibrous Histiocytoma, Malignant fibrous histiocytoma, Malignant Fibrous Histiocytoma of Bone, Malignant Glioma, Malignant Mesothelioma, Malignant peripheral nerve sheath tumor, Malignant rhabdoid tumor, Malignant triton tumor, MALT lymphoma, Mantle cell lymphoma, Mast cell leukemia, Mastocytosis, Mediastinal germ cell tumor, Mediastinal tumor, Medullary thyroid cancer, Medulloblastoma, Medulloblastoma, Medulloepithelioma, Melanoma, Melanoma, Meningioma, Merkel Cell Carcinoma, Mesothelioma, Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Metastatic urothelial carcinoma, Mixed Mullerian tumor, Monocytic leukemia, Mouth Cancer, Mucinous tumor, Multiple Endocrine Neoplasia Syndrome, Multiple Myeloma, Multiple myeloma, Mycosis Fungoides, Mycosis fungoides, Myelodysplasia Disease, Myelodysplasia Syndromes, Myeloid leukemia, Myeloid sarcoma, Myeloproliferative Disease, Myxoma, Nasal Cavity Cancer, Nasopharyngeal 2024204264   21 Jun 2024 Cancer, Nasopharyngeal carcinoma, Neoplasm, Neurinoma, Neuroblastoma, Neuroblastoma, Neurofibroma, Neuroma, Nodular melanoma, Non-Hodgkin Lymphoma, Non-Hodgkin lymphoma, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Ocular oncology, Oligoastrocytoma, Oligodendroglioma, Oncocytoma, Optic nerve sheath meningioma, Oral Cancer, Oral cancer, Oropharyngeal Cancer, Osteosarcoma, Osteosarcoma, Ovarian Cancer, Ovarian cancer, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Paget's disease of the breast, Pancoast tumor, Pancreatic Cancer, Pancreatic cancer, Papillary thyroid cancer, Papillomatosis, Paraganglioma, Paranasal Sinus Cancer, Parathyroid Cancer, Penile Cancer, Perivascular epithelioid cell tumor, Pharyngeal Cancer, Pheochromocytoma, Pineal Parenchymal Tumor of Intermediate Differentiation, Pineoblastoma, Pituicytoma, Pituitary adenoma, Pituitary tumor, Plasma Cell Neoplasm, Pleuropulmonary blastoma, Polyembryoma, Precursor T-lymphoblastic lymphoma, Primary central nervous system lymphoma, Primary effusion lymphoma, Primary Hepatocellular Cancer, Primary Liver Cancer, Primary peritoneal cancer, Primitive neuroectodermal tumor, Prostate cancer, Pseudomyxoma peritonei, Rectal Cancer, Renal cell carcinoma, Respiratory Tract Carcinoma Involving the NUT Gene onChromosome 15, Retinoblastoma, Rhabdomyoma, Rhabdomyosarcoma, Richter's transformation, Sacrococcygeal teratoma, Salivary Gland Cancer, Sarcoma, Schwannomatosis, Sebaceous gland carcinoma, Secondary neoplasm, Seminoma, Serous tumor, Sertoli-Leydig cell tumor, Sex cord-stromal tumor, Sezary Syndrome, Signet ring cell carcinoma, Skin Cancer, Small blue round cell tumor, Small cell carcinoma, Small Cell Lung Cancer, Small cell lymphoma, Small intestine cancer, Soft tissue sarcoma, Somatostatinoma, Soot wart, Spinal Cord Tumor, Spinal tumor, Splenic marginal zone lymphoma, Squamous cell carcinoma, Stomach cancer, Superficial spreading melanoma, Supratentorial Primitive Neuroectodermal Tumor, Surface epithelial-stromal tumor, Synovial sarcoma, T-cell acute lymphoblastic leukemia, T-cell large granular lymphocyte leukemia, T-cell leukemia, T-cell lymphoma, T-cell prolymphocytic leukemia, Teratoma, Terminal lymphatic cancer, Testicular cancer, Thecoma, Throat Cancer, Thymic Carcinoma, Thymoma, Thyroid cancer, Transitional Cell Cancer of Renal Pelvis and Ureter, Transitional cell carcinoma, Urachal cancer, Urethral cancer, Urogenital neoplasm, Uterine sarcoma, Uveal melanoma, Vaginal Cancer, Verner Morrison syndrome, Verrucous carcinoma, Visual Pathway Glioma, Vulvar Cancer, Waldenstrom's macroglobulinemia, Warthin's tumor, Wilms' tumor, or any combination thereof. 2024204264   21 Jun 2024

[00279] In some embodiments, said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, inflammatory bowel disease, skin diseases such as psoriasis, eczema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.

[00280] In other embodiments, said method is for treating a disease selected from breast cancer, lung cancer, pancreatic cancer, prostate cancer, colon cancer,ovarian cancer, uterine cancer, or cervical cancer.

[00281] In other embodiments, said method is for treating a disease selected from leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS), epidermoid cancer, or hemoglobinopathies such as b-thalassemia and sickle cell disease (SCD).

[00282] In yet other embodiments, said method is for treating a disease selected from CDKN2A deleted cancers; 9P deleted cancers; MTAP deleted cancers; glioblastoma, NSCLC, head and neck cancer, bladder cancer, or hepatocellular carcinoma.

[00283] Compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with a medical therapy. Medical therapies include, for example, surgery and radiotherapy (e.g., gammaradiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, systemic radioactive isotopes).

[00284] In other aspects, compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with one or more other agents.

[00285] In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with agonists of nuclear receptors agents. 2024204264   21 Jun 2024

[00286] In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with antagonists of nuclear receptors agents.

[00287] In other methods, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with an anti-proliferative agent.

[00288] In other aspects, compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered to treat any of the described diseases, alone or in combination with one or more other chemotherapeutic agents. Examples of other chemotherapeutic agents include, for example, abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, all-trans retinoic acid, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bendamustine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panobinostat, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinstat, and zoledronate, as well as any combination thereof.

[00289] In other aspects, the other agent is a therapeutic agent that targets an epigenetic regulator. Examples of epigenetic regulator agentss include, for example, bromodomain inhibitors, the histone lysine methyltransferases, histone arginine methyl transferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases, as well as any combination 2024204264   21 Jun 2024 thereof. Histone deacetylase inhibitors are preferred in some aspects, and include, for example, vorinostat.

[00290] In other methods wherein the disease to be treated is cancer or another proliferative disease, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with targeted therapy agents. Targeted therapies include, for example, JAK kinase inhibitors (e.g. Ruxolitinib), PI3 kinase inhibitors (including PI3K-delta selective and broad spectrum PI3K inhibitors), MEK inhibitors, Cyclin Dependent kinase inhibitors (e.g, CDK4 / 6 inhibitors), BRAF inhibitors, mTOR inhibitors, proteasome inhibitors (e.g., Bortezomib, Carfilzomib), HDAC-inhibitors (e.g., panobinostat, vorinostat), DNA methyl transferase inhibitors, dexamethasone, bromo and extra terminal family members, BTK inhibitors (e.g., ibrutinib, acalabrutinib), BCL2 inhibitors (e.g., venetoclax), MCL1 inhibitors, PARP inhibitors, FLT3 inhibitors, and LSD1 inhibitors, as well as any combination thereof.

[00291] In other methods wherein the disease to be treated is cancer or another proliferative disease, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with an immune checkpoint inhibitor agents. Immune checkpoint inhibitors include, for example, inhibitors of PD-1, for example, an anti-PD-1 monoclonal antibody. Examples of anti-PD-1 monoclonal antibodies include, for example, nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, and AMP-224, as well as combinations thereof. In some aspects, the anti-PDl antibody is nivolumab. In some aspects, the anti-PDl antibody is pembrolizumab. In some aspects, the immunce checkpoint inhibitor is an inhibitor of PD-L1, for example, an anti-PD-Ll monoclonal antibody. In some aspects, the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C, or any combination thereof. In some aspects, the anti-PD-Ll monoclonal antibody is MPDL3280A or MEDI4736. In other aspects, the immune checkpoint inhibitor is an inhibitor of CTLA-4, for example, and anti-CTLA-4 antibody. In some aspects, the anti-CTLA-4 antibody is ipilimumab.

[00292] In other methods wherein the disease to be treated is cancer or another proliferative disease, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with an alkylating agent (e.g., cyclophosphamide (CY), melphalan (MEL), and bendamustine), a proteasome inhibitor agent (e.g., -71 - 2024204264   21 Jun 2024 carfilzomib), a corticosteroid agent (e.g., dexamethasone (DEX)), or an immunomodulatory agent (e.g., lenalidomide (LEN) or pomalidomide (POM)), or any combination thereof.

[00293] In some embodiments, the disease to be treated is an autoimmune condition or an inflammatory condition. In these aspects, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with a corticosteroid agent such as, for example, triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone, or any combination thereof.

[00294] In other methods wherein the disease to be treated is an autoimmune condition or an inflammatory condition, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with an immune suppressant agent such as, for example, fluocinolone acetonide (RETISERT™), rimexolone (AL-2178, VEXOL™, ALCO™), or cyclosporine (RESTASIS™), or any combination thereof.

[00295] In some embodiments, the disease to be treated is beta-thalassemia or sickle cell disease. In these aspects, the compounds of the disclosure, as well as pharmaceutical compositions comprising them, can be administered in combination with one or more agents such as, for example, HYDREA™ (hydroxyurea).

[00296] The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples molecules with a single chiral center, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. Single enantiomers / diastereomers may be obtained by methods known to those skilled in the art. 2024204264   21 Jun 2024

[00297] Compounds of the disclosure include, for example, the compounds identified in Table A. TABLE A Ex. Structures MW Chemical Names 1A HQ 9^\-^ nh2 388.81 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1,3-dihydroisobenzofuran-1 -yl)tetrahydrofuran-3,4-diol 2A ho        A HO" / jO'CI nh2 386.83 (1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1,3-dihydroisobenzofuran-1 -yl)cyclopentane-1,2-diol 3A o HO 9 HO" ■                  °' nh2 400.82 (S)-3-((1S,2R,3S,4R)-4-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-d ihyd roxycyclo penty l)-6-chloroisobenzofuran-1 (3H)-one 3B o HO HO" ■ nh2 400.82 (R)-3-((1S,2R,3S,4R)-4-(4-amino-6H-7l4-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-d ihyd roxycyclo penty l)-6-chloroisobenzofuran-1 (3H)-one 1B HO 9^\__ HO" ■ ¢0 nh2 388.81 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-5-chloro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 2B HQ nh2 386.83 (1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-5-chloro-1,3-dihydroisobenzofuran-1-yl)cyclopentane-1,2-diol 4 ho HO" ¢0 F nh2 390.34 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1 -yl)tetrahydrofuran-3,4-diol 5 ho Vo    \ M     •             Cl nh2 388.8 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6-chloro-1,3-dihydroisobenzofuran-1 -yl)tetrahydrofuran-3,4-diol 6 ho HO' VO    \ F CO 389.3588 (2S,3S,4R,5R)-2-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1 -y l)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 7 ho"\J F nOC 431.4398 (2R,3R,4S,5S)-2-(4-butyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1 -yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 8 O" / / ° O" x / 'z / I    :      \___ / O AA T 433.4118 (2S,3S,4R,5R)-2-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1 -y l)-5-(4-(ethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 9 ho xAfyci CQ nh2 f 406.7984 (2R,3R,4S,5S)-2-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1,3-dihydroisobenzofuran-1 -yl)tetrahydrofuran-3,4-diol 10 o^\ ci ho v \_ / nh2 388.808 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-4-chloro-1,3-dihydroisobenzofuran-1 -yl)tetrahydrofuran-3,4-diol 11 HO XAZA HO" / J )= / Y"0 < / lx> nh2 388.808 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloro-1,3-dihydroisobenzofuran-1 -yl)tetrahydrofuran-3,4-diol 12 HO 9^= HO'"< *   \=Z r ° OO 387.82 (2S,3S,4R,5R)-2-((R)-5-chloro-1,3-dihydroisobenzofuran-1 -y l)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 13 O^\ Cl ho y \_ / HO"< i \= / r ° N' ex? 387.82 (2S,3S,4R,5R)-2-((R)-4-chloro-1,3-dihydroisobenzofuran-1 -y l)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 14 HO         , HO"< i \= / y° cr co 387.82 (2S,3S,4R,5R)-2-((R)-7-chloro-1,3-dihydroisobenzofuran-1 -y l)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 15 HO caa HO" / I / = / VO    \ Cl co 387.82 (2S,3S,4R,5R)-2-((R)-6-chloro-1,3-dihydroisobenzofuran-1 -y l)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 16 HO 00-= c x / / y=FF HO"<1 ury Co nh2 422.3642 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol 17 HO 9A-= c HO"<J w7 co 421.3762 (2R,3R,4S,5S)-2-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol 18 O^\ HO, Z H0"<J x= / ^x^N oo NH, 402.835 (2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-((R)-5-chloro-1,3-dihydroisobenzofuran-1 -y l)-3-methyltetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 19 ho, F \ / —Cl HO-CJ co 401.847 (2R,3S,4R,5R)-2-((R)-5-chloro-1,3-dihydroisobenzofuran-1 -y l)-3-methyl-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 20 Cl ex HO"pc N' Nee^ nh2 402.835 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1 -methyl-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol 21 Cl vX ho"CI ' JON co 401.847 (2S,3S,4R,5R)-2-((R)-5-chloro-1-methyl-1,3-dihydroisobenzofuran-1 -y l)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 22 n ph }—\ °\ / '"OH XO 401.847 (2S,3S,4R,5R)-2-((R)-6-chloroisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 23 Of HO 9 HC" / 7 co 423.8008 (2S,3S,4R,5R)-2-((R)-5-chloro-3,3-difluoro-1,3-dihydroisobenzofuran-1 -y l)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 24 ho ? y / ya ho"<j cx> 415.874 (2S,3S,4R,5R)-2-((R)-5-chloro-3,3-dimethyl-1,3-dihydroisobenzofuran-1 -y l)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 25 HO HO"<J cx> 403.881 (2S,3S,4R,5R)-2-((R)-5-chloro-1,3-dihydrobenzo[c]thiophen-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 26 0 HQ HO-Cf "'CVCl r 0 Co 435.879 (R)-5-ch loro-1 -((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-1,3-dihydrobenzo[c]thiophene 2,2-dioxide 27 a / ° o'" CC^sCc I :     \___ / o / =^ I 2   / )— 437.3752 (2R,3R,4S,5S)-2-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-(trifluoromethoxy)-l ,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol 28 HO CYOf HOI,<J Ov N‘ F Co 439.3666 (2S,3S,4R,5R)-2-((R)-6-fluoro-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1 -y l)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 29 HO 9^V V ho,..<C-Q° yo    \ ovn     F 455.3656 (2S,3S,4R,5R)-2-((R)-6-fluoro-5-(trifluoromethoxy)-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 30 ho 00 co 400.863 (2R,3S,4R,5R)-2-((R)-5-chloro-2-methylisoindolin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 31 o ZI"( / \-o O" I ■      \___ / o / =\ 1 2 / )-- 414.846 (R)-6-chloro-3-((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-y l)tetra hyd rofu ran-2-y l)-2-methylisoindolin-1 -one 32 HO '• Jz * HO"< 1   \= / r0 CO 354.366 (2S,3S,4R,5R)-2-((R)-1,3- dihydrofuro[3,4-c]pyridin-1 - yl)-5-(4-methyl-7H- pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 33 HO '■ O- / V- Z^r \ n HO"< 1   V= / Oo    \ Cl co 388.808 (2S,3S,4R,5R)-2-((R)-6-chloro-1,3-d i hyd rofu ro [3,4-c] py rid i n-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 34 / wo Zx. z O"\ / ° O'" C^zO ZE      :        \____ / O / =0 1 V / 360.388 (2S,3S,4R,5R)-2-((R)-4,6-dihydrofuro[3,4-d]thiazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 35 Jo —(z z i \— / O /   \      :     ZE Vz*zC"° ° \ Y'lO o o 394.83 (2S,3S,4R,5R)-2-((R)-2-ch Io ro-4,6-d i h yd rofu ro [3,4-d]th iazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 36 HO HO"< i r ° LX> 359.4 (2S,3S,4R,5R)-2-((R)-4,6-dihydrothieno[2,3-c]furan-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 37 HO"< A \^o nOO 393.842 (2S,3S,4R,5R)-2-((R)-2-chloro-4,6-dihydrothieno[2,3-c]furan-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 38 h3?>n« HO-Zj X^N oo 343.343 (2S,3S,4R,5R)-2-((R)-4,6-dihydro-1H-furo[3,4-c]pyrazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 39 Ho / ~1 r° OO 357.37 (2S,3S,4R,5R)-2-((R)-2-methyl-2,6-dihydro-4H-furo[3,4-c]pyrazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 40 HO H°-CJ N' ex? 386.84 (2R,3S,4R,5R)-2-((R)-5-chloroisoindolin-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 41 o HO x<Yycl HO"<J co 400.82 (R)-6-chloro-3-((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)isoindolin-1-one 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 42 h2n n PH ? °V / '"OH XXX 432.86 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((lR)-6-chloro-3-methoxyisochroman-1-yl)tetrahydrofuran-3,4-diol 43 h2n N / X~n pH )—\ °S / '"OH XXX 418.83 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((lR)-6-chloro-3-hydroxyisochroman-1-yl)tetrahydrofuran-3,4-diol 44 n?XX pH 5—7 °S / ’"OH XXX 431.87 (2S,3S,4R,5R)-2-((1R)-6-chloro-3-methoxyisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 45 T X P °XXP3 Cx ° ex -V   >5 399.83 (2S,3S,4R,5R)-2-((R)-6-chloro-1 H-isochromen-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 46 o     o T I 415.83 (R)-6-chloro-1 -((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)isochroman-3-one 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 47 ho,.Ao HO' OQ 429.90 (2S,3S,4R,5R)-2-((R)-6-chloro-4,4-dimethylisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 48 / CZw O"< / ° ZE     z       \____ / o / =\ 1 V / 407.87 (2S,3S,4R,5R)-2-((S)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 49 N PH }—7 °K / '"OH 366.38 (2R,3R,4S,5S)-2-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-1 H-pyrano[3,4-c]pyridin-1 -yl)tetrahydrofuran-3,4-diol 50 N pH }—\ °V / '''OH jOl X 417.85 (2S,3S,4R,5R)-2-((1R)-6-chloro-3-hydroxyisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 51 T X P <Tf ° / \ 368.39 (2S,3S,4R,5R)-2-((R)-3,4-dihydro-1 H-pyrano[3,4-c] py rid i n-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 52 F F XjX° ho„.Ao ?—N^. HO' C^N 437.83 (2S,3S,4R,5R)-2-((R)-6-chloro-4,4-difluoroisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 53 XXI ho„.Ao ?—C Nsa HO' OQ 403.82 (2S,3S,4R,5R)-2-((R)-7-chloro-4H-benzo[d][1,3]dioxin-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 54 uCr HO„.Ao '—C N^. HO' 439.80 (2S,3S,4R,5R)-2-((R)-7-chloro-2,2-difluoro-4H-benzo[d][1,3]dioxin-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 55 XP ?H XX > 417.85 (2S,3S,4R,5R)-2-((R)-7-chloro-1,5-dihydrobenzo[e][1,3]dioxepin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 56 oD’"OH XX x ci 453.83 (2S,3S,4R,5R)-2-((R)-7-chloro-3,3-difluoro-1,5-dihydrobenzo[e][1,3]dioxepin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 57 ” XT H z v \— / O-Z \ rx / ''o °Y° 6 1 o    1 431.83 (R)-7-chloro-1 -((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-1,5-dihydrobenzo[e][1,3]dioxepin-3-one 58 \   / =1   OH N J T / "OH fY X CI^^X_ / 431.87 (2S,3S,4R,5R)-2-((R)-8-chloro-5,6-dihydro-1H-benzo[e][1,3]dioxocin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 59 \   / =1   OH YvnvA N J. 1 / "OH \=N o»Y XX x or     __ / 467.85 (2S,3S,4R,5R)-2-((R)-8-chloro-3,3-difluoro-5,6-dihydro-1 H-benzo[e][1,3]dioxocin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 60 \   / =1   OH Nx / I >"'OH \=N   o^ / jOC / O cr     __ / 445.86 (R)-8-chloro-1 -((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-5,6-dihydro-1H-benzo[e][1,3]dioxocin-3-one 61 N\^^—N pH }—\ °S / '''OH 'NH 400.86 (2R,3S,4R,5R)-2-((R)-6-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 62 FxL-F ho„.Ao )—N& HO' 469.85 (2S,3S,4R,5R)-2-((1R)-6-chloro-4- (trifluoromethyl) isoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 63 F ho„.Ao ?--C N;~. HO' OQ 419.84 (2S,3S,4R,5R)-2-((1R)-6-chloro-4-fluoroisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 64 OH kjyO ho„.Ao ) HO' 417.85 (2S,3S,4R,5R)-2-((1 R)-6-chloro-4-hydroxyisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 65 HO„.Ao )—C   N-. HO' 415.87 (2S,3S,4R,5R)-2-((1R)-6-chloro-4-methylisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 66 N\5—N PH )—\ °S) / "OH XT 1 415.87 (2S,3S,4R,5R)-2-((1R)-6-chloro-3-methylisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 67 rV cr\ / \X-, / =\   ; ZO w § 1 o 403.86 (2S,3S,4R,5R)-2-((R)-6-chloro isoch roman-1 -yl-4,4-d2)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 MW 402.84 416.86 401.85 402.84 _____Chemical Names_____ (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5- ((R)-6-chloroisoch roman-1 -yl)tetrahydrofuran-3,4-diol (2S,3S,4R,5R)-2-((R)-6-chloroisoch roman-1 -yl)-5-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (2S,3S,4R,5R)-2-((R)-7-chloroisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloroisoch roman-1 -yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 MW 402.84 404.37 403.39 _____Chemical Names_____ (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5- ((R)-5-chloroisoch roman-1 -yl)tetrahydrofuran-3,4-diol (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6,7-difluoroisoch roman-1 -yl)tetrahydrofuran-3,4-diol (2S,3S,4R,5R)-2-((R)-6,7-difluoroisoch ro man-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 75 Cl X, 401.85 (2S,3S,4R,5R)-2-((R)-5-chloroisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol If y---N*       X2H "On 76 F X )- F OH 403.39 (2S,3S,4R,5R)-2-((R)-4,4-difluoroisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 77 F X.J^X (Z / ?=\ zc K ) / —N h2n 404.37 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5,6-difluoroisoch roman-1 -yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 78 F F 404.37 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-4,4-difluoroisoch roman-1 -yl)tetrahydrofuran-3,4-diol ( ) / [      Y)----N<        UH Nv«O h2n 79 X„ -py F T>H 403.39 (2S,3S,4R,5R)-2-((R)-5,6-difluoroisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 80 HO. HO^^\ cr -\ N x 401.85 (2S,3S,4R,5R)-2-((S)-6-chloroisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 81 H2N \ 418.83 (2R,3R,4S,5S)-2-(4-amino- 7H-pyrrolo[2,3-d]pyrimidin-7- ) / ,---A ( J I             H yl)-5-((R)-7-chloro-1,5- n \          V ? dihydrobenzo[e][1,3]dioxepin- \---N        | 1-yl)tetrahydrofuran-3,4-diol 0^. / .A-", / / / 0 C. 82 nh2 416.82 (R)-1-((2S,3S,4R,5R)-5-(4- amino-7H-pyrrolo[2,3- d]pyrimidin-7-yl)-3,4- HO                  ) / dihydroxytetrahydrofuran-2- / -----N-- yl)-6-chloroisochroman-3-one J\ A0 X. cr 83 F 419.84 (2S,3S,4R,5R)-2-((R)-6- chloro-5-fluoroisoch roman-1 - yl)-5-(4-methyl-7H- pyrrolo[2,3-d]pyrimidin-7- yl)tetrahydrofuran-3,4-diol O^"X^OH \ / ^N\ '—\ / /      V)----N*         OH vJO 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 84 F cX x**OH N X 1(                 °h n \  7 / fl\ h2n 420.83 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6-chloro-5-fluoro isoch roman-1 -yl)tetrahydrofuran-3,4-diol 85 z ho HO^” F rS A N X X 419.84 (2S,3S,4R,5R)-2-((R)-6-chloroisoch roman-1 -yl)-5-(5-fluoro-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 86 X ho HO^” As "A N X X 420.83 (2R,3R,4S,5S)-2-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6-chloroisoch roman-1 -yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 MW 436.29 437.28 408.88 409.87 Chemical Names (2S,3S,4R,5R)-2-((R)-6,7-dich Io roisoch roman-1 -yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6,7-dichloroisoch roman-1 -yl)tetrahydrofuran-3,4-diol (2S,3S,4R,5R)-2-((S)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 91 409.87 (2R,3R,4S,5S)-2-(4-amino- O          I HO         1        1 7H-pyrrolo[2,3-d]pyrimidin-7- yl)-5-((R)-2-chloro-4,7- S         /    A 7 dihydro-5H-thieno[2,3- HOU......<     1 c]pyran-7-yl)tetrahydrofuran- \J  s—\ 3,4-diol r                Xcl nh2 92 F 419.84 (2S,3S,4R,5R)-2-((1 R,4S)-6- = chloro-4-fluoroisoch roman-1 - yl)-5-(4-methyl-7H- pyrrolo[2,3-d]pyrimidin-7- yl)tetrahydrofuran-3,4-diol OX\^OH \ / / —c / 1     U----N*        OH 93 F 420.83 (2R,3R,4S,5S)-2-(4- _ aminopyrrolo[2,3-d]pyrimidin- Cl\ / X 7-yl)-5-[(1 R,4S)-6-chloro-4- / \ fluoro-isoch roman-1 - yl]tetrahydrofuran-3,4-diol X >-*0H \ / ^N\ *—\ "WO h2n 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 94 Ck 1 419.84 (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(1 R,4R)-6-chloro-4-fluoro-isoch ro man-1 -yl]tetrahydrofuran-3,4-diol X \ k^oh h y_ <)H 95 CK 1 >° 420.83 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-y 1)-5-((1 R, 4R)-6-chloro-4-fluoro isoch roman-1 -yl)tetrahydrofuran-3,4-diol X \ k .^OH __ N \ h2n 1 / -------- y_ X)H 97 F. F >° 405.36 (2S,3S,4R,5R)-2-((R)-7,8-difluoro-4H-benzo[d][1,3]dioxin-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol \ to y_ <)H 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 98 „o JH N cr 400.86 (2R,3S,4R,5R)-2-[(1R)-6-chloro-1,2,3,4-tetrahydroisoquinolin-1 -y l]-5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 99 — N 3^ ,£>H > / """*OH X 415.87 (2S,3S,4R,5R)-2-((R)-6-chloro-7-methylisochroman-1-y|)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 100 h2n t — N cr 3^ XOH ^’""" / OH '"'% 416.86 (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6-chloro-7-methylisoch roman-1 -yl)tetrahydrofuran-3,4-diol 101 N V      1 / -- \--N °* / H / ""'HIOH >Z""" / / O 415.87 (2S,3S,4R,5R)-2-((R)-7-chloro-1,3,4,5-tetrahydrobenzo[c]oxepin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Ex. Structures MW Chemical Names 102 H2N ) I             C>H N \        / /                ' \---N         | 0^. / .A-", / / / 0 416.86 (2R,3R,4S,5S)-2-(4-amino-6H-7l4-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloro-1,3,4,5-tetrahydrobenzo[c]oxepin-1-yl)tetrahydrofuran-3,4-diol ( ) cr 103 D \ D D-^\ / \     7---N< F\ ■PH . / """Hoh '"""'0 406.4 (2S,3S,4R,5R)-2-((R)-6,7-difluoroisoch roman-1 -yl)-5-(4-(methyl-d3)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol 2024204264   21 Jun 2024 Experimental Procedures Example 1A. Synthesis of (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)- 5-chloro-l,3-dihydroisobenzofuran-l-yl)tetrahydrofuran-3,4-diol (Ex. 1A) TBSCI, imidazole DMF, 25 °C, 2h -78 oc, 0.5 h (nBu)Li, THF THF, -78 oC, 0.5 h DIBAL-H Toluene, -78 °C, 2 h CsF DMSO,MeOH, 25 °C, 0.5 h 1Ai Ex. 1A Step 1. Synthesis of (2-bromo-5-chloro-phenyl)methoxy-terLbutyl-dimethyl-silane (lAb)

[00298] To a solution of (2-bromo-5-chloro-phenyl)methanol (lAa, 5.0 g, 22.58 mmol) in DMF (10 mL) was added TBSCI (10.21g, 67.73 mmol) and imidazole (3073.9 mg, 45.15 mmol). The reaction mixture was stirred at 25 °C for 16 h. TLC (PE : EA = 10 : 1, Rf = 0.8) showed the reaction was completed. The reaction mixture was diluted with water (100 mL) and the mixture was extracted with EA (50 mL x 3), then the organic layers were washed with brine (100 mL X 3), dried over Na2SO4 and concentrated in vacuum to give the crude product which was purified by silica chromatography column (100-200 mesh size, PE : EA = 200 : 1 to 100 : 1) to give (2-bromo-5-chloro-phenyl)methoxy-tert-butyl-dimethyl-silane (5.0 g, 14.9 mmol, 66% yield) as a colorless oil. Step 2. Synthesis of [(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin- 7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanone (lAe) 2024204264   21 Jun 2024

[00299] To a solution of (2-bromo-5-chloro-phenyl)methoxy-tert-butyl-dimethyl-silane (lAb, 4.3 g, 12.80 mmol) in THF (50 mL) was added butyllithium (0.6 g, 9.10 mmol) at -78 °C under N2. The mixture was stirred at -78 °C for 10 min to yield lAc. A solution of the (3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d] pyrimidin-7-yl)-N-methoxy-N,2,2-trimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxole-6-carboxamide (lAd, 1.4 g, 3.70 mmol) in THF (50 mL) was added. The mixture was stirred at -78 °C for 30 min. LCMS showed the reaction was complete. The reaction mixture was quenched with saturated NH4CI solution (50 mL). The mixture was extracted with ethyl acetate (100 mL X 3). The combined organic layers were washed with brine (40 mL X 3), dried over Na2SO4 and concentrated in vacuum to give the crude product which was purified by silica chromatography column (100-200 mesh size, PE : EA = 20 : 1 to 10 : 1) to give [(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin- 7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanone (lAe, 1.3 g, 2.20 mmol, 61.4 % yield) as a pale yellow oil. LCMS [M+H]: 578.2. Step 3. Synthesis of (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo [2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanol (lAf)

[00300] To a solution of [(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl- 3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanone (lAe, 50 mg, 0.11 mmol) in toluene (5 mL) was added diisobutylaluminum hydride (24.6 mg, 0.20 mmol). The reaction mixture was stirred at -78 °C for 0.5 h under N2. TLC (PE : EA = 3 : 1, Rf = 0.3) showed the reaction was complete. The reaction mixture was washed with water (10 mL X 3) brine (10 mL X 3). The organic layer was dried over Na2SO4, filtered and concentrated to afford the crude product which was purified silica chromatography column (100-200 mesh size, PE : EA =10:1 to 5:1) to give (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo [2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanol (lAf, 50 mg, 0.10 mmol, 99.7 % yield) as a pale yellow solid. 2024204264   21 Jun 2024 Step 4. Synthesis of (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo [2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a -tetrahydrofuro [3,4-d][l,3]dioxol-6-yl]-[4-chloro-2-(hydroxymethyl)phenyl]methanol (lAg)

[00301] To a solution of (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl -3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanol (lAf, 50 mg, 0.10 mmol) in DMSO (12 mL) and methanol (0.2 mL) was added CsF (39.3 mg, 0.3 mmol) and the reaction mixture was stirred at 25 °C for 0.5 h. LCMS showed the reaction was completed. The reaction mixture was filtered and purified by reversed-phase combi-flash, eluted with CH3CN in H2O (neutral condition) from 10% to 55% to give (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo [2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a -tetrahydrofuro [3,4-d][l,3]dioxol-6-yl]-[4-chloro-2-(hydroxymethyl)phenyl]methanol (lAg, 30 mg, 0.1 mmol, 71.7% yield) as a pale yellow oil. LCMS [M+H]: 466.1. Step 5. Synthesis of 7-[(3aR,4R,6R,6aR)-6-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (lAh)

[00302] To a solution of (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2- dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[4-chloro-2-(hydroxymethyl)phenyl]methanol (100.0 mg, 0.21 mmol) in THF (20 mL) was added Pyridine (0.02 mL, 0.21 mmol) at 25°C, Tributylphosphine (0.1 mL, 0.42 mmol) was added followed by DIAD (0.1 mL, 0.52 mmol) at 25 °C. The reaction was stirred at 25 °C under N2 for 4 h. TLC (PE : EA = 1 : 1, Rf = 0.4) showed the reaction was completed. The mixture was concentrated in vacuum to give crude product which was purified by silica chromatography column (100-200 mesh size, PE : EA = 10 : 1 to 1 : 1) to give togive7-[(3aR,4R,6R,6aR)-6-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (lAh, 80.0 mg, 0.2 mmol, 83.2 % yield) as a pale yellow oil. Step 6. Synthesis of 7-[(3aR,4R,6R,6aR)-6-[(lR)-5- chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (lAi) 2024204264   21 Jun 2024

[00303] A solution of 7-[(3aR,4R,6R,6aR)-6-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2- dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (lAh, 80.0 mg, 0.2 mmol) in 1,4-dioxane (3 mL) and NH3H2O (3 mL, 77.9 mmol) was stirred at 120 °C for 16 h in an autoclave. LCMS showed the reaction was complete. The mixture was concentrated in vacuum to give the crude product which was purified by reversed-phase combi-flash, eluted with CH3CN in H2O (neutral condition) from 10% to 95% to give 7-[(3aR,4R,6R,6aR)-6-[(lR)-5- chioro-1,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (lAi, 45.0 mg, 0.11 mmol, 58.8 % yield) as a pale yellow solid. LCMS [M+H]: 429.1. Step 7. Synthesis of (Ex. 1A)

[00304] A solution of 7-[(3aR,4R,6R,6aR)-6-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl- 3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (lAi, 45.0 mg, 0.10 mmol) in water (3 mL) and TFA (3 mL, 33.30 mmol) was stirred at 25 °C for 1 h. LCMS showed the reaction was completed. The reaction mixture was concentrated and purified by prep-HPLC, (0.1% NH3 H2O), eluted with CH3CN in H2O from 10% to 95% to give (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]tetrahydrofuran-3,4-diol (Ex. 1A, 6.0 mg, 0.02 mmol, 14.5 % yield) as a white solid. LCMS [M+H]: 389.1. ’H NMR (400 M Hz, DMSO-Je): 8 8.06 (s, 1 H), 7.42 (s, 1 H), 7.34-7.35 (d, J= 4.0 Hz, 1 H), 7.29-7.32 (m, 1 H), 7.22-7.24 (m, 1 H), 7.03 (s, 2 H), 6.64 (d, J= 3.6 Hz, 1 H), 6.14-6.16 (d, J= 7.6 Hz, 1 H), 5.34-5.36 (m, 1 H), 5.27-5.28 (d, J= 6.4 Hz, 1 H), 5.195.20 (d, J= 4.0 Hz, 1 H), 5.04-5.12 (m, 2 H), 4.51-4.56 (m, 1 H), 4.05-4.06 (m, 1 H), 3.93-3.95 (m, 1 H). XH NMR (400 M Hz, DMSO-J6+D2O ): 8 8.07 (s, 1 H), 7.43 (s, 1 H), 7.34-7.35 (d, J=3.6 Hz, 1 H), 7.30-7.33 (m, 1 H), 7.23-7.25 (m, 1 H), 6.65-6.66 (d, J =3.6 Hz, 1 H), 6.14-6.16 (d, J= 7.6 Hz, 1 H), 5.35-5.36 (m, 1 H), 5.08-5.10 (m, 2 H), 4.51-4.54 (m, 1 H), 4.07-4.09 (m, 1 H), 3.933.94 (m, 1 H). 2024204264   21 Jun 2024 Example IB. Synthesis of (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-5-chloro-l,3-dihydroisobenzofuran-l-yl)tetrahydrofuran-3,4-diol (Ex. IB) NaBH4 MeOH, 25 °C, 2h CsF DMSO.MeOH 1Ae                                              1Ba                                        1Bb Py / Bu3P, DIAD / THF, 25 °C NH3H2O dioxane 1Bc                                        1Bd                                     Ex. 1B Step 1. Synthesis of (IBa)

[00305] To a solution of [(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl- 3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanone (lAe, 630 mg, 1.10 mmol) in methanol (5 mL) was added NaBH4 (82.4 mg, 2.20 mmol), and the mixture was stirred at 25 °C for 1 h. TLC (PE : EA = 1 : 1, Rf = 0.4) showed the starting material was consumed. LCMS showed the reaction was complete. The reaction mixture was quenched with saturated NH4CI solution (50 mL). The mixture was extracted with ethyl acetate (100 mL X 3). The combined organic layers were washed with brine (40 mL X 3), dried over Na2SO4 and concentrated in vacuum to give the crude product which was purified by silica chromatography column (100-200 mesh size, PE : EA =10:1 to 5 : 1) to give (R)-[(3aR,4R,6R,6aR) -4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanol (lAf, 10.0 mg, 0.02 mmol, 1.6 % yield) and (S)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a -tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanol (IBa), 520 mg, 0.9 mmol, 82.3 % yield) as a pale yellow oil. 2024204264   21 Jun 2024 Step 2. Synthesis of (S)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[4-chloro-2-(hydroxymethyl)phenyl]methanol (IBb)

[00306] To a solution of (S)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl- 3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanol (IBa, 520 mg, 0.90 mmol) in DMSO (5 mL) and methanol (0.1 mL) was added CsF (408.2 mg, 2.70 mmol) and the reaction mixture was stirred at 25 °C for 1 h. LCMS showed the reaction was complete. The reaction mixture was filtered and purified by reversed-phase combi-flash, eluted with CH3CN in H2O (neutral condition) from 10% to 95% to give (S)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[4-chloro-2-(hydroxymethyl)phenyl]methanol (IBb, 300 mg, 0.64 mmol, 71.8 % yield) as a white solid. LCMS [M+H]: 466.1. Step 3. Synthesis of 7-[(3aR,4R,6R,6aR)-6-[(lS)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (IBc)

[00307] To a solution of (S)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl- 3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[4-chloro-2-(hydroxymethyl)phenyl]methanol (IBb, 250 mg, 0.5 mmol) in THF (5 mL) and was added pyridine (0.04 mL, 0.50 mmol), tributylphosphine (0.3 mL, 1.10 mmol) and DIAL) (0.2 mL, 1.10 mmol). The reaction mixture was stirred at 25 °C for 16 h. TLC (PE : EA = 3 : 1, Rf = 0.4) showed the reaction was complete. The mixture was concentrated in vacuum to give the crude product which was purified by silica chromatography column (100-200 mesh size, PE : EA = 50 : 1 to 20 : 1) to give 7-[(3aR,4R,6R,6aR)-6-[(lS)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (IBc, 180.0 mg, 0.4 mmol, 74.9 % yield) as a white solid. Step 4. Synthesis of 7-[(3aR,4R,6R,6aR)-6-[(lS)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a -tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (IBd) 2024204264   21 Jun 2024

[00308] To a solution of 7-[(3aR,4R,6R,6aR)-6-[(lS)-5-chloro-l,3-dihydroisobenzofuran-1 -yl]-2,2- dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (IBc, 180 mg, 0.40 mmol) in 1,4-dioxane (5 mL) and was added NH3H2O (5 mL, 129.81 mmol) and the reaction mixture was stirred at 25 °C for 16 h in a autoclave. LCMS showed the reaction was complete. The mixture was concentrated in vacuum to give the crude product which was purified by reversed-phase combi-flash, eluted with CH3CN in H2O (neutral condition) from 10% to 90% to give 7-[(3aR,4R,6R,6aR)-6-[(lS)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a -tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (IBd, 140 mg, 0.32 mmol, 81.3 % yield) as a white solid. LCMS [M+H]: 429.1. Step 5. Synthesis of (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl) -5-[(lS)-5-chloro-l,3-dihydroisobenzofuran-l-yl]tetrahydrofuran-3,4-diol hydrochloride (Ex. IB)

[00309] A solution of 7-[(3aR,4R,6R,6aR)-6-[(lS)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2- dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (IBd, 180 mg, 0.40 mmol) in water (5 mL) and TFA (5 mL, 67.31 mmol) was stirred at 25 °C for 1 h. LCMS showed the reaction was complete. The reaction mixture was concentrated and purified by prep-HPLC, (0.1% NH3 H2O), eluted with CH3CN in H2O from 10% to 95% and added 1 mL of HC1 (1 M) and lyophilized to obtain (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl) -5-[(lS)-5-chloro-l,3- dihydroisobenzofuran-l-yl]tetrahydrofuran-3,4-diol hydrochloride (Ex. IB, 45.1 mg, 0.10 mmol, 25.1% yield) as pale yellow solid. LCMS [M+H]: 389.1. ’H NMR (400 M Hz, DMSO-Je): 8 13.89 (s, 1 H), 9.45 (s, 1 H), 8.50 (s, 1 H), 8.36 (s, 1 H), 7.54-7.55 (d, J= 3.6 Hz, 1 H), 7.30-7.39 (m, 3 H), 7.01-7.02 (d, J= 3.6 Hz, 1 H), 6.08-6.09 (d, J= 4.8 Hz, 1 H), 5.39 (s, 1 H), 4.97-5.05 (m, 2 H), 4.32-4.38 (m, 3 H). XHNMR (400 M Hz, DMSO-J6+D2O ): 8 8.37 (s, 1 H), 7.55-7.56 (d, J= 3.6 Hz, 1 H), 7.37-7.39 (m, 1 H), 7.30-7.33 (m, 2 H), 7.01-7.02 (d, J= 3.6 Hz, 1 H), 6.08-6.10 (d, J= 7.2 Hz, 1 H), 5.39 (s, 1 H), 5.00-5.05 (m, 2 H), 4.32-4.39 (m, 3 H). 2024204264   21 Jun 2024 Example 2A. Synthesis of (lR,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)- 5-chloro-l,3-dihydroisobenzofuran-l-yl)cyclopentane-l,2-diol (Ex. 2A) n-BuLi THF, -78 °C,1 h TBAF, THF 0°C, 1 h 2Ab                                      2Ac Ex. 2A Step 1. Synthesis of [(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro -3aH-cyclopenta[d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanol (2Ab)

[00310] To a solution of (2-bromo-5-chloro-phenyl)methoxy-tert-butyl-dimethyl-silane (lAb, 1826.0 mg, 5.44 mmol) in THF (20 mL) was added butyllithium (2.8 mL, 5.44 mmol) at -78 °C. The reaction mixture was stirred at -78 °C for 0.5 h. Then, (3aS,4R,6S,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxole-6-carbaldehyde (2Aa, 1750 mg, 5.44 mmol) was added to the mixture. The reaction mixture was stirred at -78 °C for 1 h. LCMS showed the reaction was complete. The reaction was quenched with H2O (30 mL) and extracted with ethyl acetate (60 mL). The organic layer was dried over Na2SO4, filtered, and concentrated in vacuum to give the crude product which was purified by silica chromatography column (PE : EA = 3 : 1) to give [(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro -3aH-cyclopenta[d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanol (2Ab, 360.0 mg, 0.62 mmol, 11.4 % yield). LCMS [M+H]: 578.2. 2024204264   21 Jun 2024 Step 2. Synthesis of (2Ac) and (2Ad)

[00311] To a solution of [(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]methanol (2Ab, 360 mg, 0.62 mmol) in THF (5 mL) was added TBAF (0.62 mL, 1 N in THF, 0.62 mmol) at 0 °C. The mixture was stirred at 0 °C for 1 h. LCMS showed the reaction was complete. To the mixture was added ethyl acetate (50 mL) which was washed with H2O (20 mL X 3) and brine (30 mL). The organic layer was dried over Na2SO4, concentrated in vacuum to give the crude product which was purified by prep-TLC (PE: EA = 3: 1) to give (S)-[(3aS,4R,6R,6aR)-4-(4-chloropyrrolo -[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-[4-chloro-2-(hydroxymethyl)phenyl]methanol (2Ac, 42.0 mg, 0.09 mmol, 14.5 % yield) and (R)-[(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-[4-chloro-2-(hydroxymethyl)phenyl]methanol (2Ad, 55.0 mg, 0.12 mmol, 19.0 % yield). LCMS [M+H]: 464.1. Step 3. Synthesis of 7-[(3aS,4R,6R,6aR)-6-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a -tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (2Ae)

[00312] To a solution of (R)-[(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-[4-chloro-2-(hydroxymethyl)phenyl]methanol (2Ad, 100 mg, 0.22 mmol) in THF (5 mL) was added PPhs (56.5 mg, 0.22 mmol), then added DIAL) (0.04 mL, 0.22 mmol), the mixture was stirred at 25 °C for 16 h. The reaction mixture was concentrated in vacuum to give crude product which was purified by prep-TLC (PE : EA = 3 : 1) to give 7-[(3aS,4R,6R,6aR)-6-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a -tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (2Ae, 70 mg, 0.16 mmol, 72.8% yield). LCMS [M+H]: 446.2. Step 4. Synthesis of7-[(3aS,4R,6R,6aR)-6-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (2Af) 2024204264   21 Jun 2024

[00313] To a solution of 7-[(3aS,4R,6R,6aR)-6-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (2Ae, 90 mg, 0.20 mmol) in 1,4-dioxane (3 mL) was added ammonia hydrate (3 mL, 0.60 mmol), then the mixture was sealed and stirred at 120 °C for 16 h. LCMS showed the mixture was complete. The reaction mixture was concentrated in vacuum, added ethyl acetate (100 mL), and washed with brine (60 mL). The organic layer was dried over Na2SO4, concentrated in vacuum to give 7-[(3aS,4R,6R,6aR)-6-[(lR)-5-chloro-1,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (2Af, 90 mg, 0.18 mmol, 92.0 % yield). LCMS [M+H]: 427.1. Step 5. Synthesis of (lR,2S,3R,5S)-3-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]cyclopentane-l,2-diol (Ex. 2A)

[00314] To a solution of 7-[(3aS,4R,6R,6aR)-6-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (2Af, 70 mg, 0.16 mmol) in water (2 mL) was added TFA (0.9 mL, 11.45 mmol) and the reaction mixture was stirred at 30 °C for 0.5 h. LCMS showed the reaction was complete. The mixture was purified by prep-HPLC, eluted with CH3CN in H2O (0.1% NH4OH) from 5% to 95% to give (lR,2S,3R,5S)-3-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]cyclopentane-l,2-diol (Ex. 2A, 30 mg, 0.08 mmol, 47% yield) as a white solid. LCMS [M+H]: 387.3. 1HNMR(400 MHz, DMSO-J6+D2O): 8 8.00 (s, 1H), 7.31-7.37 (m, 3H), 7.15-7.16 (m, 1H), 6.52-6.53 (m, 1H), 5.41-5.42 (m, 1H), 5.10-5.14 (m, 1H), 4.99-5.03 (m, 1H), 4.78-4.85 (m, 1H), 4.18-4.21 (m, 1H), 4.04-4.06 (m, 1H), 2.47-2.50 (m, 1H), 1.71-1.79 (m, 1H) , 1.33-1.40 (m, 1H). Example 2B. Synthesis of (lR,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-5-chloro-l,3-dihydroisobenzofuran-l-yl)cyclopentane-l,2-diol (Ex. 2B) 2Ac                                    2Ba                               2Bb 2024204264   21 Jun 2024 Step 1. Synthesis of 7-[(3aS,4R,6R,6aR)-6-[(lR)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (2Ba)

[00315] To a solution of (S)-[(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-[4-chloro-2-(hydroxymethyl)phenyl]methanol (2Ac, 90 mg, 0.19 mmol) in THF (4 mL) was added PPhs (101.7 mg, 0.39 mmol) and DIAD (0.11 mL, 0.39 mmol). The mixture was stirred at 25 °C for 16 h under N2. TLC (PE : EA = 3 : 1, Rf = 0.4 ) showed the reaction was complete. The mixture was concentrated in vacuum to give the crude product which was purified by pre-TLC (PE : EA = 3 : 1) to give 7-[(3aS,4R,6R,6aR)-6-[(lR)-5-chloro-1,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (2Ba, 70 mg, 0.16 mmol, 80.9% yield). LCMS [M+H]: 446.2. Step 2. Synthesis of 7-[(3aS,4R,6R,6aR)-6-[(lS)-5-chloro-l,3-dihydroisobenzofuran -l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (2Bb)

[00316] To a solution of7-[(3aS,4R,6R,6aR)-6-[(lS)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (2Ba, 70 mg, 0.16 mmol) in 1,4-dioxane (3.5 mL) was added ammonia hydrate (3.5 mL, 0.47 mmol). The mixture was sealed and stirred at 120 °C for 16 h. LCMS showed the reaction was complete. The mixture was concentrated in vacuum to give 7-[(3aS,4R,6R,6aR)-6-[(lS)-5-chloro-1,3-dihydroisobenzofuran -l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (2Bb, 60 mg, 0.09 mmol, 59.2 % yield). LCMS [M+H]: 427.1. Step 3. Synthesis of (lR,2S,3R,5S)-3-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lS)-5-chloro-l,3-dihydroisobenzofuran-l-yl]cyclopentane-l,2-diol (Ex. 2B)

[00317] To a solution of7-[(3aS,4R,6R,6aR)-6-[(lS)-5-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin- 2024204264   21 Jun 2024 4-amine (2Bb, 60 mg, 0.09 mmol) in water (2 mL) was added TFA (1 mL, 13.0 mmol). The reaction mixture was stirred at 30 °C for 0.5 h. LCMS showed the reaction was complete. The reaction mixture was purified by prep-HPLC (0.1% NH3 H2O), eluted with CH3CN in H2O from 10% to 95% to give (lR,2S,3R,5S)-3-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lS)-5-chloro-l,3-dihydroisobenzofuran-l-yl]cyclopentane-l,2-diol (Ex. 2B, 27 mg, 0.07 mmol, 76.1% yield) as a white solid. LCMS [M+H]: 387.1. XHNMR (400 MHz, DMSO-J6+D2O): 8 8.03 (s, 1H), 7.41-7.42 (m, 1H), 7.34-7.36 (m, 2H), 7.21-7.22 (m, 1H), 6.57-6.58 (m, 1H), 5.21-5.22 (m, 1H), 4.97-5.07 (m, 2H), 4.86-4.91 (m, 1H), 4.16-4.191 (m, 1H), 3.65-3.66 (m, 1H), 2.38-2.43 (m, 1H), 2.25-2.32 (m, 1H), 1.75-1.83 (m, 1H). Example 3A. Synthesis of (S)-3-((lS,2R,3S,4R)-4-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxycyclopentyl)-6-chloroisobenzofuran-l(3H)-one (Ex. 3A) OO     0 3Aa                                   3Ac 3Ad                                               3Ae TFA, H2O 30 °C, 0.5 h Ex. 3A Step 1. Synthesis of (3R)-3-[(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2 -dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Ac) and (3S)-3-[(3aS,4R,6R,6aR)-4-(4-chloropyrrolo [2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Ad)

[00318] To a solution of methyl 5-chloro-2-iodo-benzoate (3Ab, 829.3 mg, 2.80 mmol) in THF (15 mL) was added isopropyl magnesium chloride (2.2 mL, 2.80 mmol) at -20 °C, and the solution was stirred at -20 °C for 2 h. (3aS,4R,6S,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)- 2024204264   21 Jun 2024 2,2-dimethyl -4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxole-6-carbaldehyde (3Aa, 900 mg, 2.80 mmol) in THF (10 mL) was added to the mixture and stirred at 0 °C for 2 h. LCMS showed the reaction was complete. The reaction mixture was added H2O (30 mL) and ethyl acetate (60 mL). The organic layer was washed with H2O (30 mL) and brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuum to give the crude product which was purified by silica chromatography column (PE : EA = 6 : 1) to give (3R)-3-[(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2 -dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Ac, 330 mg, 0.72 mmol, 25.6% yield) and (3S)-3-[(3aS,4R,6R,6aR)-4-(4-chloropyrrolo [2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Ad, 270.0 mg, 0.59 mmol, 21.0 % yield). LCMS [M+H]: 460.0. Step 2. Synthesis of (3S)-3-[(3aS,4R,6R,6aR)-4-(4-aminopyrrolo[2,3-d] pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Ae)

[00319] To a solution of (3S)-3-[(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Ad, 170 mg, 0.37 mmol) in 1,4-dioxane (5 mL) was added tert-butyl carbamate (86.5 mg, 0.74 mmol), Xantphos (32.1 mg, 0.06 mmol) and Pd2(dba)3 (13.5 mg, 0.01 mmol). The mixture was stirred at 80 °C 16 h under N2. LCMS showed the reaction was complete. The reaction mixture was filtered and concentrated in vacuum to give the crude product which was purified by silica chromatography column (DCM : CH3OH = 30 : 1) to give (3S)-3-[(3aS,4R,6R,6aR)-4-(4-aminopyrrolo[2,3-d] pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Ae, 100 mg, 0.23 mmol, 61.4% yield). LCMS [M+H]: 441.2. Step 3. Synthesis of (3S)-3-[(lS,2R,3S,4R)-4-(4-aminopyrrolo[2,3-d]pyrimidin -7-yl)-2,3-dihydroxy-cyclopentyl]-6-chloro-3H-isobenzofuran-l-one hydrochloride (Ex. 3A)

[00320] To a solution of (3S)-3-[(3aS,4R,6R,6aR)-4-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H- 2024204264   21 Jun 2024 isobenzofuran-l-one (3Ae, 100 mg, 0.23 mmol) in water (3 mL) was added TFA (1.5 mL, 19.47 mmol). The reaction mixture was stirred at 30 °C for 0.5 h. LCMS showed the reaction was complete. The mixture was purified by prep-HPLC, eluted with CH3CN in H2O (0.1% TFA) from 5% to 9%, added HC1 (1 mL, 2N), and lyophilized to give (3S)-3-[(lS,2R,3S,4R)-4-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-cyclopentyl]-6-chloro-3H-isobenzofuran-l-one hydrochloride (Ex. 3A, 15 mg, 0.03 mmol, 15.1% yield) as a white solid. LCMS [M+H]: 401.1. ’H NMR (400 MHz, DMSO-J6+D2O): 8 8.35 (s, 1 H), 7.94-7.95 (m, 1 H), 7.86-7.88 (m, 1 H), 7.747.76 (m, 1 H), 7.65-7.66 (m, 1 H), 6.98-6.99 (m, 1 H), 5.78-5.79 (m, 1 H), 4.93-5.00 (m, 1 H), 4.144.18 (m, 1 H), 3.54-3.56 (m, 1 H), 2.68-2.69 (m, 1 H), 2.38-2.46 (m, 1 H), 1.95-2.03 (m, 1 H). Example 3B. Synthesis of (R)-3-((lS,2R,3S,4R)-4-(4-amino-6H-714-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxycyclopentyl)-6-chloroisobenzofuran-l(3H)-one (Ex. 3B) Step 1. Synthesis of tert-butyl N-[7-[(3aS,4R,6R,6aR) -6-[(lR)-5-chloro-3-oxo-lH-isobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-yl]carbamate (3Ba)

[00321] To a solution of (3R)-3-[(3aS,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Ac, 230 mg, 0.50 mmol) in 1,4-dioxane (6 mL) was added tert-butyl carbamate (117.1 mg, 1.00 mmol), Xantphos (43.4 mg, 0.07 mmol) and Pd2(dba)3 (18.3 mg, 0.02 mmol). The mixture was stirred at 80 °C for 16 h under N2. LCMS showed the reaction was complete. The reaction mixture was filtered and concentrated in vacuum to give the crude product which was purified by silica chromatography column (DCM : CH3OH = 30 : 1) to give tert-butyl N-[7-[(3aS,4R,6R,6aR) -6-[(lR)-5-chloro-3-oxo-lH-isobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-yl]carbamate (3Ba, 100 mg, 0.18 mmol, 37% yield). LCMS [M+H]: 541.2. 2024204264   21 Jun 2024 Step 2. Synthesis of (3R)-3-[(3aS,4R,6R,6aR)-4-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Bb)

[00322] To a solution of tert-butyl N-[7-[(3aS,4R,6R,6aR)-6-[(lR)-5-chloro-3-oxo-lH-isobenzofuran-l-yl]-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-yl]carbamate (3Ba, 100 mg, 0.18 mmol) in DCM (3 mL) and was added TFA (3 mL, 38.94 mmol). The reaction mixture was stirred at 25 °C 0.5 h. LCMS showed the reaction was complete. The reaction mixture was concentrated in vacuum to give crude (3R)-3-[(3aS,4R,6R,6aR)-4-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Bb) which was used in the next step directly. LCMS [M+H]: 441.1. Step 3. Synthesis of (3R)-3-[(lS,2R,3S,4R)-4-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-cyclopentyl]-6-chloro-3H-isobenzofuran-l-one hydrochloride (Ex. 3B)

[00323] To a solution of (3R)-3-[(3aS,4R,6R,6aR)-4-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-4,5,6,6a-tetrahydro-3aH-cyclopenta[d][l,3]dioxol-6-yl]-6-chloro-3H-isobenzofuran-l-one (3Bb, 70 mg, 0.16 mmol) in water (3 mL) was added TFA (1.4 mL, 18.2 mmol). The reaction mixture was stirred at 30 °C for 0.5 h. LCMS showed the reaction was complete. The mixture was purified by prep-HPLC, eluted with CH3CN in H2O (0.1% TFA) from 5% to 95%, added HC1 (1 mL, 2 N), and lyophilized to give (3R)-3-[(lS,2R,3S,4R)-4-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxy-cyclopentyl]-6-chloro-3H-isobenzofuran-l-one hydrochloride (Ex. 3B, 14.0 mg, 0.03 mmol, 19.0% yield) as a white solid. LCMS [M+H]: 401.3. XHNMR (400 MHz, DMSO-J6+D2O): 8 8.30 (s, 1 H), 7.80-7.90 (m, 3 H), 7.48-7.49 (m, 1 H), 6.936.94 (m, 1 H), 5.94-5.95 (m, 1 H), 4.83-4.89 (m, 1 H), 4.24-4.27 (m, 1 H), 4.15-4.18 (m, 1 H), 2.682.76 (m, 1 H), 1.73-1.80 (m, 1 H), 1.18-1.26 (m, 1 H). 2024204264   21 Jun 2024 Example 5. Synthesis of (2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6- chloro-l,3-dihydroisobenzofuran-l-yl)tetrahydrofuran-3,4-diol (Ex. 5) 5b 5c THF, - 78 °C, 0.5 h 5a Step 1. Synthesis of (2-bromo-4-chloro-phenyl)methoxy-tert-butyl-dimethyl-silane (5b)

[00324] To a mixture of (2-bromo-4-chloro-phenyl)methanol (5a, 5.0 g, 22.58 mmol) and imidazole (3.07 g, 45.15 mmol) in DMF (10 mL) was added TBSC1 (5.10 g, 33.86 mmol) at 0 °C. The mixture stirred at rt for 2 h. TCL (PE : EA = 10 : 1, Rf = 0.7) showed the reaction was complete. The reaction mixture was diluted with water (100 mL) and the mixture was extracted with ethyl acetate (50 mL X 3), then the organic layers were washed with brine (100 mL X 3), dried over Na2SO4 and concentrated in vacuum to give crude product which was purified on a silica chromatography column (100-200 mesh size, PE : EA = 200 : 1 to 100 : 1) to give (2-bromo-4-chloro-phenyl)methoxy-tert-butyl-dimethyl-silane (5b, 6.80 g, 18.23 mmol, 80.7% yield) as a colorless oil. ^NMR (400 M Hz, DMSO-J6): 8 7.70 (s, 1 H), 7.49 (s, 2 H), 4.66 (s, 2 H), 0.91 (s, 9 H), 0.10 (s, 6H). Step 2. Synthesis of [(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-phenyl]methanone (5d) 2024204264   21 Jun 2024

[00325] To a solution of (2-bromo-4-chloro-phenyl)methoxy-tert-butyl-dimethyl-silane (5b, 6.74 g, 20.06 mmol) in THF (50 mL) was added butyllithium (8.6 mL, 13.79 mmol) at -78 °C under N2. The resulting solution of 5c was stirred at -78 °C for 10 min under N2. A solution of the (3aR,4R,6S,6aS)-4- (4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-N-methoxy-N,2,2-trimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxole-6-carboxamide (lAd, 2.4 g, 6.27 mmol) in THF (50 mL) was added and the mixture was stirred at -78 °C for 30 min under N2. LCMS showed the reaction was complete. The reaction mixture was quenched with saturated NH4Q solution (50 mL). The mixture was extracted with ethyl acetate (100 mL X 3). The combined organic layers were washed with brine (40 mL X 3), dried over Na2SO4, concentrated in vacuum to give the crude product which was purified by silica chromatography column (100-200 mesh size, PE : EA = 20 : 1 to 10 : 1) to give [(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-phenyl]methanone (5d, 3.36 g, 5.81 mmol, 92.6% yield) as a pale yellow oil. LCMS [M+H]: 578.1. Step 3. Synthesis of (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo [2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-phenyl]methanol (5e)

[00326] To a solution of [(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a- tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-phenyl]methanone (5d, 3.3 g, 5.71 mmol) in toluene (100 mL) was added diisobutylaluminum hydride (9.5 mL, 14.26 mmol) at -78 °C under N2. The reaction mixture was stirred at -78 °C for 0.5 h under N2. TLC (PE : EA = 3 : l,Rf=0.3) showed the reaction was complete. The reaction mixture was washed with water (10 mL X 3) and brine (10 mL X 3). The organic layer was dried over Na2SO4, filtered and concentrated to afford crude product which was purified silica chromatography column (100-200 mesh size, PE : EA =10: lto8: l)to give (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo [2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-phenyl]methanol (5e, 1.8 g, 2.67 mmol, 46.7% yield) as a white solid. LCMS [M+H]: 580.2. Step 4. Synthesis of (R)-[(3aR,4R,6R,6aR)-4- (4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[5-chloro-2-(hydroxymethyl)phenyl]methanol (5f) - 114- 2024204264   21 Jun 2024

[00327] To a solution of (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4, 6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-phenyl]methanol (5e, 1.8 g, 3.10 mmol) in DMSO (12 mL) and methanol (0.2 mL) was added CsF (1.2 g, 9.3 mmol). The reaction mixture was stirred at 25 °C for 4 h. LCMS showed the reaction was complete. The reaction mixture was filtered and purified by reversed-phase combi-flash, eluted with CH3CN in H2O (neutral condition) from 10% to 95% to give (R)-[(3aR,4R,6R,6aR)-4- (4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[5-chloro-2-(hydroxymethyl)phenyl]methanol (5f, 560 mg, 1.19 mmol, 38.3% yield) as a white solid. LCMS [M+H]: 466.1. Step 5. Synthesis of 7-[(3aR,4R,6R,6aR)-6-[(lR)-6-chloro-l,3 -dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (5g)

[00328] To a solution of (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4, 6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[5-chloro-2-(hydroxymethyl)phenyl]methanol (5f, 510 mg, 1.09 mmol) in THF (15.0 mL) was added pyridine (0.1 mL, 1.09 mmol), tributylphosphine (0.6 mL, 2.19 mmol) and DIAL) (0.2 mL, 2.3 mmol). The reaction mixture was stirred at 25 °C for 2 h. TLC (PE : EA = 3 : 1, Rf = 0.4 ) showed the reaction was complete. The mixture was concentrated in vacuum to give the crude product which was purified by silica chromatography column (100-200 mesh size, PE : EA = 20 : 1 to 10 : 1) to give 7-[(3aR,4R,6R,6aR)-6-[(lR)-6-chloro-l,3 -dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (5g, 350 mg, 0.78 mmol, 71.4% yield) as a white solid. LCMS [M+H]: 448.1. Step 6. Synthesis of 7-[(3aR,4R,6R,6aR)-6-[(lR)-6-chloro-l,3 -dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (5h)

[00329] A mixture of 7-[(3aR,4R,6R,6aR)-6-[(lR)-6-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl- 3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (5g, 48.1 mg, 0.11 mmol), 1,4-dioxane (0.5 mL) andNHsHLO (0.5 mL, 12.98 mmol) was stirred at 120 °C for 16 h in a autoclave. LCMS showed the reaction was complete. The mixture was concentrated in vacuum to give 7-[(3aR,4R,6R,6aR)-6-[(lR)-6-chloro-l,3 - 2024204264   21 Jun 2024 dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (5h, 50 mg, 0.10 mmol, 94.6% yield) as a white solid. LCMS [M+H]: 429.1. Step 7. Synthesis of (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-l,3-dihydroisobenzofuran-l-yl]tetrahydrofuran-3,4-diol (Ex. 5)

[00330] A mixture of 7-[(3aR,4R,6R,6aR)-6-[(lR)-6-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl- 3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (5h, 50 mg, 0.12 mmol), water (0.5 mL) and TFA (0.8 mL, 9.06 mmol) was stirred at 40 °C for 16 h. LCMS showed the reaction was complete. The reaction mixture was concentrated and purified by prep-HPLC, (0.1% NFLTLO), eluted with CH3CN in H2O from 10% to 95% to give (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-l,3-dihydroisobenzofuran-l-yl]tetrahydrofuran-3,4-diol (Ex. 5, 19.5 mg, 0.05 mmol, 42.9% yield) as a white solid. LCMS [M+H]: 389.1. XHNMR (400 M Hz, DMSO-76): 8 8.07 (s, 1 H), 7.37 (s, 3 H), 7.30 (s, 1 H), 7.03 (br, 2 H), 6.65 (d, J= 3.6 Hz, 1 H), 6.16 (d, J= 7.6 Hz, 1 H), 5.36 (d, J= 2.0 Hz, 1 H), 5.26 (d, J= 7.2 Hz, 1 H), 5.19 (d, J= 4.0 Hz, 1 H), 5.04-5.13 (m, 2 H), 4.52 (dd, Ji = 7.2 Hz, J2 = 5.2 Hz, 1 H), 4.11 (d, 7= 4.8 Hz, 1 H), 3.93 (t, 7= 4.4 Hz, 1 H). XH NMR (400 M Hz, DMSO-76+D2O ): 8 8.07 (s, 1 H), 7.37 (s, 3 H), 7.29 (s, 1 H), 6.66 (d, 7= 3.6 Hz, 1 H), 6.15 (d, 7= 3.6 Hz, 1 H), 5.37 (br, 1 H), 5.04-5.13 (m, 2 H), 4.52 (dd, Ji = 2.0 Hz, J2 = 5.2 Hz, 1 H), 4.11 (d, 7= 5.2 Hz, 1 H), 3.93 (d, 7 = 4.8 Hz, 1 H). Example 15. Synthesis of (2S,3S,4R,5R)-2-((R)-6-chloro-l,3-dihydroisobenzofuran-l-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (Ex. 15) 5g                                          15a                                    Ex. 15 Step 1. Synthesis of 7-[(3aR,4R,6R,6aR)-6-[(lR) -6-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-methyl-pyrrolo[2,3-d]pyrimidine (15a) 2024204264   21 Jun 2024

[00331] To a solution of 7-[(3aR,4R,6R,6aR)-6-[(lR)-6-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-chloro-pyrrolo[2,3-d]pyrimidine (5g, 200.0 mg, 0.45 mmol) in THF (5 mL) was added dimethylzinc (4.5 mL, 4.46 mmol) at 25 °C. The reaction mixture was stirred at 80 °C for 2 h. LCMS showed the reaction was complete. The mixture was cooled to room temperature and quenched with saturated NaHCOs (aq) and extracted with ethyl acetate (100 mL X 3). The organic layer was washed with brine (50 mL X 3), dried over anhydrous Na2SO4, filtered and concentrated in vacuum to give 7-[(3aR,4R,6R,6aR)-6-[(lR) -6-chloro-l,3-dihydroisobenzofuran-l-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-methyl-pyrrolo[2,3-d]pyrimidine (15a, 206 mg, 0.40 mmol, 90.6% yield) as a brown solid. LCMS [M+H]: 428.1. Step 2. Synthesis of (2S,3S,4R,5R)-2-[(lR)-6-chloro-l,3 -dihydroisobenzofuran-l-yl]-5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (Ex. 15)

[00332] A mixture of 7-[(3aR,4R,6R,6aR)-6-[(lR)-6-chloro-l,3-dihydroisobenzofuran-l-yl] -2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]-4-methyl-pyrrolo[2,3-d]pyrimidine (15a, 106 mg, 0.25 mmol), water (0.5 mL) and TFA (0.8 mL, 8.33 mmol), was stirred at 40 °C for 2 h. LCMS showed the reaction was complete. The reaction mixture was filtered and purified by prep-HPLC (0.1% NH3H2O), eluted with CH3CN in H2O from 10% to 95% to give (2S,3S,4R,5R)-2-[(lR)-6-chloro-l,3-dihydroisobenzofuran-l-yl]-5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (Ex. 15, 36.6 mg, 0.09 mmol, 37.1% yield) as a white solid. LCMS [M+H]: 388.1. XHNMR (400 M Hz, DMSO-76):8 8.67 (s, 1 H), 7.78 (d, J= 3.6 Hz, 1 H), 7.38 (s, 2 H), 7.31 (s, 1 H), 6.83 (d, J= 3.6 Hz, 1 H), 6.29 (d, J= 7.2 Hz, 1 H), 5.33-5.40 (m, 3 H), 5.06-5.15 (m,2H), 4.55-4.58 (m, 1 H), 4.18 (d, 7= 4.8 Hz, 1 H), 3.93 (d, 7= 4.8 Hz, 1 H), 2.68 (s, 3 H). XHNMR (400 M Hz, DMSO-76+D2O ):8 8.67 (s, 1 H), 7.77 (d, 7= 4.0 Hz, 1 H), 7.38 (s, 2 H), 7.31 (s, 1 H), 6.84 (d, 7= 4.0 Hz, 1 H), 6.29 (d, 7= 3.2 Hz, 1 H), 5.39 (br, 1 H), 5.06-5.16 (m, 2 H), 4.55-4.58 (m,l H), 4.18 (d, 7= 4.0 Hz, 1 H), 3.93 (d, 7= 3.2 Hz, 1 H), 2.68 (s, 3 H). 2024204264   21 Jun 2024 Example 22. Synthesis of (2S,3S,4R,5R)-2-((R)-6-chloroisochroman-l-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (Ex. 22) Fe(acac)3, MeMgBr THF, 5°C, 1 h 40°C, 2 h 22g HCI / MeOH Ex. 22 Step 1. Synthesis of 2-(2-bromo-5-chloro-phenyl)ethanol (22a)

[00333] To a solution of 2-(2-bromo-5-chloro-phenyl)acetic acid (20.0 g, 80.16 mmol) in THF (200 mL), borane in THF (240.49 mL, 240.49 mmol) was added, and the mixture was stirred at 40°C for 8 h. The mixture was quenched with MeOH at 0°C, concentrated, and extracted with EA (400 mL><2). The combined organic layers were dried, concentrated and purified by combi flash eluting with CH3CN / H2O (neutral) from 5 / 95 to 95 / 5 to give 22b (18.1 g, 76.854 mmol, 95.9% yield) as a colorless oil. LCMS [M-18]: 217.0 / 219.0. Step 2. Synthesis of 2-(2-bromo-5-chloro-phenyl)ethoxy-tert-butyl-dimethyl-silane (22b)

[00334] To a solution of 22a (18.1 g, 76.85 mmol) in DMF (200 mL), imidazole (7.85 g, 115.28 mmol) and TBDMSC1 (13.9 g, 92.23 mmol) were added and the mixture was stirred at 25°C for 8 h. EA (800 mL) was added and the mixture was washed with brine (400 mLx2). The organic layer was concentrated and purified by flash column (PE) to give 22b (26.7 g, 76.34 mmol, 99.3% yield) as a colorless oil. 2024204264   21 Jun 2024 Step 3. Synthesis of [2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-phenyl]-[(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (22c)

[00335] To a solution of 22b (8.91 g, 25.6 mmol) in dry THF (50 mL) was added n-BuLi (12.8 mL, 20.48 mmol) at -78°C and the mixture was stirred for 10 min under nitrogen. A solution of lAd (4.0 g, 10.24 mmol) in dry THF (20 mL) was added andthe mixture was stirred for 5 min at -78°C. TLC (PE:EA=8:1) showed the reaction was complete. The reaction was poured into dilute HC1 (pH = 6; pH kept <8 during the process of quenching.) The mixture was extracted with EA (200 mL><2), the combined organic layers were dried, concentrated and purified by combi-flash eluting with CH3CN / H2O (neutral) from 5 / 95 to 95 / 5 to give 22c (5.1 g, 8.60 mmol, 84% yield) as yellow solid. Step 4. Synthesis of (R)-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-5-chloro-phenyl]methanol (22d)

[00336] To a solution of 22c (5.0 g, 8.44 mmol) in THF (30 mL) at -78°C, DIBAL-H (16.88 mL, 25.31 mmol) was added and the mixture was stirred at -78°C for 30 min. TLC (PE / EA=8 / 1) showed SM Rf=0.5 has been completely consumed with the main product Rf=0.4. The reaction was poured into dilute HC1 (pH = 6, 400 mL, keeping the pH < 8 during the process of quenching.) The mixture was extracted with EA (300 mLx2) and the combined organic layers were dried and concentrated to give the crude 22d (5.0 g) as a yellow solid. Step 5. Synthesis of 2-[5-chloro-2-[(R)-hydroxy-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methyl]phenyl]ethanol (22e)

[00337] To a solution of 22d (3.0 g, 5.17 mmol) in THF (50 mL) was added tetrabutylammonium fluoride (5.17 mL, 5.17 mmol). The mixture solution was stirred at 25°C for 40 min. The reaction mixture was poured into aqueous NH4CI and extracted with EA (100 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and the solvent 2024204264   21 Jun 2024 was concentrated under reduced pressure. The crude product was purified by flash column (PE:EA = 15:1 to 3:1) to give 22e (2 g, 4.08 mmol, 79% yield) as a white solid. LCMS [M+H]: 480.1. Step 6. Synthesis of 4-chloro-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloroisochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (22f)

[00338] To a solution of 22e (2.0 g, 4.16 mmol) in THF (100 mL) and was added tributylphosphine (2.1 mL, 8.33 mmol), isopropyl (NE)-N-isopropoxycarbonyliminocarbamate (1.72 mL, 8.74 mmol) and pyridine (0.34 mL, 4.16 mmol), and the reaction mixture was stirred at 25°C for 16 h.

[00339] TLC (PEZEA = 3 / 1, Rf = 0.4 ) showed that the starting material was consumed. The solvent was removed in vacuo and the crude product was purified by column chromatography on silica gel using petroleum ether / EtOAc (10:1-5:1) as eluent to give 22f (1.7 g, 3.68 mmol, 88% yield) as a yellow oil. LCMS [M+H]: 462.1. Step 7. Synthesis of 4-methyl-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloroisochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (22g)

[00340] Methyl magnesium bromide (3.68 mL, 11.04 mmol) was added dropwise to a solution of ferric acetyl acetonate (0.13 g, 0.37 mmol) and 22f (1.7 g, 3.68 mmol) in THF (100 mL) at 5°C under nitrogen. The reaction mixture was warmed to rt and stirred for Ih. TLC (EA : PE = 1 : 1, Rf= 0.3) showed the reaction was complete. Saturated NH4CI was added dropwise to quench the reaction, which was extracted with EA (200 mLX2), then dried over Na2SO4 and concentrated. The residue was purified by flash column (PE:EA = 10:1 to 1:1) to give 22g (900 mg, 1.93 mmol, 52.6% yield) as a white solid. Step 8. Synthesis of (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloroisochroman-l-yl]tetrahydrofuran-3,4-diol (Ex. 22)

[00341] To a solution of HC1 (6.0 mL, 12 mmol) in methanol (10 mL) and was added 22g (900 mg, 2.04 mmol) and the reaction mixture was stirred at 40°C for 2 h. The reaction mixture was concentrated, and the residue was stirred with EA (50 ml) and filtered. The solid was purified by prep-HPLC eluting with CH3CNZH2O (0.1 % NH4OH) from 5 / 95 to 95 / 5. The product fractions - 120- 2024204264   21 Jun 2024 were extracted with EA (100 mlx2) and the extracts concentrated to yield Ex. 22 (550 mg, 1.34 mmol, 66% yield) as a white solid. LCMS [M+H]: 402.3. 1H NMR (400 M Hz, DMSO-d6): 8 8.67 (s, 1 H), 7.76 (d, J = 4.0 Hz, 1 H), 7.22 -7.31 (m, 3 H), 6.81 (d, J = 3.6 Hz, 1 H), 6.31 (d, J = 7.6 Hz, 1 H), 5.26 (d, J = 7.2 Hz, 1 H), 5.13 (d, J = 4.0 Hz, 1 H), 4.90 (d, J = 3.6 Hz, 1 H), 4.48-4.54 (m, 1 H), 4.42-4.43 (m, 1 H), 4.23-4.27 (m, 1 H), 3.84-3.86 (m, 1 H), 3.66-3.72 (m, 1 H), 2.91-2.99 (m, 1 H), 2.70-2.74 (m, 1 H), 2.67 (s, 3 H). 1H NMR (400 M Hz, DMSO-d6+D2O ): 8 8.86(s, 1 H), 7.77 (d, J = 4 Hz, 1 H), 7.22-7.31 (m, 3 H), 6.82 (d, J = 3.6 Hz, 1 H), 6.31 (d, J = 7.6 Hz, 1 H), 4.90 (d, J = 3.6 Hz, 1 H), 4.49-4.53 (m, 1 H), 4.42-4.43 (m, 1 H), 4.24-4.28 (m, 1 H), 3.83-3.85 (m, 1 H), 3.66-3.72 (m, 1 H), 2.91-2.99 (m, 1 H), 2.70-2.75 (m, 1 H), 2.69 (s, 3 H). Example 44. Synthesis of (2S,3S,4R,5R)-2-((lR)-6-chloro-3-methoxyisochroman-l-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (Ex. 44) Step 1. Synthesis of l-bromo-4-chloro-2-(2-methoxyvinyl)benzene (44b)

[00342] To a solution of (methoxymethyl)triphenylphosphonium chloride (22.96 g, 66.98 mmol) in THF (100 mL) was added potassium tert-butoxide (7.16 g, 63.79 mmol) under N2 at -10 °C. After 5 minutes, 2-bromo-5-chloro-benzaldehyde (44a; 7.0 g, 31.9 mmol) was added. The solution was stirred at -10 °C for 2 h. TLC (PE = 100%, Rf = 0.8) showed the reaction was complete. The reaction mixture was poured into H2O (200 mL). The mixture was extracted with EA 2024204264   21 Jun 2024 (200 mL), washed with water (60mL) and brine (60 mL), dried over Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography, eluting with PE (100 %) to give 44b (7.2 g, 29.09 mmol, 91.2% yield, mixture of E and Z isomers) as a yellow oil. 'HNMR (400 MHz, DMSO-J6) 8 7.99 (d, J = 2.8 Hz, 1 H), 7.61 - 7.56 (m, 2 H), 7.43 - 7.40 (m, 1 H), 7.15 - 7.10 (m, 2 H), 6.58 (d, J = 6.8 Hz, 1 H), 5.93 (d, J = 12.8 Hz, 2 H), 5.44 (d, J = 7.2 Hz), 3.84 (s, 3H), 3.71 (s, 3H). Step 2. Synthesis of l-bromo-4-chloro-2-(2-methoxyvinyl)benzene (44c)

[00343] To a mixture of / i-toluenesulfonic acid (537 mg, 2.83 mmol) in methanol (70 mL) was added 44b (7.0 g, 28.28 mmol). The mixture was stirred at 66 °C for 16 h. TLC (PE = 100%, Rf = 0.4) showed the reaction was complete. The reaction mixture was poured into H2O (200 mL). The mixture was extracted with EA (200 mL), washed with water (60mL) and brine (60 mL), dried over Na2SO4, filtered and concentrated. The crude product was purified by silica gel column chromatography, eluting with PE (100 %) to give 44c (7.2 g, 25.7 mmol, 91% yield) as a yellow oil. 'HNMR (400 MHz, CDCh) 6 7.62 (d, J = 8.8 Hz, 1 H), 7.43 (d, J = 2.4 Hz, 1 H), 7.25 (dd, J = 8.4, 2.8 Hz, 1 H), 4.62 (t, J = 5.2 Hz, 1 H), 3.26 (s, 6H), 2.99 (d, J = 5.6 Hz, 2 H). Step 3. Synthesis of [4-chloro-2-(2,2-dimethoxyethyl)phenyl]-[(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (44e)

[00344] To a mixture of 44c (3.0 g, 10.73 mmol) in THF (30 mL) was added n-BuLi (2.04 g, 10.73 mmol) at -78 °C. The resulting solution of 44d was stirred at -78 °C for 1 min, and lAd (3.24 g, 8.46 mmol) in THF (20 mL) was added at -78 °C. The reaction mixture was stirred at -78 °C for 30 min. TLC (PE : EA = 5 : 1, Rf= 0.5) showed the reaction was complete. The reaction was quenched with NH4CI (aq, 100 mL) and water (100 mL). The aqueous layer was extracted with EA (300 mL X 3). The organic layers were concentrated to give a crude product which was purified by silica gel column chromatography, eluting with PE : EA = 10 : 1 to give 44e (3 g, 5.74 mmol, 53.5% yield) as a yellow oil. LCMS [M+H]: 522.3 2024204264   21 Jun 2024 Step 4. Synthesis of (S)-[4-chloro-2-(2,2-dimethoxyethyl)phenyl]-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (44f)

[00345] To a mixture of 44e (3.0 g, 5.74 mmol) in toluene (30 mL) was added DIBAL-H (1.33 mL, 11.49 mmol) at -78 °C. The mixture was stirred at -78 °C for 30 min. LCMS showed the reaction was complete. The reaction mixture was poured into H2O (100mL) and extracted with DCM (200 mL), dried over Na2SO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography, eluting with DCM : MeOH = 5 : 1 to give 44f (3 g, 5.72 mmol, 99.6% yield) as a yellow oil. LCMS [M+H]: 524.4 Step 5. Synthesis of 4-chloro-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-3-methoxy-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (44g)

[00346] To a mixture of (S)-[4-chloro-2-(2,2-dimethoxyethyl)phenyl]-[(3aR,4R,6R,6aR)-4 -(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (2.0 g, 3.81 mmol) in methanol (20 mL) was added TsOH (0.03 mL, 5.72 mmol at 0 °C. The mixture was stirred at 25 °C for 2 h. TLC (PE : EA = 5 : 1, Rf = 0.5) showed the reaction was complete. The reaction mixture was poured into H2O (30 mL) and extracted with DCM (50 mL X 3). The organic phase was washed with saturated NaCl (100 mL), dried over Na2SO4, filtered and concentrated. The crude product which was purified by silica gel column chromatography, eluting with PE : EA = 10 : 1 to give 44g (1.36 g, 2.76 mmol, 72% yield) as a yellow oil. LCMS [M+H]: 492.2 Step 6. Synthesis of 4-methyl-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-3-methoxy-isochroman -l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (44h)

[00347] To a mixture of 44g (200 mg, 0.41 mmol) and ferric acetylacetonate (71.73 mg, 0.20 mmol) in THF (2 mL) was added MeMgBr (484 mg, 4.06 mmol) at -10 °C. The reaction mixture was warmed to 0 °C and stirred fori h. TLC (PE : EA = 5 : 1, Rf = 0.7) showed the reaction was complete. The reaction mixture was poured into H2O (10 mL), extracted with DCM (10 mL X 3), washed with saturated NaCl (20 mL), dried over Na2SO4, filtered, and concentrated. The crude 2024204264   21 Jun 2024 product was purified by silica gel column chromatography, eluting with PE : EA = 7 : 1 to give 44h (110 mg, 0.23 mmol, 57.4% yield) as a yellow oil. LCMS [M+H]: 472.4 Step 7. Synthesis of (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-3-methoxy-isochroman-l-yl]tetrahydrofuran-3,4-diol (Ex. 44)

[00348] To a mixture of 44h (110 mg, 0.23 mmol) in methanol (2 mL) was added HC1 (42 mg, 1.17 mmol). The mixture was stirred at 25 °C for 1 h. TLC (PE : EA = 5 : 1, Rf = 0.7) and LCMS showed the reaction was complete. The reaction mixture was poured into H2O (10 mL), extracted with DCM (10 mL X 3), washed with saturated NaCl (20 mL), dried over Na2SO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography, eluting with PE : EA = 7 : 1 to give a crude product which was further purified by prep-HPLC, eluting with CH3CN in H2O (0.1%NH3.H2O) from 10% to 95%) to give Ex. 44 (25 mg, 0.047 mmol, 20% yield) as a white solid. LCMS [M+H]: 432.4 ’H NMR (400 MHz, DMSO-J6) 8 8.67 (s, 1 H), 7.797.81 (d, 1 H), 7.22-7.32 (m, 3 H), 6.82-6.84 (m, 1 H), 6.31-6.34 (m, 1 H), 5.15-5.30(m,3H), 4.82 (d, 1H), 4.46-4.58 (m, 2 H), 3.89-3.91 (t, 1 H), 3.38 (s, 3 H), 3.08-3.13(m, 1 H), 2.77 (d,l H), 2.67 (s,3 H). 'HNMR (400 MHz, DMSO-J6+D2O) 88.68 (s, 1 H), 7.81 (d, 1 H), 7.22-7.32 (m, 3H),6.83 (d, 1 H), 6.32 (d, 1 H), 5.26 (d, 1H), 4.83 (d, 1H), 4.78-4.57 (m, 2 H), 3.89 (d, 1 H), 3.08 (d, 1 H), 2.77 (d, 1 H), 2.67 (s, 3H). 2024204264   21 Jun 2024 Example 46. Synthesis of (lR)-6-chloro-l-[(2S,3S,4R,5R)-3,4-dihydroxy- 5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl]isochroman-3-one (Ex. 46) 46a                                                      46b                                46c Step 1. Synthesis of l-bromo-4-chloro-2-(2-methoxyvinyl)benzene (46b)

[00349] To a solution of (methoxymethyl)-triphenylphosphonium chloride (26.24 g, 76.55 mmol) in THF (70 mL) was added potassium tert-butoxide (4.65 mL, 72.91 mmol) at -25 °C under N2. A few minutes later, 2-bromo-5-chloro-benzaldehyde (46a, 8.0 g, 36.45 mmol) was added. The solution was stirred at -25 °C for 2 h. The reaction was monitored by TLC (petroleum ether = 100% , Rf= 0.8). The reaction mixture was poured into water (200 mL). Ethyl acetate (200 mL) was added and the organic phase was separated. The solution was washed with water (100 mL) and brine (100 mL), dried (Na2SO4), filtered, and concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel with petroleum ether (100%) to give 1-bromo-4-chloro-2-(2-methoxyvinyl)benzene (46b, 8.75 g, 35.351 mmol, 97% yield) as a yellow oil. LCMS [M+H]: 247.1. 2024204264   21 Jun 2024 Step 2. Synthesis of l-bromo-4-chloro-2-(2,2-dimethoxyethyl)benzene (46c)

[00350] To a mixture of TsOH (672 mg, 3.54 mmol) in methanol (70 mL) was added 1-bromo-4-chloro-2-(2-m ethoxy vinyl)benzene (46b, 8.75 g, 35.35 mmol) and the mixture was stirred at 75 °C for 16 h. TLC (petroleum ether = 100%, Rf = 0.4) showed the reaction was complete. The reaction mixture was poured into water (200 mL) and ethyl acetate (200 mL) was added. The organic layer was washed with saturated NaCl (100 mL), dried over Na2SO4, filtered and concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel with petroleum ether (100%) to give l-bromo-4-chloro-2-(2,2-dimethoxyethyl)benzene (46c, 5.5 g, 19.674 mmol, 56% yield) as a yellow oil. LCMS [M+H]: 279.1. Step 3. Synthesis of [4-chloro-2-(2,2-dimethoxyethyl)phenyl]-[(3aR,4R,6S,6aS)-4 -(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (46d)

[00351] To a mixture of l-bromo-4-chloro-2-(2,2-dimethoxyethyl)benzene (46c, 5.5 g, 19.7 mmol) in THF (30 mL), BuLi (3.74 g, 19.7 mmol) was added at -78 °C and stirred for 1 min. (3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-N-methoxy-N,2,2-trimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxole-6-carboxamide (lAd, 5.94 g, 15.52 mmol) was added at -78 °C and the reaction was stirred for 30 min at -78 °C. TLC (petroleum ether : ethyl acetate = 5 : 1, Rf = 0.5) showed the reaction was complete. The reaction was quenched with NH4CI (100 mL) and water (100 mL). The aqueous layer was extracted with ethyl acetate (300 mL x 3), dried over Na2SO4, and concentrated in vacuum. The crude product was purified by column chromatography on silica gel with petroleum ether : ethyl acetate (10 : 1) to give [4-chloro-2-(2,2-dimethoxyethyl)phenyl]-[(3aR,4R,6S,6aS)-4 -(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (46d, 2.0 g, 3.8286 mmol, 19.5% yield) as a yellow oil. LCMS [M+H]: 522.3. Step 4. Synthesis of (S)-[4-chloro-2-(2,2-dimethoxyethyl)phenyl]-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo -[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (46e) 2024204264   21 Jun 2024

[00352] To a mixture of [4-chloro-2-(2,2-dimethoxyethyl)phenyl]-[(3aR,4R,6S,6aS)-4 -(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (46d, 2.0 g, 3.83 mmol) in toluene (30 mL) was added DIBAL-H (0.89 mL, 7.66 mmol) at -78 °C. The mixture was stirred at -78 °C for 30 min. The reaction was poured into water (100 mL) and extracted with DCM (200 mL). The aqueous layer was extracted with DMC (300 mL X 3), dried over Na2SO4, and concentrated in vacuum. The crude product was purified by column chromatography on silica gel with DCM : MeOH = 5:1 to give (S)-[4-chloro-2-(2,2-dimethoxyethyl)phenyl]-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo-[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (46e, 2 g, 3.81 mmol, 100% yield) as a yellow oil. LCMS [M+H]: 524.3. Step 5. Synthesis of 4-chloro-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6 -[(lR)-6-chloro-3-methoxy-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (46f)

[00353] To a mixture of (S)-[4-chloro-2-(2,2-dimethoxyethyl)phenyl]-[(3aR,4R,6R,6aR) -4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (46e, 2.0 g, 3.81 mmol) in methanol (20 mL) was added TsOH (0.03 mL, 5.72 mmol) at 0 °C, then the mixture was stirred at 25 °C for 2 h. TLC (petroleum ether : ethyl acetate = 5 : 1, Rf = 0.5) and LCMS showed showed the reaction was complete. The reaction mixture was poured into water (30 mL) and extracted with DCM (50 mL X 3). The organic layers were dried over Na2SO4 and concentrated in vacuum. The crude product was purified by column chromatography on silica gel with petroleum ether : ethyl acetate = 10 : 1 to give 4-chloro-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6 -[(lR)-6-chloro-3-methoxy-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (46f, 1.6 g, 3.25 mmol, 85% yield) as a yellow oil. LCMS [M+H]: 492.0. Step 6. Synthesis of 4-methyl-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-3-methoxy-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (46g)

[00354] To a mixture of 4-chloro-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-3 -methoxy-isochroman-l-yl]-3a, 4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (46f, 800 mg, 1.62 mmol) and ferric acetylacetonate (287 mg, 0.81 mmol) in THF (10 2024204264   21 Jun 2024 mL), was added methylmagnesium bromide (1937.48 mg, 16.25 mmol) at -10 °C. The mixture was warmed to 0 °C and stirred for 1 h. TLC (petroleum ether : ethyl acetate = 5 : 1, Rf = 0.7) showed the reaction was complete. The reaction mixture was poured into water (30 mL) and extracted with DCM (50 mL X 3). The organic layers were dried over Na2SO4 and concentrated in vacuum. The crude product was purified by column chromatography on silica gel with petroleum ether : ethyl acetate = 7 : 1 to give 4-methyl-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-3-methoxy-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (46g, 610 mg, 1.29 mmol, 80% yield) as ayellow oil. LCMS [M+H]: 472.1. Step 7. Synthesis of (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-3-hydroxy-isochroman-l-yl]tetrahydrofuran-3,4-diol (46h)

[00355] To a mixture of 4-methyl-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro -3-methoxy-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (46g, 590 mg, 1.25 mmol) in water (6 mL) was added trifluoroacetic acid (228 mg, 2 mmol). The mixture was stirred at 25 °C for 1 h. TLC (petroleum ether : ethyl acetate =2 : 1, Rf = 0.3) showed the reaction was complete. The reaction mixture was poured into water (30 mL) and extracted with ethyl acetate (50 mL X 3). The organic layers was dried over Na2SO4, and concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel with petroleum ether : ethyl acetate = 7 : 1 to give (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-3-hydroxy-isochroman-l-yl]tetrahydrofuran-3,4-diol (46h, 280 mg, 0.54 mmol, 43% yield) as a yellow oil. LCMS [M+H]: 418.1. Step 8. Synthesis of (lR)-6-chloro-l-[(3aR,4R,6R,6aR)-2,2-dimethyl-4-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-ol (46i)

[00356] To a mixture of (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5 -[(lR)-6-chloro-3-hydroxy-isochroman-l-yl]tetrahydrofuran-3,4-diol (46h, 50 mg, 0.12 mmol) in acetone (10 mL) was added TsOH (8.24 mg, 0.05 mmol) at 0 °C. The mixture was stirred at 25 °C for 3 h. TLC (petroleum ether : ethyl acetate = 5 : 1, Rf = 0.3) showed the reaction was complete. The reaction mixture was poured into water (30 mL) and extracted with DCM (50 mL X 3). The organic layers was dried over Na2SO4, concentrated in vacuum to give the crude product which was 2024204264   21 Jun 2024 purified by column chromatography on silica gel with petroleum ether : ethyl acetate = (7 : 1) to give (lR)-6-chl oro-1-[(3aR,4R,6R,6aR)-2,2-dimethyl-4-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-ol (46i, 76 mg, 0.13 mmol, 112% yield) as a white solid. LCMS [M+H]: 458.1. Step 9. Synthesis of 6-chloro-l-[(3aR,4R,6R,6aR)-2,2-dimethyl-4-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-one (46j)

[00357] To a mixture of 6-chloro-l-[(3aR,4R,6R,6aR)-2,2-dimethyl-4-(4-methylpyrrolo -[2,3-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-ol (46i, 75 mg, 0.16 mmol) in DCM (3 mL) was added PCC (0.09 mL, 0.49 mmol) at 0 °C and the mixture was stirred at 0 °C for 30 min. Then the reaction was warmed to 25 °C until the reaction was complete. The reaction mixture was poured into water (30 mL) and extracted with DCM (3x50 mL). The organic layers was dried over Na2SO4 and concentrated in vacuum to give 6-chloro-1 -[(3aR,4R,6R,6aR)-2,2-dimethyl-4-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-one (46j, 79 mg, 0.172 mmol, 100% yield) as a white solid which was used without further purification in the next step. LCMS [M+H]: 456.3. Step 10. Synthesis of (lR)-6-chloro-l-[(2S,3S,4R,5R)-3,4-dihydroxy- 5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl]isochroman-3-one (Ex. 46)

[00358] To a mixture of (lR)-6-chloro-l-[(3aR,4R,6R,6aR)-2,2-dimethyl-4 -(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-one (46j, 78 mg, 0.17 mmol) in water (2 mL), trifluoroacetic acid (31.19 mg, 0.27 mmol) was added and the mixture was stirred at 25 °C for 1 h. LCMS showed the reaction was complete. The reaction was neutralized with NaHCOs and purified by prep-HPLC, eluting with CH3CN in water (0.1%TFA) from 10% to 95%) to give (lR)-6-chloro-l-[(2S,3S,4R,5R)-3,4-dihydroxy- 5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl]isochroman-3-one (Ex. 46, 3.4 mg, 0.0078 mmol, 4.6% yield) as an off white solid. LCMS [M+H]:416.0. ^NMR (400 MHz, DMSO-Je) 8 8.74 (s, 1 H), 7.58 (s, 1 H), 7.30 (m, 3 H), 6.86 (s, 1 H), 6.23 (d, 7=5.6 Hz, 1 H), 5.73 (d, J= 4.8 Hz, 1 H), 4.48 (m, 2 H), 4.26 (s, 1 H), 3.77 (d, J= 4.8 Hz, 2 H), 2.72 (s, 3 H). 1HNMR (400 MHz, DMSO-J6+D2O) 8 8.82 (s, 1 H), 7.62 (d, 7= 3.2 Hz, 1 H), 7.29 (m, 3 H), 6.93 (d, 7= 3.2 2024204264   21 Jun 2024 Hz, 1 H), 6.24 (d, J= 5.6 Hz, 1 H), 5.73 (d, J= 5.2 Hz, 1 H), 4.49 (m, 2 H), 4.26 (s, 1 H), 3.76 (s, 2 H), 2.76 (s, 3 H). Example 50. Synthesis of (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-3-hydroxy-isochroman-l-yl]tetrahydrofuran-3,4-diol (Ex. 50)

[00359] To a mixture of 44h (100 mg, 0.21 mmol) in water (2 mL) was added trifluoroacetic acid (38.63 mg, 0.34 mmol). The mixture was stirred at 25 °C for 1 h. TLC (PE : EA = 5 : 1, Rf = 0.7) and LCMS showed the reaction was complete. The reaction mixture was poured into H2O (10 mL), extracted with DCM (10 mL X 3), washed with saturated NaCl (20 mL), dried over Na2SO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography, eluting with PE : EA = 7 : 1 to give a crude product which was further purified by prep-HPLC, eluted with CH3CN in H2O (0.1%NH3.H2O) from 10% to 95%) to give Ex. 50 as a mixture of diastereomers (10 mg, 0.019 mmol, 9% yield) as white solid. [M+H]: 418.3. XHNMR (400 MHz, DMSO-J6) 8 8.67 (s, 1 H), 8.00 (d, 1 H), 7.21-7.35 (m, 3 H), 6.75-6.82 (m, 1 H), 6.306.36 (m, 1 H), 5.05-5.25(m, 2H), 4.98-5.04 (m, 2H), 4.45-4.59 (m, 2 H), 3.74-3.87 (m, 1 H), 2.913.05 (m, 1 H), 2.72-2.81(m, 1 H), 2.50-2.51 (m, 3 H). XHNMR (400 MHz, DMSO-J6+D2O) 8 8.66 (s, 1 H), 7.81-8.00 (q, 1 H), 7.22-7.34 (m, 3H), 6.79-6.81 (t, 1 H), 6.30-6.34 (q, 1 H), 4.98-5.05 (q, 2H), 4.45-4.59 (m, 2H), 3.74-3.87 (m, 1 H), 2.79-2.91 (m, 1 H), 2.72 (s, 1 H), 2.68 (s, 3 H). 2024204264   21 Jun 2024 Example 55. Synthesis (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-7- chloro-l,5-dihydro-2,4-benzodioxepin-l-yl]tetrahydrofuran-3,4-diol of (Ex. 55) TBSCI, imidazole DMF, 25 °C, 3 h n-BuLi THF, -78 °C, 10 mins THF ■78 °C, 30 mins 55a                                     55b 55f Ex. 55 Step 1. Synthesis of (2-bromo-5-chloro-phenyl)methoxy-tert-butyl-dimethyl-silane (55b)

[00360] To a solution of (2-bromo-5-chlorophenyl)methanol (55a, 6.0 g, 27.09 mmol) and imidazole (3.69 g, 54.18 mmol) in DCM (50 mL) was slowly added Lbutylchlorodiphenylsilane (4.9 g, 32.51 mmol) at rt. The mixture was stirred at 30 °C for 3 h. TLC (petroleum ether, Rf= 0.4) showed the reaction was complete. The reaction mixture was concentrated in vacuum to give the crude product which was purified by silica gel column chromatography (petroleum ether) to give (2-bromo-5-chloro-phenyl)methoxy-tert-butyl-dimethyl-silane (55b, 9.0 g, 26.81 mmol, 99% yield) as colorless oil. ^NMR (400 MHz, DMSO-de): 8 7.51 (d, J= 8.4, 1H), 7.81 (d, J= 2.8, 1H), 7.227.19 (m, 1H), 4.57(s, 1H), 0.83-0.81 (m, 9H), 0.02-0.01 (m, 6H). Step 2. Synthesis of [2-[[tert-butyl(dimethyl)-silyl]oxymethyl]-4-chloro-phenyl]-[(3aR,4R,6S,6aS)-4-(4 -chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (55c)

[00361] To a solution of (2-bromo-5-chloro-phenyl)methoxy-tert-butyl-dimethyl-silane (55b, 9 g, 26.8 mmol) in dry THF (50 mL) was stirred at -78 °C under Ar. n-BuLi (12.02 mL, 30.04 mmol) was added and stirred at -78 °C for 10 mins. (3aR,4R,6S,6aS)-4-(4-chloropyrrolo -[2,3-d]pyrimidin-7-yl)-N-methoxy-N,2,2-trimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxole-6- 2024204264   21 Jun 2024 carboxamide (lAd, 4.6 g, 12.02 mmol) in anhydrous THF (50 mL) was added, then the reaction mixture was stirred at -78 °C for 30 mins. TLC (petroleum ether : ethyl acetate = 5 : 1) and LCMS showed the reaction was complete. The mixture was adjusted to pH = 6 with HC1 (IN). The reaction was extracted with EtOAc (2x100 mL) and the organics washed with water (100 mL X 2), then brine (50 mL X 2). The organic layers were dried over MgSO4, filtered, and concentrated. The crude product was purified by silica gel column chromatography (petroleum ether : ethyl acetate = 10 : 1 to 5 : 1) to give [2-[[tert-butyl(dimethyl)-silyl]oxymethyl]-4-chloro-phenyl]-[(3aR,4R,6S,6aS)-4-(4 -chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (55c, 4.03 g, 6.97 mmol, 58% yield). LCMS [M+H]: 578.2. XHNMR (400 MHz, DMSO-Je): 8 8.67 (s, 1H), 7.68 (d, J= 3.6, 1H), 7.62 (d, J= 8.4, 1H), 7.47-7.46 (m, 2H), 7.35 (d, J= 8.0, 1H), 7.26-7.20 (m, 2H), 6.49 (d, J= 3.6, 1H), 6.42 (s, 1H), 5.53-5.51 (m, 2H), 5.42 (d, J= 5.6, 1H), 5.27-5.25 (m, 1H), 4.54-4.44 (m, 3H), 1.52(s, 3H), 1.3 l(s, 3H), 0.69(s, 9H), 0.01- -0.070 (m, 6H). Step 3. Synthesis of (R)-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]-[(3aR,6R, 6aR)-2,2-dimethyl-4-[(7S)-4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (55d)

[00362] To a solution of [2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]-[(3aR,4R,6S,6aS) -4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (55c, 4.39 g, 7.59 mmol) in toluene (10 mL) was added diisobutylaluminum hydride dropwise (3.23 g, 22.77 mmol, IM in toluene) at -78 °C. The reaction was stirred at -78 °C for 30 mins. The mixture was quenched with NH4Q (50 mL). The reaction mixture was concentrated in vacuum and extracted with ethyl acetate (2x100 mL). The combined organic layers were dried over MgSO4. The solvent was removed in vacuum to afforded crude (R)-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]-[(3aR,6R,6aR)-2,2-dimethyl-4-[(7S)-4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (55d, 4.2 g) which was used without further purification in the next step. LCMS [M+H]: 580.2. Step 4. Synthesis of (R)-[4-chloro-2-(hydroxymethyl)phenyl]-[(3aR,6R,6aR)-2,2-dimethyl-4-[(7S)-4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (55e) 2024204264   21 Jun 2024

[00363] To a solution of (R)-[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-chloro-phenyl]-[(3aR,6R,6aR)-2,2-dimethyl-4-[(7S)-4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (55d, 4.2 g, 7.23 mmol) in THF (5 mL) was added TBAF (IM) (3.78 mL, 14.47 mmol). The mixture was stirred at 25 °C for 2 h in N2. The mixture was quenched with NH4Q (50 mL). The reaction mixture was concentrated in vacuum and purified by silica gel column chromatography (petroleum ether : ethyl acetate = 3 : 1) to give (R)-[4-chloro-2-(hydroxymethyl)phenyl]-[(3aR,6R,6aR)-2,2-dimethyl-4-[(7S)-4-chloropyrrolo[2,3-d]pyrimi din-7-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (55e, 1.8 g, 3.78 mmol, 52% yield). XHNMR (400 MHz, DMSO-Je): 8 8.69 (d, J= 3.2, 1H), 8.03 (d, J =3.6, 1H), 7.53 (d, J= 8, 1H), 7.39-7.29 (m, 2H), 6.79 (d, J= 3.6, 1H), 6.32 (d, J= 3.6, 1H), 5.96 (d, J= 4.4, 1H), 5.27-5.17 (m, 3H), 4.94-4.91 (m, 1H), 4.46-4.41 (m, 1H), 4.26-4.19 (m, 1H), 1.5l(s, 3H), 1.30(s, 3H). LCMS [M+H]: 466.1. Step 5. Synthesis of (R)-[4-chloro-2 -(hydroxymethyl)phenyl]-[(6R)-2,2-dimethyl-4-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (55f)

[00364] To a solution of ferric acetylacetonate (22.72 mg, 0.06 mmol) and (R)-[4-chloro-2 -(hydroxymethyl)phenyl]-[(6R)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (55e, 300 mg, 0.64 mmol) in THF (5 mL) was added methylmagnesium bromide (721.9 mg, 6.43 mmol) ) at 0 °C under N2. The reaction mixture was warmed to rt and stirred for 1 h. TLC (ethyl acetate : petroleum ether = 5 : 1, Rf = 0.6) showed the reaction was complete. Sat. NH4CI was added dropwise to quench the reaction. The reaction mixture was extracted with ethyl acetate (2x50 mL), dried over Na2SO4 and concentrated in vacuum. The crude product was purified by silica gel column chromatography (petroleum ether : ethyl acetate = 10 : 1 to 5 : 1) to give (R)-[4-chloro-2 -(hydroxymethyl)phenyl]-[(6R)-2,2-dimethyl-4-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (55f, 105 mg, 0.23 mmol, 37% yield) as a colorless oil. ’H NMR (400 MHz, DMSO-Je): 8 8.74 (s, 1H), 7.82 (d, J= 3.6, 1H), 7.53 (d, J= 8, 1H), 7.39-7.35 (m, 2H), 6.81 (d, J= 3.6, 1H), 6.27 (d, J= 4, 1H), 6.00 (d, J= 4.4, 1H), 5.25-5.15 (m, 3H), 4.92-4.90 (m, 1H), 4.47-4.41 (m, 1H), 4.24-4.19 (m, 2H), 2.68-2.62 (m, 3H), 1.51 (s, 3H), 1.30 (s, 3H). LCMS [M+H]: 446.1. Step 6. Synthesis of 4-methyl-7-[(3aR,4R,6R,6aR) -2,2-dimethyl-6-[(lR)-7-chloro-l,5-dihydro-2,4-benzodioxepin-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (55g) 2024204264   21 Jun 2024

[00365] To a solution of (R)-[4-chloro-2-(hydroxymethyl)phenyl]-[(3aR,4R,6R,6aR)-2,2-dimethyl-4-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (55f, 150 mg, 0.34 mmol) in DCM (1.2 mL) and DMF (2.5 mL) was added sodium hydride (80.74 mg, 3.36 mmol). The mixture solution was stirred at 80 °C for 2 h. LCMS showed the reaction was complete. The reaction mixture was quenched with NH4Q (50 mL). The solvent was removed in vacuum to give the crude product which was purified by silica gel column chromatography (DCM : MeOH = 50 : 1) to give 4-methyl-7-[(3aR,4R,6R,6aR) -2,2-dimethyl-6-[(lR)-7-chloro-l,5-dihydro-2,4-benzodioxepin-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (55g, 160 mg, 0.33 mmol, 97% yield) as a yellow oil. XHNMR (400 MHz, DMSO-Je): 8 8.73 (s, 1H), 7.71 (d, 7=3.6, 1H), 7.38 (d, 7=1.6, 1H), 73.31-7.30 (m, 2H), 6.80 (d, 7=3.6, 1H), 6.48 (d,7=4, 1H), 5.33-5.3l(m, 1H), 5.20-5.14 (m, 2H), 5.05-5.01 (m, 2H), 4.834.78 (m, 3H), 2.68-2.62 (m, 3H), 1.60 (s, 3H), 1.34 (s, 3H). LCMS [M+H]: 458.1. Step 7. Synthesis of (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-7-chloro-l,5-dihydro-2,4-benzodioxepin-l-yl]tetrahydrofuran-3,4-diol (Ex. 55)

[00366] To a solution of 4-methyl-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-7-chloro-l,5-dihydro-2,4-benzodioxepin-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (55g, 160 mg, 0.35 mmol) in water (1 mL) was added 2,2,2-trifluoroacetic acid (2.0 mL, 2 mmol) and the mixture was stirred at 25 °C for 30 mins. NH3 water was added until pH=7 and the mixture was concentrated in vacuum. The residue was purified by prep-HPLC, eluting with MeCN in water (0.1% NH3 water) from 10% to 90% to give (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-7-chl oro-1,5-dihydro-2,4-benzodioxepin-l-yl]tetrahydrofuran-3,4-diol (Ex. 55, 31 mg, 0.073 mmol, 21% yield) as a white solid. LCMS [M+H]: 418.1. 1HNMR(400 MHz, DMSO-76): 8 8.68 (s, 1H), 7.64 (d, 7= 4, 1H), 7.41 (s, 1H), 7.32 (d, 7= 1.2, 2H), 6.78 (d, 7 = 3.6, 1H), 6.32 (d, 7= 8.0, 1H), 5.51 (d,7=4.4, 1H), 5.41 (d,7=7.2, 1H), 5.34-5.31 (m, 1H), 5.09 (d, 7 = 4.8, 1H), 5.04 (d, 7= 6.4, 1H), 4.99-4.95 (m, 1H), 4.85-4.81 (m, 1H), 4.62-4.56 (m, 2H), 4.19-4.17 (m, 1H), 2.66 (s, 3H). 2024204264   21 Jun 2024 Example 69. Synthesis of (2S,3S,4R,5R)-2-((R)-6-chloroisochroman-l-yl)-5-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (Ex. 69) ch3nh2 / h2o 1,4-dioxane, 120°C, 16 h 22f TFA / H2O 40°C, 2 h Ex. 69 Step 1. Synthesis of N-methyl-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloroisochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (69a)

[00367] To a solution of 22f (100 mg, 0.22 mmol) in 1,4-dioxane (2 mL), methylamine in water (2.0 mL, 0.09 mmol) was added. The mixture was stirred at 120°C for 16 h. The mixture was purified by prep-HPLC eluting with CH3CN / H2O (neutral) from 5 / 95 to 95 / 5. The product fractions were lyophilized to give 69a (75 mg, 0.16 mmol, 75% yield) as a yellow solid. LCMS [M+H]: 457.1. Step 2. Synthesis of (2S,3S,4R,5R)-2-((R)-6-chloroisochroman-l-yl)-5-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol (Ex. 69)

[00368] To a solution of 69a (75 mg, 0.16 mmol) in MeCN (1 mL), TFA / H2O (0.97 mL, 0.39 mmol) was added. The mixture was stirred at 40°C for 2 h. The mixture was purified by prep-HPLC eluting with CH3CN / H2O (0.1 % NH4OH) from 5 / 95 to 95 / 5 and lyophilized to give Ex. 69 (36.5 mg, 0.087 mmol, 53% yield) as a white solid. LCMS [M+H]: 417.3. 1HNMR (400 MHz, DMSO-d6):6 8.15 (s, 1 H), 7.48-7.49 (m, 1 H), 7.36-7.37 (m, 1 H), 7.28-7.30 (m, 2 H), 7.21-7.23 (m, 1 H), 6.63 (d, J = 3.2 Hz, 1 H), 6.18 (d, J = 7.6 Hz, 1 H), 5.16 (d, J = 7.6 Hz, 1 H), 5.04 (d, J = 4.0 Hz, 1 H), 4.86-4.87 (m, 1 H), 4.42-4.48 (m, 1 H), 4.35-4.36 (m, 1 H), 4.20-4.24 (m, 1 H), 3.833.86 (m, 1 H), 3.65-3.71 (m, 1 H), 2.96 (d, J = 7.6 Hz, 3 H), 2.89-2.94 (m, 1 H), 2.69-2.74 (m, 1 H). Example 76. Synthesis of (Ex. 76) 2024204264   21 Jun 2024 Cu, DMSO NaBH4, MeOH 30 °C, 0.5 h 76b                           76c nBuLi, THF THF, -78 °C, 0.5 h 1Ad Step 1. Synthesis of ethyl 2-(2-bromophenyl)-2,2-difluoro-acetate (76a)

[00369] To a solution of copper (898.6 mg, 14.14 mmol) in DMSO (10 mL) was added ethyl 2-bromo-2,2-difluoro-acetate (5739.98 mg, 28.28 mmol) and the mixture was stirred at rt under nitrogen, l-bromo-2-iodo-benzene (2000 mg, 7.07 mmol) was added to the mixture 1 h later. After 16 h, added aqueous NH4Q (50 mL) to the mixture and extracted with EA (50.0 mLX3). The organic phases were combined, washed with water (100 mL) and brine (100 mL), dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash column (PE:EA=40:1) to give 76a (750 mg, 2.66 mmol, 38% yield). 1H NMR (400 M Hz, CDC13):6 7.75 - 7.73 (m, 1 H), 7.65 - 7.62 (m, 1 H), 7.46 - 7.42 (m, 1 H), 7.38 - 7.34 (m, 1 H), 4.36 (q, J = 7.2 Hz, 2 H), 1.32 (t, J = 7.2 Hz, 3 H). Step 2. Synthesis of 2-(2-bromophenyl)-2,2-difluoro-ethanol (76b)

[00370] To a solution of 76a (5.8 g, 20.78 mmol) in methanol (50 mL) was added NaBH4 (1.57 g, 41.57 mmol) at 0 °C, and the reaction mixture was stirred at rt for 30 mins. TLC (PE:EA = 10:1, Rf = 0.1) showed the reaction was complete. The reaction was concentrated and HC1 (1 M) was added. The mixture was extracted with EA (30.0 mLX3). The organic phases were combined, 2024204264   21 Jun 2024 washed with water (50 mL) and brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by flash column (PE:EA=10:l) to give 76b (5.1 g, 19.36 mmol, 93% yield) as an oil. 1H NMR (400 M Hz, CDCh):5 7.67 - 7.633 (m, 2 H), 7.40 (t, J = 7.6 Hz, 1 H), 7.33 - 7.26 (m, 1 H), 4.21 (t, J = 13.8 Hz, 2 H). Step 3. Synthesis of [2-(2-bromophenyl)-2,2-difluoro-ethoxy]-tert-butyl-dimethyl-silane (76c)

[00371] To a solution of 76b (5.1 g, 21.52 mmol) and imidazole (2.93 g, 43.03 mmol) in DCM (20 mL) was slowly added t-butylchlorodiphenylsilane (4.86 g, 32.27 mmol), and the reaction mixture was stirred for 2 h at rt. TLC (PE, Rf = 0.7) showed a new spot and the SM was consumed. The solvent was removed in vacuo and the crude product was purified by column chromatography on silica gel (PE) to give 76c (6.2 g, 15.88 mmol, 74% yield) as white-off oil. 1H NMR (400 M Hz, CDCh):5 7.67 - 7.633 (m, 2 H), 7.39 (t, J = 7.6 Hz, 1 H), 7.32 - 7.29 (m, 1 H), 4.23 (t, J = 13.0 Hz, 2 H), 0.82 (s, 9 H), 0.0 (s, 6 H). Step 4. Synthesis of [2-[2-[tert-butyl(dimethyl)silyl]oxy-l,l-difluoro-ethyl]phenyl]-[(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (76d)

[00372] To a solution of 76b (1.03 g, 2.95 mmol) in dry THF (10 mL) was added n-BuLi (1.5 mL, 2.4 mmol) at -78 °C, and the mixture was stirred for 10 min under nitrogen. lAd (720 mg, 1.84 mmol) in dry THF (5 mL) was added and the mixture was stirred for 30 min at -78 °C. TLC (PE:EA=10:1, starting material Rf=0.3, product Rf=0.4) showed the reaction was complete. The reaction was poured into dilute HC1 (0.05 M), keeping the pH < 8 during the process of quenching. The mixture was extracted with EA (200 mLx2), the combined organic layers were dried, concentrated and purified by silica gel column (PE:EA = 100 to 10:1) to give 76d (610 mg, 1.02 mmol, 55% yield) as yellow oil. LCMS [M+H]: 594.3. Step 5. Synthesis of (R)-[2-[2-[tert-butyl(dimethyl)silyl]oxy-l,l-difluoro-ethyl]phenyl]-[(3aR,6R,6aR)-2,2-dimethyl-4-[(7S)-4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (76e) 2024204264   21 Jun 2024

[00373] To a solution of 76d (610 mg, 1.03 mmol) in toluene (20 mL) was added diisobutylaluminium hydride (2.05 mL, 3.08 mmol) at -78 °C under nitrogen and the reaction mixture was stirred for 30 min at -78 °C. The reaction mixture was diluted with saturated NH4Q (aq) and the mixture was extracted with EA and washed with brine. The organic layer was dried with anhydrous Na2SO4 and the solvent was removed in vacuo to give 76e (600 mg, 0.93622 mmol, 91% yield) as a crude product which was used without further purification. Step 6. Synthesis of 2,2-difluoro-2-[2-[(R)-hydroxy-[(3aR,4R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methyl]phenyl]ethanol (76f)

[00374] To a solution of 76e (270 mg, 0.45 mmol) in THF (0.03 mL) was added TBAF (0.24 mL, 0.91 mmol) and the reaction mixture was stirred at rt for Ih. The reaction mixture was diluted with saturated NH4Q solution (100 mL), the mixture was extracted with EA (50 mL x 3), and the combined organics were washed with saturated NaCl (100 mL). The organics were dried with anhydrous Na2SO4 and the solvent was removed in vacuo. The residue was purified by silica gel chromatorgraphy (PE:EA = 50 :1 to 10:1) to give 76f (120 mg, 0.2291 mmol, 51% yield) as a solid. LCMS [M+H]: 482.3. Step 7. Synthesis of 4-chloro-7-[(3aR,4R,6aR)-2,2-dimethyl-6-[(lR)-4,4-difluoroisochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (76g)

[00375] To a solution of 76f (100 mg, 0.21 mmol) in THF (4 mL) was added NaH (33.2 mg, 0.83 mmol) and stirred for 10 min. TSC1 (39.56 mg, 0.21 mmol) was added and the reaction was stirred for 1 h. The reaction mixture was poured into saturated NH4CI solution, extracted with EA the organics were washed with saturated NaCl. The organic phase was dried over anhydrous Na2SO4 and the solvent was concentrated under reduced pressure to give a crude product which was purified by prep-TLC (PE:EA = 5:1, Rf = 0.3) to give 76g (50 mg, 0.10 mmol, 48% yield) as a white solid. LCMS [M+H]: 464.2. Step 8. Synthesis of 4-methyl-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-4,4-difluoroisochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (76h) 2024204264   21 Jun 2024

[00376] To a solution of 76g (50 mg, 0.11 mmol) and ferric acetylacetonate (3.81 mg, 0.01 mmol) in THF (6 mL) was added methylmagnesium bromide, 3.2 M in MeTHF (0.36 mL, 1.08 mmol) at 0 °C under nitrogen. The reaction was stirred at rt for 1 hour. The mixture was poured into aqueous NH4CI (30 mL) and extracted with EA (30.0 mLX3). The organic phases were combined, dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by flash column (PE:EA=8:1—PE:EA=3:1) to give 76h (45 mg, 0.10148 mmol, 94% yield). LCMS [M+H]: 444.3. Step 9. Synthesis of (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-4,4-difluoroisochroman-l-yl]tetrahydrofuran-3,4-diol (Ex. 76)

[00377] To a solution of 76h (45 mg, 0.10 mmol) in water (1 mL) was added TFA (0.5 mL, 6.49 mmol) and the mixture was stirred at rt for 30 mins. The residue was purified by pre-HPLC, eluted with CH3CN in H2O (0.1% NH4OH) from 5.0 % to 95.0 % to give Ex. 76 (8.58 mg, 0.021 mmol, 20.5% yield) as a white solid. LCMS [M+H]: 404.3. 1H NMR (400 MHz, DMSO-d6) 8 8.68 (s, 1 H), 7.75-7.72 (m, 2 H), 7.57-7.48 (m, 3 H), 6.81 (d, J = 3.6 Hz, 1 H), 6.34 (d, J = 8 Hz, 1 H), 5.35 (d, J = 6.8 Hz, 1 H), 5.20 (d, J = 4 Hz, 1 H), 5.09 (m, 1 H), 4.61 (d, J = 3.2 Hz, 1 H), 4.564.46 (m, 2 H), 4.16 - 4.07 (m,lH), 3.82 (t, J= 4.4 Hz, 1 H), 2.68 (s, 3 H). 1HNMR (400 MHz, DMSO-d6+D2O) 8 8.66 (s, 1 H), 7.74 - 7.71 (m, 2 H), 7.55 - 7.46 (m, 3 H), 6.81 (d, J = 3.6 Hz, 1 H), 6.32 (d, J= 8 Hz, 1 H), 5.08 (m, 1 H), 4.60 (d, J = 3.2 Hz, 1 H), 4.55 - 4.46 (m, 2 H), 4.14 - 4.04 (m, 1H), 3.80 (d, J = 5.2 Hz, 1 H), 2.66 (s, 3 H). 2024204264   21 Jun 2024 Example 81. Synthesis of (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-7-chloro-l,5-dihydro-2,4-benzodioxepin-l-yl]tetrahydrofuran-3,4-diol (Ex. 81) Ex. 81 Step 1. Synthesis of (R)-[4-chloro-2-(hydroxymethyl)phenyl]-[(3aR,4R,6R,6aR)-4 -[4-[bis[(4-methoxyphenyl)methyl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (81a)

[00378] A mixture of K2CO3 (292.98 mg, 2.12 mmol), (R)-[4-chloro-2-(hydroxymethyl)phenyl]-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (55e, 300 mg, 0.64 mmol) and bis-(4-methoxybenzyl)amine (331 mg, 1.29 mmol) in tert-butanol (5 mL) was stirred at 95 °C for 2 h under N2. LCMS showed the reaction was complete. The reaction was concentrated in vacuum to dryness and the residue was extracted with EtOAc (2x50 mL) and the organic layers were washed with water (2x10 mL), then brine (2x10 mL). The organics layers were dried with MgSO4, filtered, and concentrated in vacuum. The crude product was purified by silica gel column chromatography (ethyl acetate : petroleum ether = 1 : 1) to give (R)-[4-chloro-2-(hydroxymethyl)phenyl]-[(3aR,4R,6R,6aR)-4 -[4-[bis[(4-methoxyphenyl)methyl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (81a, 80 mg, 0.10 mmol, 16% yield) as a white solid. LCMS [M+H]: 687.2. Step 2. Synthesis of N,N-bis[(4-methoxyphenyl)methyl]-7 -[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-7-chloro-l,5-dihydro-2,4-benzodioxepin-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (81b) 2024204264   21 Jun 2024

[00379] To a solution of (R)-[4-chloro-2-(hydroxymethyl)phenyl]-[(3aR,4R,6R,6aR)-4-[4-[bis[(4-methoxyphenyl)methyl]amino]pyrrolo[2,3-d]pyrimidin-7-yl]-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (81a, 80 mg, 0.12 mmol) in DCM (1.2 mL) and DMF (2.5 mL) was added sodium hydride (28 mg, 1.16 mmol). The mixture was stirred at 80 °C for 2 h. The reaction mixture was quenched with NH4Q (50 mL). The solvent was removed in vacuum to give N,N-bis[(4-methoxyphenyl)methyl]-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-7-chloro-l,5-dihydro-2,4-benzodioxepin-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (81b, 90 mg, 0.10 mmol, 87% yield) as yellow oil. LCMS [M+H]: 699.3. Step 3. Synthesis of (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-7-chloro-l,5-dihydro-2,4-benzodioxepin-l-yl]tetrahydrofuran-3,4-diol (Ex. 81)

[00380] To a solution of N,N-bis[(4-methoxyphenyl)methyl]-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-7-chloro-l,5-dihydro-2,4-benzodioxepin-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (81b, 90 mg, 0.13 mmol) in water (1 mL) was added 2,2,2-trifluoroacetic acid (0.74 mL, 0.74 mmol). The reaction mixture was stirred at 25 °C for 30 mins. NFL water was added until pH = 7 and the mixture was concentrated in vacuum. The residue was purified by prep-HPLC, eluting with MeCN in water (0.1% NH3 water) from 10% to 90% to give crude product. The crude product was further purified by prep-HPLC, eluted with MeCN in water (0.1% TFA) from 10% to 90% to give (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-7-chl oro-1,5-dihydro-2,4-benzodioxepin-l-yl]tetrahydrofuran-3,4-diol (Ex. 81, 2.7 mg, 0.0063 mmol, 5% yield) as a white solid. LCMS [M+H]: 419.1. ’H NMR (400 MHz, DMSO-J6+D2O) 8: 8.33 (s, 1H), 7.51 (d, J =3.6, 1H), 7.45 (s, 1H), 7.42 (d, J= 1.6, 2H), 6.94 (d, J= 3.2, 1H), 6.32 (d, J= 8.0, 1H), 5.33 (d, J= 6, 1H), 5.07-5.03 (m, 2H), 4.97 (d, J=1.2,1H), 4.83 (d, J= 14.4, 1H), 4.61 (d, J= 4.8, 1H), 4.54-4.51 (m, 1H), 4.17 (d, J= 4.8, 1H). 2024204264   21 Jun 2024 Example 82. Synthesis of (lR)-6-chloro-l-[(2S,3S,4R,5R) -5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]isochroman-3-one;2,2,2-trifluoroacetic acid (Ex. 82) dioxane, NH40 PPC, DCM 0-25 °C, 5h 82d 110 °C, 16h TFA, H2O TsOH, acetone 82a                                              82b                                                82c Ex. 82 Step 1. Synthesis of 7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-3-methoxy-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (82a)

[00381] To a mixture of 4-chloro-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro -3-methoxy-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (46f, 700 mg, 1.42 mmol) in 1,4-dioxane (8 mL), ammonium hydroxide (0.03 mL, 14.22 mmol) was added. The mixture was stirred at 120 °C overnight. TLC (petroleum ether : ethyl acetate = 5 : 1, Rf = 0.5) and LCMS showed the reaction was complete. The reaction mixture was poured into water (30 mL) and extracted with DCM (50 mL X 3). The organic layers were washed with saturated NaCl (100 mL), dried over Na2SO4, filtered, concentrated in vacuum to give the crude product which was purified by column chromatography on silica gel with petroleum ether: ethyl acetate = 7 : 1 to give 7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-3-methoxy-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (82a, 460 mg, 0.97 mmol, 68% yield) as a yellow solid. LCMS [M+H]: 458.1. Step 2. Synthesis of (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro -3-hydroxy-isochroman-l-yl]tetrahydrofuran-3,4-diol (82b)

[00382] To a mixture of 7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-3-methoxy-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidin-4-amine (82a, 460 mg, 0.97 mmol) in water (5 mL) was added trifluoroacetic acid (177 mg, 1.56 mmol). - 142- 2024204264   21 Jun 2024 The reaction mixture was stirred at 25 °C for 1 h. TLC (petroleum ether : ethyl acetate = 3 : 1, Rf = 0.3) and LCMS showed the reaction was complete. The reaction was neutralized with NaHCOs and purified by column chromatography on silica gel with petroleum ether : ethyl acetate = 7 : 1 to give the crude product which was further purified by prep-HPLC, eluted with CH3CN in water (0.1% NH3 / water) from 10% to 95%) to give (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-3-hydroxy-isochroman-l-yl]tetrahydrofuran-3,4-diol (82b, 50 mg, 0.11 mmol, 12% yield) as an off-white solid. LCMS [M+H]: 419.1. Step 3. Synthesis of (lR)-6-chloro-l-[(3aR,4R,6R,6aR)-4-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-ol (82c)

[00383] To a mixture of (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-3-hydroxy-isochroman-l-yl]tetrahydrofuran-3,4-diol (82b, 230.5 mg, 0.55 mmol) in acetone (10 mL), TsOH (38 mg, 0.22 mmol) was added at 0 °C. The reaction mixture was stirred at 25 °C for 3 h. TLC (petroleum ether : ethyl acetate =5 : 1, Rf = 0.3) and LCMS showed the reaction was complete. The reaction mixture was poured into water (10 mL) and extracted with DCM (10 mL X 3). The organic layers were washed with saturated NaCl (100 mL), dried over Na2SO4, filtered, and concentrated in vacuum. The crude product was purified by column chromatography on silica gel with petroleum ether : ethyl acetate = 7 : 1) to give (lR)-6-chloro-l-[(3aR,4R,6R,6aR)-4-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-ol (82c, 180 mg, 0.32 mmol, 58% yield) as a white solid. LCMS [M+H]: 458.1. Step 4. Synthesis of 6-chloro-l-[(3aR,4R,6R,6aR)-4-(4-aminopyrrolo-[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-one (82d)

[00384] To a mixture of 6-chloro-l-[(3aR,4R,6R,6aR)-4-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-ol (82c, 44 mg, 0.10 mmol) in DCM (10 mL) was added PCC (0.05 mL, 0.29 mmol) at 0 °C. The mixture was stirred at 0 °C for 30 min, then warmed to 25 °C until the reaction was complete. The reaction mixture was poured into water (10 mL) and extracted with DCM (2x10 mL). The organics were concentrated in vacuum to give 6-chloro-l-[(3aR,4R,6R,6aR)-4-(4-aminopyrrolo -[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-one (82d, 35 mg, 2024204264   21 Jun 2024 0.076 mmol, 79.5% yield) as a white solid. The crude product was used without further purification in the next step. LCMS [M+H]: 457.1. Step 5. Synthesis of (lR)-6-chloro-l-[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]isochroman-3-one; 2,2,2-trifluoroacetic acid (Ex. 82)

[00385] To a mixture of (lR)-6-chloro-l-[(3aR,4R,6R,6aR)-4-(4-aminopyrrolo-[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochroman-3-one (82d, 35 mg, 0.08 mmol) in water (2 mL) was added trifluoroacetic acid (14 mg, 0.12 mmol) and the mixture was stirred at 25 °C for Ih. TLC (petroleum ether : ethyl acetate = 3 : 1, Rf= 0.3) and LCMS showed the reaction was complete. The reaction was neutralized with NaHCOs and extracted with DCM (3x3 mL), the organics were washed with saturated NaCl (20 mL), dried over Na2SO4, filtered, concentrated in vacuum. The crude product was purified by column chromatography on silica gel with petroleum ether : ethyl acetate = 7 : 1 and further purified by prep-HPLC, eluted with CH3CN in water (0.1%TFA) from 10% to 95% to give (lR)-6-chloro-l-[(2S,3S,4R,5R)-5-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]isochroman-3-one;2,2,2-trifluoroacetic acid (Ex. 82, 3 mg, 0.0052 mmol, 7% yield) as a white solid. LCMS [M+H]: 417.1. XHNMR (400 MHz, DMSO-Je) 8: 8.50-8.64 (m, 2 H), 8.30 (s, 1 H), 7.30-7.44 (m, 4H), 6.91 (s, 1 H), 6.10 (s, 1 H), 5.83 (s, 1 H), 5.55-5.67 (m, 2 H), 4.37-4.41 (m, 3 H), 3.74 (m, 2 H). XHNMR (400 MHz, DMSO-J6+D2O) 88.30 (s, 1 H), 7.31-7.42 (m, 4 H), 6.93 (s, 1 H), 6.10 (d, J= 4 Hz, 1 H), 5.83 (s, 1 H), 4.38-4.43 (m, 3 H), 3.74 (m, 2 H). Example 83. Synthesis of (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-5-fluoro-isochroman-l-yl]tetrahydrofuran-3,4-diol (Ex. 83) ci—(%-Br    DMF, LOA    C|—(Y6'    RhjP'Cr      tBuOK.THF                   _HCI_MeCN / HjO_^ /              THF, -78 °C, 1 h       F                                   -10 °C, 10 min        °        'T* Cl       60 °C, overnight      c O                                               F 83a                                  83b                                                         83c Cl                                            Cl T |[A                       | ifA Cl Y         n-BuLi      JT T        + SAn / THF -78°C , SAn TBSO*^ T^CI THF, -78 °C C<        ^OTBS                'll—     30 min          A"0 F          F       0 yA        °AAA 83f                                           ~b° H 0                           H O 'ot 1Ad                                    83g Cl                                                                  Cl                                                                               I 7'11 S        ci                                          ci 1¾.               1- /            DIAD, PPh3, THF       1¾.                    /          MeMgBr, Ferric acetylacetonate '    X V~F                  '              V V~F                          '          / "O V . / O ^- /           25 °C,2h            Vt )= /            THF,5-10 °C, 2 h                    1 / o< L / \                  o< 1^ / \                        9 V-vA J                \                              J            )                                              y h O' -^0 H OH   XOH                           H 0- /                                "Y^O 831                                                         83j                                                               83k Brs--^                         Br^ ||    |               NaBH4                     T| |         TBSCI, imidazole C'     MeOH, 25 "C, 2 h     "°'     T 'Cl     OOM. 25 "C, 2 h 83d                                       83e Cl DIBAL-H         1¾. XA ,__ / Cl        trap __________________N N      /            IBAF toluene. -78 °C, 0.5 h                               F         THF BS                                 H 0H    OTBS 83h Cl                                               Cl _ /                 N*If %        / A F tfa / h2o I^An' —\          rt, 30 min               ? / \ 7                                 / HOZ H Ex. 83 2024204264   21 Jun 2024 Step 1. Synthesis of 6-bromo-3-chloro-2-fluorobenzaldehyde (83b)

[00386] To a solution of 4-bromo-l-chloro-2-fluoro-benzene (83a, 10 g, 47.75 mmol) in THF (60 mL) was added LDA (30 mL, 57.3 mmol) at -78°C. The reaction mixture was stirred at -78°C for 1 h, then DMF (7.4 mL, 95.5 mmol) was added to the mixture and the reaction was stirred at -78°C for Ih. The reaction was quenched with NH4Q (aq, 100 mL) and water (100 mL). The aqueous layer was extracted with ethyl acetate (3x300 mL). The organic layers were concentrated in vacuum to give the crude product which was purified by silica gel column chromatography, eluted with petroleum ether : ethyl acetate = 10 : 1 to give 6-bromo-3-chloro-2-fluorobenzaldehyde (83b, 6.1 g, 25.69 mmol, 54% yield) as a yellow oil. ’H NMR (400 MHz, CDCh) 10.39 (s, 1 H), 7.86 (s, 1 H), 7.56 (dd, J=8Hz, 1 H). Step 2. Synthesis of l-bromo-4-chl oro-3-fluoro-2-[(E)-2-methoxyvinyl]benzene (83c)

[00387] To a solution of (methoxymethyl)triphenylphosphonium chloride (83b, 18.2 g, 53.06 mmol) in THF (60 mL) was added potassium / -butoxide 1.0M in THF (5.67 g, 50.54 mmol) at -10 °C. The reaction was stirred at -10 °C for 10 mins. The reaction was diluted with water (150 mL) and extracted with ethyl acetate (150 mL). The organic layer was concentrated in vacuum and the residue was purified by silica gel column chromatography, eluted with petroleum ether : ethyl acetate = 10 : 1 to give l-bromo-4-chloro-3-fluoro-2-[(E)-2-methoxyvinyl]benzene (83c, 4.50 g, 16.1 mmol, 64% yield) as a white solid. XH NMR (400 MHz, DMSO-Je) 7.64 (s, 1 H), 7.51 (dd, J= 10.8Hz, 1 H), 7.24 (dd, J=13.2Hz, 1 H), 5.73 (d, J=13.2Hz, 1 H), 3.71 (s, 3 H). Step 3. Synthesis of 2-(6-bromo-3-chloro-2-fluoro-phenyl)acetaldehyde (83d)

[00388] To a solution of l-bromo-4-chloro-3-fluoro-2-[(E)-2-methoxyvinyl]benzene (83c, 4.5 g, 16.95 mmol) in acetone (45 mL) was added HC1 (1.86 g, 50.85 mmol) and the mixture was stirred at 60 °C overnight. TLC (petroleum ether) showed the reaction was complete. The reaction mixture was concentrated in vacuum and extracted with ethyl acetate (50 mL). The organic layer was concentrated in vacuum to afford 2-(6-bromo-3-chloro-2-fluoro-phenyl)acetaldehyde (83d, 4.0 g, 14.32 mmol, 84.5% yield) as a yellow solid. ’H NMR (400 MHz, DMSO-Je) 9.72 (s, IH), 7.71 (s, 1 H), 7.58 (d, J=11.2Hz, IH), 4.02 (d, J= 8.4Hz, 2H). 2024204264   21 Jun 2024 Step 4. Synthesis of 2-(6-bromo-3-chloro-2-fluoro-phenyl)ethanol (83e)

[00389] To a solution of 2-(6-bromo-3-chloro-2-fluoro-phenyl)acetaldehyde (83d, 3.3 g, 13.12 mmol) in methanol (30 mL) was added sodium borohydride (1.5 g, 39.37 mmol) at 0 °C. The reaction mixture was stirred at rt. for 1 h. TLC (petroleum ether) showed the reaction was complete. The mixture was concentrated in vacuum and the residue was extracted with ethyl acetate (50 mL), washed with brine (50 mL) and the organic layer was concentrated in vacuum to obtain 2-(6-bromo-3-chloro-2-fluoro-phenyl)ethanol (83e, 3.20 g, 11.99 mmol, 91% yield) as a yellow oil. 'HNMR (400 MHz, DMSO-de) 7.62 (s, 1 H), 7.48 (dd, J= 92 Hz, 1 H), 4.85 (t, J= 5.6Hz, 1 H), 7.52 (dd, 7=12.8 Hz, 2H), 2.88 (dd, J =12 Hz, 2 H). Step 5. Synthesis of tert-butyl-[2-(3-chloro-2,6-difluoro-phenyl)ethoxy] -dimethyl-silane (83f)

[00390] To a solution of 2-(3-chloro-2,6-difluoro-phenyl)ethanol (83e, 3.20 g, 16.62 mmol) in DCM (30 mL) was added tert-butyldimethylchlorosilane (3.01 g, 19.94 mmol) and imidazole (2.26 g, 33.23 mmol). The reaction was stirred at 25 °C for 2 h. The reaction mixture was concentrated in vacuum and the residue was extracted with ethyl acetate (3x50 mL) and washed with brine (3x50 mL). The organic layers were concentrated in vacuum to give the crude product which was purified by silica gel column chromatography, to yield tert-butyl-[2-(3-chloro-2,6-difluoro-phenyl)ethoxy]-dimethyl-silane (83f, 3.9 g, 12.07 mmol, 73% yield) as an colorless oil. LCMS [M+H]: 306.8. Step 6. Synthesis of [2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-3-fluoro-phenyl]-[(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (83g)

[00391] To a solution of 2-(6-bromo-3-chloro-2-fluoro-phenyl)ethoxy-tert-butyl-dimethyl-silane (83f, 3074 mg, 8.36 mmol) in THF (20 mL) was added n-BuLi (535.5 mg, 8.36 mmol) at -78 °C. The mixture was stirred for 10 min under N2. (3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin -7-yl)-N-methoxy-N,2,2-trimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxole-6-carboxamide (lAd, 1.6 g, 4.18 mmol) in THF (10 mL) was added. The mixture was stirred for 30 min at -78 °C. TLC (petroleum ether : ethyl acetate = 10 : 1) showed the reaction was complete. The reaction was added to dilute HC1 (0.05 mol / L) and kept the pH < 8 during the process of - 146- 2024204264   21 Jun 2024 quenching. The mixture was extracted with ethyl acetate (2x200 mL), the combined organic layers were dried, concentrated in vacuum and purified by silica gel column chromatography (petroleum ether : ethyl acetate = 100% to 10:1) to give [2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-3-fluoro-phenyl]-[(3aR,4R,6S,6aS)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (83g, 1.2 g, 1.87 mmol, 45% yield) as a yellow oil. LCMS [M+H]: 610.1. Step 7. Synthesis of (R)-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-3-fluoro-phenyl]-[(3aR,6R,6aR)-2,2-dimethyl-4-[(7S)-4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (83h)

[00392] To a solution of [2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-3-fluoro-phenyl]-[(3aR,6S,6aS)-2,2-dimethyl-4-[(7S)-4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanone (83g, 1.1 g, 1.8 mmol) in toluene (15 mL) was added diisobutylaluminium hydride (3.6 mL, 5.4 mmol) at -78 °C under N2. The reaction mixture was stirred at -78 °C for 30 min. Water (50 mL) was added, and the mixture was extracted with ethyl acetate (100 mL) and washed with saturated NaCl (2x50 mL). The organic layers were dried over anhydrous Na2SO4 and the solvent was removed in vacuum to give (R)-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-3-fluoro-phenyl] -[(3aR,6R,6aR)-2,2-dimethyl-4-[(7S)-4-chloropyrrolo[2,3-d]pyrimidin-7-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (83h, 1.0 g, 1.55 mmol, 86% yield) which was used for the next step directly. LCMS [M+H]: 612.2. Step 8. Synthesis of 2-[3-chloro-2-fluoro-6-[(R)-hydroxy-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methyl]phenyl]ethanol (83i)

[00393] To a solution of (R)-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-3-fluoro-phenyl]-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (83h, 1.0 g, 1.63 mmol) in THF (3 mL) was added TBAF (0.85 mL, 3.26 mmol). The reaction mixture was stirred at rt for 1 h. TLC (petroleum ether : ethyl acetate = 10:1) showed the reaction was complete. The mixture was concentrated in vacuum and purified by silica gel column chromatography (petroleum ether : ethyl acetate = 50 : 1 2024204264   21 Jun 2024 to 10 : 1) to give 2-[3-chloro-2-fluoro-6-[(R)-hydroxy-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methyl]phenyl]ethanol (83i, 670 mg, 1.30 mmol, 80% yield) as a white solid. LCMS [M+H]: 498.1. Step 9. Synthesis of 4-chloro-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-5-fluoro-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (83j)

[00394] To a solution of 2-[3-chloro-2-fluoro-6-[(R)-hydroxy-[(3aR,4R,6R,6aR)-4-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methyl]phenyl]ethanol (83i, 500 mg, 1 mmol) in THF (5 mL) was added PPhs (526 mg, 2.01 mmol), DIAD (0.56 mL, 2.01 mmol) under Ar. The reaction mixture was stirred at 25 °C for 1 h. The mixture was concentrated in vacuum and the residue was purified by silica gel column chromatography to yield 4-chloro-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-5-fluoro-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (83j, 390 mg, 0.77 mmol, 77% yield). LCMS [M+H]: 480.1. Step 10. Synthesis of 4-methyl-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-5-fluoro-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (83k)

[00395] To a solution of 4-chloro-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-5-fluoro-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (83j, 100 mg, 0.21 mmol) in THF (2 mL) was added ferric acetylacetonate (7.35 mg, 0.02 mmol) and methylmagnesium bromide (0.21 mL, 0.63 mmol) drop-wise under N2. The reaction was stirred at rt for 30 min. The mixture was extracted with ethyl acetate (3x10 mL) and washed with water (2x10 mL). The organic layer was concentrated in vacuum to yield 4-methyl-7-[(3aR,4R,6R,6aR)-2,2-dirnethyl-6-[(lR)-6-chloro-5-fluoro-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (83k, 90 mg, 0.19 mmol, 89% yield) as a yellow oil. LCMS [M+H]: 460.2. Step 11. Synthesis of (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-5-fluoro-isochroman-l-yl]tetrahydrofuran-3,4-diol (Ex. 83) 2024204264   21 Jun 2024

[00396] To a solution of 4-methyl-7-[(3aR,4R,6R,6aR)-2,2-dimethyl-6-[(lR)-6-chloro-5-fluoro-isochroman-l-yl]-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-4-yl]pyrrolo[2,3-d]pyrimidine (83k, 100 mg, 0.22 mmol) in water (2 mL) was added TFA (1.1 mL, 12.34 mmol). The mixture was stirred at rt for 30 mins. The residue was purified by pre-HPLC, eluted with CH3CN in water (0.1% NH4OH) from 5% to 95% to give (2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloro-5-fluoro-isochroman-l-yl]tetrahydrofuran-3,4-diol (Ex. 83, 18 mg, 0.042 mmol, 19% yield) as a white solid. ’H NMR (400 MHz, DMSO-Je) 8.67 (s, 1H), 7.78 (d, J= 4 Hz, 1H), 7.32- 7.28 (m, 2H), 6.82 (d, J= 4 Hz, 1H), 6.31 (d, J= 7.6 Hz, 1H), 5.31 (d, J= 6.8 Hz, 1H), 5.20 (d, J= 4 Hz, 1H), 4.91 (d, J= 7.2 Hz, 1H), 4.52-4.46 (m, 2H), 4.32 (s, 1 H), 3.88 (t, J= 4 Hz, 1H), 3.69 (s, 1 H), 2.73 (s, 2H), 2.67 (d, J= 8 Hz, 3H). ’H NMR (400 MHz, DMSO-J6+D2O) 8.67 (s, 1H), 7.78 (d, J= 4 Hz, 1H), 7.32-7.28 (m, 2H), 6.82 (d, J= 4 Hz, 1H), 6.31 (d, J= 7.6 Hz, 1H), 4.91 (d, J= 7.2 Hz, 1H), 4.52 -4.46 (m, 2H), 4.32 (s, 1 H), 3.88 (t, J= 4 Hz, 1H), 3.69 (s, 1H), 2.73 (s, 2H), 2.67 (d, J=8Hz, 3H). Example 86. Synthesis of (2R,3R,4S,5S)-2-(4-amino-5-fluoro-pyrrolo[2,3-d]pyrimidin-7-yl) -5- [(lR)-6-chloroisochroman-l-yl]tetrahydrofuran-3,4-diol (Ex. 86) Step 1. Synthesis of (R)-[2-[2-[tert-butyl(dimethyl)silyl] oxyethyl]-4-chloro-phenyl]-[(3aR,4R,6R,6aR)-4-methoxy-2,2-dimethyl-3a,4,6,6atetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (86b)

[00397] To a solution of 2-(2-bromo-5-chloro-phenyl)ethoxy-tert-butyl-dimethyl-silane (22b, 23.6 g, 68 mmol) in dry THF (50 mL) was added n-BuLi (34 mL, 54.4 mmol) at -78 °C. The reaction mixture was stirred at -78 °C for 10 min under N2. (3aR,4R,6S,6aR)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro [3,4-d][l,3]dioxole-6-carbaldehyde (86a, 5.5 g, 27.2 mmol) in dry THF (10 mL) was added to the mixture. The mixture was stirred for 5 min at -78 °C. The - 149- 2024204264   21 Jun 2024 reaction was added into dilute HC1 (300 mL, 0.6 M), and maintaining pH = 6. The mixture was concentrated in vacuum to give the crude product which was purified was purified by silica gel column chromatography, eluting with petroleum ether : ethyl acetate = 5 : 1 to give (R)-[2-[2-[tert-butyl(dimethyl)silyl] oxyethyl]-4-chloro-phenyl]-[(3aR,4R,6R,6aR)-4-methoxy-2,2-dimethyl-3a,4,6,6atetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (86b, 5.8 g, 11.6 mmol, 43% yield) as a yellow oil. ^NMR (400 MHz, CDCh) 6 7.54 (d, J= 8.4 Hz, 1H), 7.22-7.29 (m, 2H), 5.36 (s, 2H), 4.95 (d, J =6.0 Hz, 1H), 4.68 (d, 7= 5.6 Hz, 1H), 4.50 (s, 1H), 4.31 (s, 1H), 3.83-3.90 (m, 2H), 3.43 (s, 3H), 2.78-2.99 (m, 2H), 1.47 (s, 3H), 1.30 (s, 3H), 0.87 (s, 9H), 0.02 (s, 6H). Step 2. Synthesis 2-[5-chloro-2-[(R)-hydroxy-[(3aR,4R,6R,6aR)-4-methoxy-2,2-dimethyl -3a,4,6,6a -tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methyl]phenyl]ethanol (86c)

[00398] To a solution of (R)-[2-[2-[tert-butyl(dimethyl)silyl]oxyethyl]-4-chloro-phenyl]-[(3aR,4R,6R, 6aR)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methanol (86b, 4.8 g, 10.1 mmol) in THF (10 mL) was added tetrabutyl ammonium fluoride (10.1 mL, 10.1 mmol) at rt. The mixture was stirred at rt for 1 h. The mixture was poured into 50 ml of NH4Q (aq) and extracted with ethyl acetate (2x50 mL). The organic layers were concentrated in vacuum to give the crude product which was purified by silica gel column chromatography, eluting with petroleum ether to petroleum ether : ethyl acetate = 5 : 1) to give 2-[5-chloro-2-[(R)-hydroxy-[(3aR,4R,6R,6aR)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methyl]phenyl]ethanol (86c, 3.8 g, 9.5 mmol, 94% yield) as a colorless oil. XHNMR (400 MHz, CDCh) 6 7.54 (d, J= 8.4 Hz, 1H), 7.22-7.29 (m, 2H), 5.01 (s, 2H), 4.95 (d, J= 6.0 Hz, 1H), 4.65 (d, J= 6.0 Hz, 1H), 4.55 (s, 1H), 4.33 (br, 1H), 3.85-3.96 (m, 2H), 3.41 (s, 3H), 2.78-3.06 (m, 2H), 1.47 (s, 3H), 1.30 (s, 3H). Step 3. Synthesis of (lR)-6-chloro-l-[(3aR,4R,6R,6aR)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochromane (86d)

[00399] To a solution of 2-[5-chloro-2-[(R)-hydroxy-[(3aR,4R,6R,6aR)-4-methoxy-2,2-dimethyl- 3a,4,6,6atetrahydrofuro[3,4-d][l,3]dioxol-6-yl]methyl]phenyl]ethanol (86c, 2.3 g, 6.4 mmol) in THF (50 mL was added isopropyl(NE)-N-isopropoxycarbonyliminocarbamate (2.5 mL, 12.8 mmol) and triphenylphosphine (3.3 g, 12.8 mmol), and the reaction mixture was stirred at 25 °C for 16 h. The mixture was concentrated in vacuum to give a crude product which was purified by silica gel column chromatography, eluting with petroleum ether : ethyl acetate = 20 : 1 to 5 : 1 to give (lR)-6-chloro-l-[(3aR,4R,6R,6aR)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4- 2024204264   21 Jun 2024 d][l,3]dioxol-6-yl]isochromane (86d, 2.1 g, 6.1 mmol, 96% yield) as a white solid. XHNMR (400 MHz, CDCk) 6 7.58 (d, J= 8.4 Hz, 1H), 7.12-7.17 (m, 2H), 5.09 (s, 2H), 4.56-4.62 (m, 2H), 4.144.28 (m, 2H), 3.71-3.77 (m, 1H), 3.70 (s, 3H), 2.65-3.01 (m, 2H), 1.47 (s, 3H), 1.25 (s, 3H). Step 4. Synthesis of (3R,4S,5S)-5-[(lR)-6-chloroisochroman-l-yl]tetrahydrofuran-2,3,4-triol (86e)

[00400] To a solution of (lR)-6-chloro-l-[(3aR,4R,6R,6aR)-4-methoxy-2,2-dimethyl-3a,4,6,6a-tetrahydrofuro[3,4-d][l,3]dioxol-6-yl]isochromane (86d,1.6 g, 4.7 mmol) in trifluoroacetic acid (16 mL, 215.4 mmol) was added water (10 mL) at rt. The mixture was stirred at 40 °C for 24 h. The reaction mixture was concentrated in vacuum and purified by silica gel column chromatography, eluting with petroleum ether : ethyl acetate = 5 : 1 to 1 : 1 to give (3R,4S,5S)-5-[(lR)-6-chloroisochroman-l-yl]tetrahydrofuran-2,3,4-triol (86e, 700 mg, 2.4 mmol, 42% yield) as a colorless oil. LCMS [M+H]: 286.1. Step 5. Synthesis of (2R,3R,4S,5S)-2-(4-chloro-5-fluoro-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloroisochroman-l-yl]tetrahydrofuran-3,4-diol (86g)

[00401] To a solution of 4-chloro-5-fluoro-7H-pyrrolo[2,3-d]pyrimidine (86f, 461 mg, 2.7 mmol) and pyridine (0.8 mL, 9.8 mmol) in dry THF (10 mL) was added tributylphosphane (1.2 mL, 4.9 mmol) and DIAL) (1.0 mL, 5.1 mmol) under N2. (3R,4S,5S)-5-[(lR)-6-chloroisochroman-l-yl] tetrahydrofuran-2,3,4-triol (86e, 700 mg, 2.4 mmol) and pyridine (0.8 mL, 9.8 mmol) was added at once. The reaction mixture was stirred at 30 °C for 1.5 h under N2. The reaction mixture was concentrated in vacuum and the residue was purified by silica gel column chromatography, eluting with petroleum ether : ethyl acetate = 5 : 1 to 1 : 1) to give (2R,3R,4S,5S)-2-(4-chloro-5-fluoro-pyrrolo [2,3-d]pyrimidin-7-yl)-5-[(lR)-6- chloroisochroman-l-yl]tetrahydrofuran-3,4-diol (86g, 160 mg, 0.4 mmol, 15% yield) as a yellow oil. LCMS [M+H]: 440.1. Step 6. Synthesis of (2R,3R,4S,5S)-2-(4-amino-5-fluoro-pyrrolo[2,3-d]pyrimidin-7-yl) -5-[(lR)-6-chloroisochroman-l-yl]tetrahydrofuran-3,4-diol (Ex. 86)

[00402] A mixture solution of (2R,3R,4S,5S)-2-(4-chloro-5-fluoro-pyrrolo[2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloroisochroman-l-yl]tetrahydrofuran-3,4-diol (86g, 156 mg, 0.35 mmol) in ammonium hydroxide (10 mL, 260 mmol) and 1,4-dioxane (10 mL) was stirred at 105 °C in a sealed tube overnight. The mixture solution was concentrated in vacuum and the residue was purified by prep-HPLC, eluting with CH3CN in water from 5% to 95%. The product fraction were extracted with ethyl acetate (2x50 ml) and concentrated in vacuum to give a yellow solid which was triturated with petroleum ether : ethyl acetate =100 :1 (50 ml), filtered, and dried in vacuum to 2024204264   21 Jun 2024 afford (2R,3R,4S,5S)-2-(4-amino-5-fluoro-pyrrolo [2,3-d]pyrimidin-7-yl)-5-[(lR)-6-chloroisochroman-l-yl]tetrahydrofuran-3,4-diol (Ex. 86, 74 mg, 0.17 mmol, 49% yield) as a white solid. LCMS [M+H]: 421.1. XHNMR (400 MHz, DMSO-J6) 8 8.08 (s, 1H), 7.23-7.3 l(m, 4H), 7.01 (s, 2H), 6.23 (d, J =7.6 Hz, 1H), 5.23(d, J= 6.8 Hz, 1H), 5.08 (s, 1H),4.87 (s, 1H), 4.35-4.39 (m, 2H), 4.23-4.26 (m, 1H), 3.79-3.82 (m, 1H), 3.66-3.71 (m, 1H), 2.89-2.96 (m, 1H), 2.70-2.74 (m, 1H). ’H NMR (400 MHz, DMSO-J6+D2O) 8 8.08 (s, 1H), 7.23-7.30 (m, 4H), 6.23 (d, J= 6.0 Hz, 1H), 4.87 (s, 1H), 4.35-4.39 (m, 2H), 4.23-4.26 (m, 1H), 3.79-3.81 (m, 1H), 3.65-3.71 (m, 1H), 2.89-2.96 (m, 1H), 2.70-2.74 (m, 1H). 19F NMR (377 MHz, DMSO-J6) 8 -166.8. Example 88. Synthesis of (2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[...

Claims

2024204264   05 Aug 2026What is claimed:

1. A compound, or pharmaceutically acceptable salt or solvate thereof, wherein the compound is:(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1,3-dihydroisobenzofuran-1-yl)cyclopentane-1,2-diol;(S)-3-((1S,2R,3S,4R)-4-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxycyclopentyl)-6-chloroisobenzofuran-1(3H)-one;(R)-3-((1S,2R,3S,4R)-4-(4-amino-6H-7l4-pyrrolo[2,3-d]pyrimidin-7-yl)-2,3-dihydroxycyclopentyl)-6-chloroisobenzofuran-1(3H)-one;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-5-chloro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(1R,2S,3R,5S)-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-5-chloro-1,3-dihydroisobenzofuran-1-yl)cyclopentane-1,2-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-butyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-5,6-difluoro-1,3-dihydroisobenzofuran-1-yl)-5-(4-(ethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-4-chloro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloro-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-5-chloro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-4-chloro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-7-chloro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6-chloro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;2024204264   05 Aug 2026(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(2R,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-((R)-5-chloro-1,3-dihydroisobenzofuran-1-yl)-3-methyltetrahydrofuran-3,4-diol;(2R,3S,4R,5R)-2-((R)-5-chloro-1,3-dihydroisobenzofuran-1-yl)-3-methyl-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloro-1-methyl-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-5-chloro-1-methyl-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-5-chloro-3,3-difluoro-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-5-chloro-3,3-dimethyl-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-5-chloro-1,3-dihydrobenzo[c]thiophen-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(R)-5-chloro-1-((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-1,3-dihydrobenzo[c]thiophene 2,2-dioxide;(2R,3R,4S,5S)-2-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-(trifluoromethoxy)-1,3-dihydroisobenzofuran-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6-fluoro-5-(trifluoromethyl)-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6-fluoro-5-(trifluoromethoxy)-1,3-dihydroisobenzofuran-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3S,4R,5R)-2-((R)-5-chloro-2-methylisoindolin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(R)-6-chloro-3-((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-2-methylisoindolin-1-one(2S,3S,4R,5R)-2-((R)-1,3-dihydrofuro[3,4-c]pyridin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6-chloro-1,3-dihydrofuro[3,4-c]pyridin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-4,6-dihydrofuro[3,4-d]thiazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-2-chloro-4,6-dihydrofuro[3,4-d]thiazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;2024204264   05 Aug 2026(2S,3S,4R,5R)-2-((R)-4,6-dihydrothieno[2,3-c]furan-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-2-chloro-4,6-dihydrothieno[2,3-c]furan-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-4,6-dihydro-1H-furo[3,4-c]pyrazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-2-methyl-2,6-dihydro-4H-furo[3,4-c]pyrazol-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3S,4R,5R)-2-((R)-5-chloroisoindolin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(R)-6-chloro-3-((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)isoindolin-1-one;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((1R)-6-chloro-3-methoxyisochroman-1-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((1R)-6-chloro-3-hydroxyisochroman-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((1R)-6-chloro-3-methoxyisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6-chloro-1H-isochromen-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(R)-6-chloro-1-((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)isochroman-3-one;(2S,3S,4R,5R)-2-((R)-6-chloro-4,4-dimethylisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((S)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-1H-pyrano[3,4-c]pyridin-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((1R)-6-chloro-3-hydroxyisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-3,4-dihydro-1H-pyrano[3,4-c]pyridin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6-chloro-4,4-difluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-7-chloro-4H-benzo[d][1,3]dioxin-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-7-chloro-2,2-difluoro-4H-benzo[d][1,3]dioxin-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;2024204264   05 Aug 2026(2S,3S,4R,5R)-2-((R)-7-chloro-1,5-dihydrobenzo[e][1,3]dioxepin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-7-chloro-3,3-difluoro-1,5-dihydrobenzo[e][1,3]dioxepin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(R)-7-chloro-1-((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-1,5-dihydrobenzo[e][1,3]dioxepin-3-one;(2S,3S,4R,5R)-2-((R)-8-chloro-5,6-dihydro-1H-benzo[e][1,3]dioxocin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-8-chloro-3,3-difluoro-5,6-dihydro-1H-benzo[e][1,3]dioxocin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(R)-8-chloro-1-((2S,3S,4R,5R)-3,4-dihydroxy-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-2-yl)-5,6-dihydro-1H-benzo[e][1,3]dioxocin-3-one;(2R,3S,4R,5R)-2-((R)-6-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((1R)-6-chloro-4-(trifluoromethyl)isochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((1R)-6-chloro-4-fluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((1R)-6-chloro-4-hydroxyisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((1R)-6-chloro-4-methylisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((1R)-6-chloro-3-methylisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6-chloroisochroman-1-yl-4,4-d2)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6-chloroisochroman-1-yl)-5-(4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-7-chloroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloroisochroman-1-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5-chloroisochroman-1-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6,7-difluoroisochroman-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6,7-difluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;2024204264   05 Aug 2026(2S,3S,4R,5R)-2-((R)-5-chloroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-4,4-difluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-5,6-difluoroisochroman-1-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-4,4-difluoroisochroman-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-5,6-difluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((S)-6-chloroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloro-1,5-dihydrobenzo[e][1,3]dioxepin-1-yl)tetrahydrofuran-3,4-diol;(R)-1-((2S,3S,4R,5R)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxytetrahydrofuran-2-yl)-6-chloroisochroman-3-one;(2S,3S,4R,5R)-2-((R)-6-chloro-5-fluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6-chloro-5-fluoroisochroman-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6-chloroisochroman-1-yl)-5-(5-fluoro-4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-5-fluoro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6-chloroisochroman-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6,7-dichloroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6,7-dichloroisochroman-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((S)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((S)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-2-chloro-4,7-dihydro-5H-thieno[2,3-c]pyran-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((1R,4S)-6-chloro-4-fluoroisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-[(1R,4S)-6-chloro-4-fluoro-isochroman-1-yl]tetrahydrofuran-3,4-diol;2024204264   05 Aug 2026(2R,3R,4S,5S)-2-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)-5-[(1R,4R)-6-chloro-4-fluoro-isochroman-1-yl]tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((1R,4R)-6-chloro-4-fluoroisochroman-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-7,8-difluoro-4H-benzo[d][1,3]dioxin-4-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3S,4R,5R)-2-[(1R)-6-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-(4-methylpyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-6-chloro-7-methylisochroman-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-6-chloro-7-methylisochroman-1-yl)tetrahydrofuran-3,4-diol;(2S,3S,4R,5R)-2-((R)-7-chloro-1,3,4,5-tetrahydrobenzo[c]oxepin-1-yl)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol;(2R,3R,4S,5S)-2-(4-amino-6H-7l4-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-7-chloro-1,3,4,5-tetrahydrobenzo[c]oxepin-1-yl)tetrahydrofuran-3,4-diol; or(2S,3S,4R,5R)-2-((R)-6,7-difluoroisochroman-1-yl)-5-(4-(methyl-d3)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol.

2. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof.

3. A method of inhibiting a protein arginine methyltransferase 5 (PRMT5) enzyme, comprising: contacting the PRMT5 enzyme with an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition of claim 2.

4. A method of treating a disease or disorder associated with aberrant PRMT5 activity in a subject comprising administering to the subject, a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition of claim 2.

5. The method of claim 4, wherein the disease or disorder associated with aberrant PRMT5 activity is breast cancer, lung cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, uterine cancer, cervical cancer, leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS), epidermoid cancer, hemoglobinopathies such as b-thalassemia and sickle cell disease (SCD), CDKN2A deleted cancers; 9P deleted cancers; MTAP deleted2024204264   05 Aug 2026cancers; glioblastoma, NSCLC, head and neck cancer, bladder cancer, or hepatocellular carcinoma.

6. The method of claim 4, wherein the disease or disorder associated with aberrant PRMT5 activity is adenoid cystic carcinoma (ACC), primary central nervous system lymphoma, fallopian tube cancer, or non-Hodgkin lymphoma.

7. Use of a compound of claim 1, or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for treating a disease or disorder associated with aberrant PRMT5 activity.

8. The use of claim 7, wherein the disease or disorder associated with aberrant PRMT5 activity is breast cancer, lung cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, uterine cancer, cervical cancer, leukemia such as acute myeloid leukemia (AML), acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, hairy cell leukemia, myelodysplasia, myeloproliferative disorders, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), mastocytosis, chronic lymphocytic leukemia (CLL), multiple myeloma (MM), myelodysplastic syndrome (MDS), epidermoid cancer, hemoglobinopathies such as b-thalassemia and sickle cell disease (SCD), CDKN2A deleted cancers; 9P deleted cancers; MTAP deleted cancers; glioblastoma, NSCLC, head and neck cancer, bladder cancer, or hepatocellular carcinoma.

9. The method of claim 7, wherein the disease or disorder associated with aberrant PRMT5 activity is adenoid cystic carcinoma (ACC), primary central nervous system lymphoma, fallopian tube cancer, or non-Hodgkin lymphoma.